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SUMMARY 
Trypanosomatid parasites are the causative agents of neglected tropical diseases for 
which current therapies are inadequate.  As primitive eukaryotic organisms, they also 
represent a useful model system to investigate fundamental cellular biology while 
studies of potential drug targets endeavour to develop new drug molecules.  Aspects of 
both of these areas are explored in this thesis. 
 
Microtubules are polymers of tubulin and are essential in eukaryotes for cell division, 
motility and maintenance of cell morphology.  Five tubulin-binding cofactors (TBC, 
named A-E) are proteins implicated in the folding, polymerisation and processing of 
tubulin, the major component of the trypanosomatid cytoskeleton.  At the initiation of 
this study, there was no structural information available for any trypanosomatid TBC.  
We therefore sought to investigate these proteins by X-ray crystallography and assess 
their potential tubulin-interaction capabilities to support the current functional model.  
The crystal structure of tubulin-binding cofactor A (TBCA) from Leishmania major is 
presented, determined using diffraction data to 1.9 Å resolution.  Prior to tubulin 
polymerisation, TBCA forms a complex with β-tubulin in the pathway to αβ-tubulin 
heterodimerisation.  It maintains a soluble pool of β-tubulin and can prevent premature 
polymerisation.  This is a short helical protein, similar in structure to published 
homologues.  The similarities and some distinct local features that may impact on β-
tubulin binding are discussed.  In particular, the surface properties of a prominent bend 
in the helix bundle represents an area that may be capable of interacting with its tubulin 
partner. 
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Tubulin-binding cofactor C (TBCC) is implicated in stimulating the hydrolysis of GTP 
bound to β-tubulin prior to release of the assembly-competent αβ-tubulin heterodimer 
from a supercomplex between TBCC, TBCD, TBCE and both tubulin subunits.  Full-
length recombinant Trypanosoma brucei and Leishmania major tubulin-binding TBCC 
were degraded and crystallisation could not be achieved.  However, crystals of a 
truncated TBCC construct were obtained.  Despite efforts to optimise crystallisation and 
diffraction data, the structure was not solved for inclusion in this thesis.  Instead, 
homologous structures were analysed and a potential tubulin interaction site is 
suggested based on the proposed GTPase-stimulating activity of TBCC and the 
similarity with the human protein, Retinitis Pigmentosa 2 (RP2), predicted to contain a 
domain with similar fold.  Progress towards the soluble recombinant expression of the 
other cofactors also lays the foundation for future investigations into trypanosomatid 
TBC structure and function. 
 
Pteridine reductase 1 (PTR1), an enzyme unique to trypanosomatids, is the subject of 
Part II of this thesis.  PTR1 is a broad-spectrum NADPH-dependent reductase, 
catalysing the two-stage reduction of biopterin to dihydrobiopterin and 
tetrahydrobiopterin and that of folate to dihydrofolate and tetrahydrofolate.  As such, it 
can provide a bypass mechanism for the reduction of folates, reducing the therapeutic 
action of traditional antifolate molecules in these organisms.  Inhibition of PTR1 is 
therefore desirable from a drug discovery viewpoint.  The crystal structure of 
Leishmania donovani PTR1 was determined using data extending to 2.5 Å resolution 
with a view to generating ligand-complex structures and providing a model for inhibitor 
design.  This structure was found to contain a disordered active site, with several loop 
regions not modelled or relocated.  A sulfate molecule from the crystallisation mixture 
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binds in the cofactor phosphate binding-site and the sequential binding of cofactor 
before substrate or inhibitor can not occur.  Although this crystal form was considered 
unsuitable for further studies, it provides the only structure of PTR1 in the absence of 
cofactor. 
 
With an established crystallisation protocol, Trypanosoma brucei PTR1 then forms the 
basis of a collaborative investigation of over 100 novel potential inhibitory molecules.  
Kinetic evaluation, isothermal titration calorimetry (ITC) and co-crystallisation were 
applied to generate ligand-binding profiles of pyrrolopyrimidine derivatives.  Several 
interesting binding features were identified from the 24 ligand complex structures 
obtained. These include the discovery of two covalent inhibitors, confirming the 
reactivity of a non-conserved active site cysteine, and molecules that are able to bind 
simultaneously at two locations within the active site pocket, exploiting hydrogen-
bonding interactions with key catalytic and other nearby residues.  The thermodynamic 
binding profiles of seven inhibitors also provide insight into the enthalpic and entropic 
contributions to ligand binding.  We assessed the suitability of ITC for this system and 
while a high attrition rate was observed, chemical substitutions were able to enhance the 
binding entropy.  These studies have strengthened our understanding of the structure-
activity relationship between PTR1 and inhibitors, offering opportunities to develop 
new molecules that focus on increasing the potency generated by favourable enthalpy 
alongside improving the drug-like properties. 
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PREFACE 
This thesis contains research in two project areas.  Both topics are based on proteins 
from species of trypanosomatid parasites.  Part I describes work towards providing 
structural knowledge of tubulin-binding cofactor proteins involved in the formation and 
dynamics of microtubules.  Part II provides structural, thermodynamic and kinetic 
details of a series of inhibitors of the enzyme, pteridine reductase 1.  Although 
somewhat distinct, some experimental methodologies cross between both subjects and 
each part should therefore not be read in complete isolation.  A brief introduction to 
trypanosomatid parasites and crystallographic methods are included in Part I Chapter 
1 alongside an overview of microtubule organisation and tubulin-binding cofactors.  
Pteridine reductase 1 is introduced in Part II Chapter 4. 
 
Part of this work has been published, cited below, and additional manuscripts are in 
preparation. 
 
Dawson, A., Tulloch, L.B., Barrack, K.L., Hunter, W.N., (2010). High-resolution 
structures of Trypanosoma brucei pteridine reductase ligand complexes inform on the 
placement of new molecular entities in the active site of a potential drug target. Acta 
Crystallogr D Biol Crystallogr 66, 1334–1340. 
 
Barrack, K.L., Tulloch, L.B., Burke, L.A., Fyfe, P.K., Hunter, W.N., (2011). Structure 
of recombinant Leishmania donovani pteridine reductase reveals a disordered active 
site. Acta Crystallogr Sect F Struct Biol Cryst Commun 67, 33–37. 
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PART I 
Tubulin-binding cofactors 
1. Introduction 
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1.1. Trypanosomatid parasites 
Leishmania and Trypanosoma are digenetic genera of the Trypanosomatidae family 
from the order Kinetoplastida (Bush et al., 2001).  These primitive eukaryotic protozoan 
parasites are responsible for human diseases that include Leishmaniasis and African 
sleeping sickness, also known as human African trypanosomiasis (HAT), and Chagas 
disease.  The flagellated trypanosomatids are potentially valuable organisms to study 
processes involved in the folding of tubulin and the organisation of microtubules as 
these form the main component of the trypanosomatid cytoskeleton.  In particular, 
Leishmania major and Trypanosoma brucei are well characterised biochemically and 
genetically and have been selected as models for the studies presented in this thesis. 
 
1.1.1. Leishmaniasis 
Leishmaniasis is transmitted by the bite of a female sandfly (Desjeux, 2004).  Two 
forms of Leishmaniases include cutaneous and visceral infections, caused by L. major 
and L. donovani, respectively, which are just two of more than 20 species of 
Leishmania parasites (Desjeux, 1996).  When an infected sandfly takes a blood meal 
from a human host, the infective promastigote form of the parasite are injected into the 
the host.  Inside host macrophages, phagocytosed promastigotes then transform into 
amastigotes, multiplying in various host tissues.  The insect stage of the life cycle 
continues when infected macrophages are ingested during further sandfly blood meals 
and the amastigotes transform into promastigotes and proliferate in the insect midgut 
before migration to the proboscis to be transmitted to a new host (Centres for Disease 
Control and Prevention, 2013). 
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Leishmaniasis presents a serious health risk in 88 countries (Desjeux, 1996) and it is 
estimated that approximately 12 million people are currently infected.  The most serious 
form, visceral Leishmaniasis, has an incidence of approximately 500,000 new cases per 
year (Desjeux, 2001).  Visceral Leishmaniasis is fatal if untreated as the infection, 
which presents as ulcerative lesions weeks or months following the infective insect bite, 
can disseminate through internal organs including the liver, spleen, bone marrow and 
distant lymph nodes (Murray et al., 2005).  The more common cutaneous infection 
(approximately 1.5 million cases annually; Desjeux, 2001), where lesions remain 
localised to the skin, is less serious but can lead to disabling manifestations if untreated.  
Such estimates may be under-representations of the true epidemiology due to 
incomplete reporting of disease incidence and insufficient diagnostic capabilities 
(Desjeux, 2004). 
 
1.1.2. Trypanosomiasis 
The tsetse fly is the insect vector responsible for transmission of HAT, which is 
prevalent in 36 countries in sub-Saharan Africa.  Two T. brucei parasite subspecies, T. 
b. rhodesiense and T. b. gambiense, are causative agents of acute and chronic infections 
in humans, respectively.  Acute infections present within weeks of the initial injection 
of the trypomastigote form of the parasite into the host while symptoms of chronic 
infection can emerge several years later.  The parasites enter the host bloodstream via 
the lymphatic system.  The bloodstream trypomastigotes multiply and travel throughout 
the body where they can be injested by further tsetse flies taking a blood meal from an 
infected individual.  Within the insect vector, the parasites undergo further 
transformation into procyclic trypomastigotes in the midgut of the fly, epimastigotes 
following departure from the midgut and finally in the salivary gland of the tsetse fly, 
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the cells proliferate and mature into metacyclic trypomastigotes, ready for injection into 
another mammalian host (Vickerman, 1985; McKean, 2003; Centres for Disease 
Control and Prevention, 2012).  The chronic form of HAT involves two stages.  The 
first stage presents with non-specific flu-like symptoms including fever, headache and 
joint pain. Cardiac and kidney disease can also develop, amongst other serious 
complications, if untreated.  The second stage manifests when the parasite migrates 
across the blood-brain barrier, resulting in neurological symptoms such as confusion, 
depleted coordination, sensory disturbances and disruption to the normal sleeping cycle.  
Ultimately, progressive mental deterioration can then lead to coma and death. 
 
With over 70 million people estimated to be at risk of contracting HAT (Simarro et al., 
2012), the majority of reported cases are of the chronic form (Simarro et al., 2011) but 
both are fatal if left untreated (Fairlamb, 2003; Simarro et al., 2008).  The subspecies, T. 
b. brucei (named from this point simply as T. brucei) is often used for laboratory studies 
as it presents a lesser risk of human infection (Gibson, 2012). 
 
Chagas disease, sometimes known as American trypanosomiasis, is spread to humans 
via the infected faeces of a triatomine bug (often known as the ‘kissing bug’) through 
ingestion of contaminated foods, blood transfusions or from mother to foetus during 
pregnancy.  Like HAT, Chagas disease also occurs with acute and chronic phases.  
Acute infection often results in swelling around the site of transmission and other mild 
symptoms including fever, headache and muscle pain, but can also lead to severe 
inflammation of heart or brain tissue.  The chronic phase follows the acute phase with 
many people remaining asymptomatic.  While parasitaemia may be low or 
undectectable during this stage, localisation of the parasites to cardiac, neurological or 
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gastrointestinal tissues can lead to the development of abnormalities in these organs, 
particularly serious in immunocompromised individuals (Prata, 2001; Nunes et al., 
2013).  It is estimated that approximately 8 million people in at least 21 countries are 
infected with the causative organism, Trypanosoma cruzi (WHO, 2013a).  The disease 
presents a serious medical and socioeconomic burden to endemic regions of Latin 
America (Dias et al., 2002).  While proteins from T. cruzi are not directly under study 
within the scope of this thesis, it is possible that information gathered may also be 
extended to this related parasite. 
 
1.1.3. Current therapies 
Examples of the treatment options available for Leishmaniasis include pentavelent 
antimonials, miltefosine, the first choice oral treatment, and amphotericin B, an agent 
that attacks the cell wall.  Antimonial treatments are invasive and can result in toxic 
side-effects (Berman, 1997). Miltefosine has teratogenic properties and a poor 
pharmacokinetic profile, which may contribute to increased drug resistance while 
amphotericin B is also able to attack the host cell membrane, and has itself been the 
cause of fatalities (Reithinger et al., 2007). Drugs approved for the treatment of HAT 
include suramin, pentamidine, eflornithine, melarsoprol and nifurtimox (Fairlamb, 
2003) but these are also prone to resistance or adverse side-effects.  It is therefore clear 
that, with high cost, high toxicity, difficult administration and increasing drug resistance 
as major contributors to the poor overall efficacy (Fairlamb, 2003; Croft et al., 2006), 
current therapies for Leishmaniasis and HAT, as well as Chagas disease, are inadequate 
and new drugs are sought.  The World Health Organisation considers these amongst the 
17 neglected tropical, or ‘orphan’, diseases (WHO, 2013b; Fairlamb, 2003) and a 
greater understanding of trypanosomatid biology, with a particular focus on microtubule 
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biogenesis here, may aid in the discovery of improved treatments. 
 
1.2. Microtubules 
Microtubules are dynamic polymers of αβ-tubulin heterodimers that play an important 
role in many diverse eukaryotic cellular processes.  The heterodimers are arranged in 
protofilaments in a head-to-tail manner with a plus end, where the β-tubulin subunit is 
exposed, and a minus end.  Multiple individual polar protofilaments, usually thirteen, 
are organised to form a hollow microtubule (Figure 1.1).  Each tubulin subunit binds a 
guanine nucleotide.  For α-tubulin, guanosine-5'-triphosphate (GTP) is permanently 
bound and is inaccessible due to its location at the dimer interface while the nucleotide 
bound to β-tubulin can be hydrolysed to GDP and/or exchanged.  Microtubule growth 
via the addition of dimer units typically occurs at the microtubule plus end (Margolis 
and Wilson, 1998; Howard and Hyman, 2009) and is affected by the status of the β-
tubulin guanine nucleotide.  Polymerisation takes place at the GTP-β-tubulin 
microtubule tip and subsequent hydrolysis ensures the microtubule is comprised mainly 
of GDP-tubulin with only a ‘GTP-cap’ (Howard and Hyman, 2003).  Exposed GDP-β-
tubulin at the plus end leads to microtubule depolymerisation, or catastrophe (Drechsel 
and Kirschner, 1994; Howard and Hyman, 2009).  Cytoskeleton structure, cell motility 
and cell division (Steinborn et al., 2002) are dependent on the correct architecture and 
dynamic behaviour of these cylindrical polymers, with microtubule growth and 
catastrophe supported by numerous microtubule-associated proteins (MAPs).  The 
tubulin subunits within microtubules can be the target of various post-translational 
modifications, including polyglutamylation, polyglycylation and tyrosination of the 
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carboxyl terminus, which influence the behaviour and affinity of these MAPs, 
modulating the activity of the microtubules concerned (Bonnet et al., 2001). 
 
 
Figure 1.1. A typical microtubule 
A schematic representation of a microtubule (left) with tubulin subunits depicted as cyan and 
purple circles.  α- and β-tubulin are also shown in cartoon form (PDB 1tub; Nogales et al., 
1998; right) with bound nucleotides represented by yellow spheres. 
 
1.2.1. Trypanosomatid microtubules 
In trypanosomatids, microtubules are abundant in the flagellum (Gallow and Anderton, 
1983; Seebeck et al., 1983), facilitating cell movement (Ralston et al., 2009), while a 
complex network of subpellicular microtubules beneath the cell membrane maintains 
the overall parasite shape (Gallo and Precigout, 1988; Gull, 1999).  The precise 
arrangement of microtubules is dependent on their function.  For example, flagellar 
microtubules extend from the basal body along the trypanosome flagellar attachment 
zone and adopt a 9+2 arrangement in the axoneme that is typical of eukaryotic flagella.  
Two single microtubules are in the centre of a larger tubule formation consisting of nine 
fused-doublet microtubules, one of which contains thirteen protofilaments while the 
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fused component is an incomplete ten-protofilament microtubule (Ralston and Hill, 
2008; Ralston et al., 2009).  The flagella is required for pathogenicity as well as 
motility, attaching the parasite to the salivary gland of the insect vector prior to the 
infection of a new host and also contributing to the evasion of the host immune system 
(Engstler et al., 2007; Ralston and Hill, 2008).  Downregulation of α- and β-tubulin 
gene expression in high-throughput T. brucei RNA interference studies resulted in 
significant loss of cell fitness (Alsford et al., 2011).  Anti-trypanosome tubulin 
antibodies prevent in vitro cell growth (Lubega et al., 2002) and tubulin polymerisation 
is the target of studies that seek to identify new therapeutic agents for diseases caused 
by trypanosomatids (Morgan et al., 2008), highlighting the importance of tubulin and 
microtubules in these organisms. 
 
1.3. Tubulin-binding cofactors 
Complex protein folding mechanisms exist in many systems to ensure correct protein 
structure and function.  To form the thirteen protofilaments that constitute the typical 
microtubule, the folding of the α-­‐ and β-tubulin subunits must be carefully regulated to 
ensure their correct tertiary structure and to prevent spontaneous aggregation or 
premature polymerisation (Lundin et al., 2010).  Improper tubulin folding can have a 
detrimental effect on many cellular functions.  The tubulin-binding cofactors (TBC) 
were first identified through their ability to associate with individual tubulin subunits 
and implicated in the folding and heterodimerisation process (Fontalba et al., 1993; Gao 
et al., 1993; Melki et al, 1996; Tian et al., 1997; Lopez-Fanarraga et al., 2001). 
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Tubulin polypeptides are first processed by prefoldin (Vainberg et al., 1998) and the 
cytosolic chaperonin containing T-complex polypeptide 1, CCT (Valpuesta et al., 
2002).  The route to tubulin dimerisation is not fully validated but a working model 
suggests that at least five TBCs, named A-E, capture the quasi-native tubulin monomers 
when released from CCT (Gao et al. 1992; Melki et al., 1993; Tian et al., 1995).  A 
pathway of transfer of the individual subunits follows (Figure 1.2).  α- and β-tubulin 
are first acquired by tubulin-binding cofactor B (TBCB, Tian et al., 1997) and TBCA 
(Gao et al., 1993; 1994) and transferred to TBCs E and D, respectively.  Tubulin 
subunits are brought together in a supercomplex along with cofactors C, D and E (Tian 
et al., 1997).  Hydrolysis of GTP by β-tubulin, influenced by TBCC, then enables the 
release of the αβ-tubulin heterodimer that, following nucleotide exchange, can proceed 
to polymerisation (Fontalba et al., 1993; Tian et al., 1996; Kirik et al., 2002; Lundin et 
al., 2010).  It should be noted that the tubulin-binding cofactors can be named 
differently throughout the literature whereby the terms tubulin-binding and tubulin-
folding as well as cofactor and chaperone are often used interchangeably.  For clarity 
here, all are named tubulin-binding cofactors (TBC) followed by the respective A-E 
identifier, except in cases where a homologous protein is universally given a unique 
notation. 
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Figure 1.2 Schematic model of tubulin dimerisation 
A simplified schematic representation depicting the potential involvement of TBCs A-E in the 
pathway to the dimerisation of α- and β-tubulin (based on models from Tian et al., 1997; 
Bhamidipati et al., 2000; Lopez-Fanarraga et al., 2001; Grynberg et al., 2003; Lundin et al., 
2010).  Quasi-native α- and β-tubulin subunits following release from CCT are depicted as cyan 
and purple squares while assembly-competent subunits are shown as circles of the same colour.  
TBCs are represented by the appropriate A-E identifier.  Grey or dashed arrows indicate 
potential pathways that are not fully understood. 
 
In addition to their participation in the post-translational folding of tubulin prior to 
heterodimerisation and polymerisation (Gao et al., 1994), there is growing evidence that 
the TBCs also contribute to the dissociation of microtubules with a greater involvement 
in microtubule dynamics (Martín et al., 2000; Bhamidipati et al., 2000; Kortazar et al., 
2007).  Microtubule dynamics, the elongation or shrinkage of most microtubules (Desai 
and Mitchison, 1997), are influenced by many MAPs.  The TBCs are thought to be 
distinct from other MAPs that only bind to polymerised microtubules but interactions 
with fully folded native tubulin have been reported (Bhamidipati et al., 2000; Kortazar 
et al., 2007).  TBCD is able to disrupt the αβ-tubulin heterodimer to sequester GTP-β-
tubulin.  Cells overexpressing TBCD result in a substantial loss of detectable 
microtubules (Martín et al., 2000) or cell death unless rescued by β-tubulin (Hirata et 
al., 1998) or prevented by an additional modulator, Arl2 (ADP ribosylation factor-like 
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2; Bhamidipati et al., 2000).  Similarly, disruption to the genes encoding TBCs B and E 
in fission yeast is lethal (Hirata et al., 1998).  These two cofactors may form a ternary 
complex with α-tubulin following dissociation of the αβ-tubulin heterodimer while free 
β-tubulin is captured by TBCA (Kortazar et al., 2007).  Additionally, TBCA can 
prevent spontaneous over-polymerisation through the maintenance of a reservoir of 
excess soluble β-tubulin (Lopez-Fanarraga et al., 2001) and microtubule assembly can 
be compromised if TBCA levels are altered (Archer et al., 1995).  Tubulin monomers 
acquired through the dissociation process can then be recycled through subsequent 
dimerisation and incorporated into growing microtubules or these pools may act as an 
intermediate in the route towards degradation (Fanarraga et al., 1999). 
 
The complex functions exhibited by the TBCs as outlined above are only beginning to 
be dissected.  There is a lack of detailed evidence to substantiate the tubulin 
dimerisation pathway shown in Figure 1.2 and analysis of the three-dimensional 
structures of the TBCs can support such validation efforts.  Secondary structure 
predictions and domain analysis suggest that each TBC possesses its own distinct 
structural features (Grynberg et al., 2003).  Crystal structures are available for three 
TBCA homologues (PDB 1qsd, Steinbacher, 1999; 1h7c, Guash et al., 2002; 3mxz, Lu 
et al., 2010) and nuclear magnetic resonance (NMR) studies afford insight into 
fragments of TBCB (1t0y, Lytle et al., 2004; 1v6e, Zhao et al., unpublished; 1whg, 
Saito et al., unpublished; 2kj6, Mani et al., unpublished; 2kjr, Ramelot et al., 
unpublished), TBCC (2l3l, Garcia-Mayoral et al., 2011; 2yuh, Saito et al., unpublished) 
and TBCE (1wjn, Sato et al., unpublished).  Several cofactors contain motifs implicated 
in protein-protein interactions.  In particular, TBCs B and E are believed to contain both 
ubiquitin-like and cytoskeleton-associated protein-glycine-rich (CAP-Gly) domains.  
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CAP-Gly modules are found in a number of other MAPs, important for microtubule 
recognition and binding (Weisbrich et al., 2007).  TBCE also contains a leucine-rich 
linker segment and TBCD is a large protein with a HEAT repeating motif, both of 
which are involved in mediating interactions with other proteins (Grynberg et al., 2003).  
TBCA and TBCC consist of compact helical regions while TBCC is extended by an 
additional β-stranded domain, sharing similarity with the human protein, retinitis 
pigmentosa 2 (RP2). 
 
At the beginning of the studies presented in this thesis, no structure of a protist TBC 
was known.  It is desirable to understand how the distinct structural folds of each TBC 
impacts on function and to compare trypanosomatid TBC structures with those of other 
organisms to build a more complete model of their complex functional capabilities. 
 
1.4. Crystallisation and structure determination 
Crystallographic methods are the primary source of structural information presented in 
this thesis.  A crystal structure can provide detailed atomic information and inform on 
protein functionality, which is inherently linked to overall and local structural features.  
Interaction potential can be analysed and protein-protein or protein-ligand complexes 
can provide molecular details of an interaction captured in crystalline form.  Numerous 
texts are currently available to aid the study and application of protein crystallography.  
Notably, Rupp (2009) provides a comprehensive review of biomolecular 
crystallography and only an outline of selected experimental methodologies utilised in 
both Part I and Part II is presented here. 
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1.4.1. Crystallisation 
Protein crystals are comprised of individual molecules repeating in a uniform manner in 
a crystal lattice.  Prior to crystallisation, protein samples should usually be 
homogeneous and in the purest form possible to ensure that no impurities impede on the 
ordered packing of protein molecules.  Crystal growth takes place in the metastable 
region of the crystallisation phase diagram (Asherie, 2004; Figure 1.3) where the 
concentrations of protein and the mixture of chemicals added to induce crystallisation 
(precipitant) are optimal.  These concentrations and the composition of the precipitant 
mixture are unknown and cannot be accurately estimated.  Rather, proteins are purified 
to homogeneity and subjected to screening procedures to search for suitable 
crystallisation-inducing agents.  Before crystal growth can occur, a nucleation event 
must first begin the process.  This can be spontaneous through first entering the labile 
zone but the state must return to the metastable region (Stura et al., 1994) as 
overnucleation can hinder the formation of single crystals suitable for diffraction 
studies.  Alternatively, a seed can be introduced to a metastable mixture to initiate 
crystallisation (Bergfors, 2003) such as a fragment of a previous nucleated crystal, a 
whole crystal to increase the crystal size or via an exogenous or artificial seed (Chayen 
et al., 2001; D’Arcy et al., 2003a).  
 
The main methods of crystallisation utilised in the studies presented in this thesis are 
sitting drop and hanging drop vapour diffusion.  Sitting drops consist of a protein-
precipitant mixture ‘sitting’ on a ledge adjacent to each of the 96-wells of a screening 
plate and are typically used for initial robotic screening of potential crystallisation 
conditions.  Hanging drops for the optimisation or reproduction of known crystallisation 
conditions are used in a 24-well format where a larger volume drop can be placed on a 
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siliconised coverslide, inverted over a reservoir containing approximately 1 mL 
precipitant mixture and sealed.  Additionally, some microbatch and under-oil 
crystallisation experiments were attempted.  While vapour diffusion methods allow the 
equilibration of the concentrated reservoir and less concentrated protein-precipitant 
drops through net transfer of water, microbatch procedures capture the state within the 
phase diagram immediately following preparation (Chayen et al., 1990).  Using oils of 
different composition, such as silicone oil in place of paraffin oil, can allow the 
investigator to manipulate the rate of vapour diffusion (Chayen, 1997a; 1997b; 1999; 
D’Arcy et al., 2004). 
 
Figure 1.3. Crystallisation phase diagram 
A generic crystallisation phase diagram (based on Asherie, 2004).  Crystal growth occurs in the 
metastable zone following a nucleation event.  Increased protein and precipitant concentration 
leads to greater supersaturation but beyond the labile region, protein precipitation or aggregation 
occurs.  Proteins remain in solution in the undersaturated, stable zone. 
 
1.4.2. Crystal structure determination 
Following the successful growth of suitable crystals of a target protein, X-ray 
diffraction data are obtained.  Monochromatic X-rays are directed at a single crystal 
suspended within a cryoprotective mixture, mounted on a goniometer and cooled in a 
stream of gaseous nitrogen.  Electrons within the ordered crystal lattice diffract the 
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incident X-rays, a phenomenon first discovered by von Laue in 1912 (von Laue, 1915; 
Schmahl and Steurer, 2012).  A series of spots or reflections are detected on a 
diffraction image when Bragg’s law (Bragg, 1913; Bragg and Bragg, 1913) is satisfied, 
given as 𝒏𝝀 = 𝟐𝒅𝐬𝐢𝐧𝜽 
where n is any integer, λ is the X-ray wavelength, d is the spacing between lattice planes 
and θ is the incident angle of the wave.  Multiple diffraction images are collected as the 
crystal is rotated.  The diffraction experiment can then provide two of the three 
necessary parameters to obtain the three-dimensional structure of the protein.  The X-
ray wavelength used in the experiment is known and the amplitude of the wave can be 
derived from the intensity of the reflections.  However, the phase of the wave cannot be 
measured directly (Hauptman, 1991).  This is known as the crystallographic ‘phase 
problem’ and is the major hurdle common to solving any macromolecular crystal 
structure (Taylor, 2003). 
 
Ab initio methods for phase estimation can be employed in simple cases with atomic 
resolution diffraction, such as that of small molecule crystals.  However, this approach 
has limited application to macromolecular structure solution although improved large-
scale computing clusters are providing increased capabilities for such methods (for 
example, ARCIMBOLDO; Rodríguez et al, 2012).  Otherwise, methods of determining 
the phase include molecular replacement (MR), single or multiple wavelength 
anomalous dispersion (SAD or MAD) and single or multiple isomorphous replacement 
(SIR or MIR) (Taylor, 2003).  A combined use of isomorphous and anomalous 
scattering methods are also possible (SIRAS or MIRAS). 
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MR can be employed when a structure of a related protein is available (Rossmann and 
Blow, 1962).  The model must share a structurally similar fold as the target protein 
which is typically indicated by a sequence identity of at least 25 % (Taylor, 2003), 
although there will undoubtedly be exceptions.  Patterson maps can be calculated 
without knowledge of the phases for both the target protein using the amplitudes of the 
diffraction data and for the homologous structure based on the known atomic 
coordinates.  The Patterson function, originally introduced by Patterson (1934; 1935), 
can be described as 
𝑷 𝒖,𝒗,𝒘 =   𝟏𝐕 |𝑭(𝒉𝒌𝒍)|𝟐𝐞  !𝟐𝝅𝒊  (𝒉𝒖!𝒌𝒗!𝒍𝒘  )𝒉𝒌𝒍  
where V is the volume of the unit cell, (u,v,w) is a point on the Patterson map and 
|F(hkl)| represents the amplitudes for a set of indices, hkl.  It can be applied to obtain 
information relating to the interatomic distances within the structure.  A successful 
solution requires the superimposition of the search model Patterson function onto that of 
the target (Rossmann and Blow, 1962), first identifying the correct orientation by 
rotation and subsequently the translated positional component. 
 
Isomorphous crystals can be soaked with heavy atoms and intensity differences for the 
derivatives used to solve the phase problem (Perutz, 1956).  Diffraction datasets are 
collected from a native crystal and one (SIR) or more (MIR) heavy atom derivatives and 
the differences in measured reflection intensities can allow the heavy atom locations to 
be derived by the analysis of Patterson maps. 
 
Anomalous dispersion methods, SAD and MAD, exploit wavelength-dependent 
properties of certain atoms within a native or derivative crystal (Hendrickson et al., 
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1985).  In particular, sulfur atoms of cysteine and methionine residues can provide 
sufficient anomalous signal at a Cu Kα home source (Doutch et al., 2012) or crystals 
grown using protein that incorporates seleno-methionine in place of methionine 
(Hendrickson et al., 1990) can be used to identify the selenium atoms at synchrotron 
beamlines by utilising a shorter wavelength.  Many other elements can be used in this 
manner, including iodine or other heavy atoms soaked or co-crystallised with the target 
protein, and each display a unique absorption curve (Merritt, 2012).  These profiles 
provide the elemental absorption edge, when the X-ray photons of a particular 
wavelength are absorbed by the atom to promote an electron from an inner shell.  X-
rays are then scattered with an altered phase  For native data, Friedel’s law denotes that 
the intensities of a reflection, (h,k,l), are equal to that of the symmetry-related reflection, 
(-h,–k,–l), but this does not hold in the presence of an anomalous scatterer (Taylor, 
2010).  The resultant difference, the anomalous or Bijvoet difference, can then be used 
to derive the positions of the anomalous scattering atoms, producing a substructure that 
can be used to provide phases for the rest of the structural model (Taylor, 2010).  The 
anomalous differences are apparent at all wavelengths but are greatest at the absorption 
edge.  Data collected at more than one wavelength during a MAD experiment 
maximises the effect, where the absorption peak, inflection and remote X-ray energies 
are typically selected (Burla et al., 2004).  Accurate measurements are required as the 
differences can be relatively small and highly redundant data are usually necessary to 
ensure this accuracy.  Providing radiation damage is not significant, SAD or MAD can 
be performed using a single crystal and in the absence of a structurally similar model 
suitable for MR, the popularity of SAD, typically at or close to the absorptive peak 
wavelength, to solve the phase problem is increasing (Liu et al., 2012). 
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Once known, phases can be used to provide an electron density map (Hauptman, 1991).  
Phases can be improved through density modification and cycles of model building by 
interpretation of the electron density maps and refinement procedures.  More structural 
information provides improved phases, which can then present more interpretable 
features.  One way to monitor progress of the cyclic model fitting process is the 
calculation of residual factors or R-factors.  A subset of data, typically around 5 % of 
the total, are excluded from the calculations of the working R-factor, Rwork, so that this 
Rfree should remain unbiased (Brünger, 1992).  Overall, the R-factors reflect how well 
the structural model represents the experimental data and can act as a guide to the 
investigator, or an observer, as to the quality of the structural model.  Rwork and Rfree 
should generally remain within approximately 5 % of each other.  In a perfect structural 
model, an Rfactor of zero would result but in macromolecular crystallography, this figure 
is often much higher (Wilson, 1950) due to errors in the data and model and is usually 
related to the diffraction data resolution. 
 
1.5. Aims 
Trypanosomatids represent a valuable eukaryotic model organism and in particular, 
studies of the biology of the flagellum and the architecture of the trypanosome 
cytoskeleton are areas that may offer wider scientific relevance.  Despite the importance 
of microtubules in these organisms, there is currently little biochemical and structural 
information on tubulin folding and microtubule formation in trypanosomatid parasites.  
At the beginning of the studies presented in this thesis, no structure of a protist TBC 
was known.  We aim to generate recombinant gene expression systems for the TBCs 
from the genetically tractable species, T. brucei and L. major.  Isolation and 
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crystallisation of these proteins will then form the basis of structural examination using 
X-ray crystallographic methods.  Structural features that are conserved between 
organisms can contribute to a fundamental understanding of eukaryotic biology while 
differences between the TBCs from different organisms can provide insight into 
specialist features of trypanosomatid parasites.  Ultimately, advancement in the 
biological understanding of the trypanosomatids can provide a stronger basis for drug 
development. 
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2.1. Materials 
2.1.1. General reagents 
All chemical reagents were purchased from Sigma-Aldrich, VWR International (BDH 
Prolabo and AnalaR Normapur branded products) or Formedium unless otherwise 
indicated.  Restriction endonucleases were purchased from New England Biolabs UK.  
Oligonucleotides were custom synthesised by Thermo Fisher Scientific.  HyperLadder I 
DNA standard molecular weight marker was purchased from Bioline Reagents Ltd. 
 
Materials for routine SDS-PAGE were purchased from both Life Technologies and Bio-
Rad including pre-cast Novex NuPAGE Bis-Tris gels, Mini-PROTEAN TGX Stain-
Free gels and corresponding running buffers.  Protein standard markers were also from 
either Life Technologies (SeeBlue Plus2 Pre-Stained Standard) or Bio-Rad (Precision 
Plus Protein All Blue and Unstained standards).  Coomassie-based InstantBlue protein 
stain was obtained from Expedeon. 
 
2.1.2. Bacteria and media 
All strains of Escherichia coli were purchased from Stratagene unless included within a 
molecular biology cloning kit, such as Life Technologies’ TOP10 competent cells.  
Lysogeny Broth (LB; Bertani, 1951) and Autoinduction (AI) liquid media (Studier, 
2005) were prepared by the College of Life Sciences Media Services (University of 
Dundee).  LB-agar plates were also provided by this service.  
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2.2. Molecular biology 
2.2.1. Tubulin-binding cofactors 
Genes predicted to encode TBCs A-E were identified in T. brucei and L. major strains 
927 and Friedlin, respectively, from annotations available in GeneDB (Logan-Klumpler 
et al., 2012).  Oligonucleotide primers were designed to amplify the full-length open 
reading frames from genomic DNA (gDNA) by polymerase chain reaction (PCR).  
Additional nucleotides were engineered at both the 5ʹ′ and 3ʹ′ ends based on known 
restriction endonuclease recognition sequences to allow subcloning into the expression 
vector, pET15b-TEV (modified from pET15b, Novagen).  Under the control of the T7 
promoter, this vector produces protein with an N-terminal hexa-histidine tag that is 
cleavable by tobacco etch virus (TEV) protease.  A full list of primers is given in Table 
2.1.  PCR was carried out using KOD Hot Start DNA polymerase (Life Technologies) 
according to the manufacturer’s guidelines. Typically, a 50 µL reaction mixture was 
composed of 0.3 µM sense and anti-sense primers, 0.2 mM each dNTP, 1.5 mM 
MgSO4, 0-2.5 % (v/v) DMSO, 100 ng gDNA template and 1 U polymerase in 
associated buffer.  Thermal cycling conditions are summarised in Table 2.2. 
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Target 
Protein 
GeneDB ID PCR Primers (5ʹ′  to 3ʹ′) Restriction 
enzyme 
TbTBCA Tb11.01.7825 CATATGTCGACAAGTGAGGGCAATGC 
GGATCCTTATTGTTTAGACAAAGTTAGCTGTGC
AC 
NdeI 
BamHI 
 
TbTBCB Tb10.61.2930 --- --- 
TbTBCC Tb11.01.1240 CATATGGAGGAAAGGTTTCTTAGAACG 
GGATCCTCATACCGCAGCAGCATCC 
NdeI 
BamHI 
TbTBCD Tb927.8.6200 ATTAATATGGATGGTGAACAATTAGAAACAGAT
CCCCTCACG 
AGATCTTCAGTACCCTGCCTCATGTACGAGATG
TAGGTATG 
AseI 
 
BglII 
TbTBCE Tb927.3.2680 CTCGAGATGGCGAGTCCGGAAGTCAG 
CTCGAGTCAACTCCGAAGGGATGTGTC 
XhoI 
XhoI 
LmTBCA LmjF32.2970 CATATGATGTCTGATTCTACTGAATCCACC 
GGATCCTTACGAAACTGCCGCTTGGCCGTC 
NdeI 
BamHI 
LmTBCB LmjF18.0460 CATATGTCTATTGTAAAGGTAATGATC 
GGATCCTCAGTATTCTTGAGGAGGAAAG 
NdeI 
BamHI 
LmTBCC LmjF36.3160 CATATGGAGGCGAAGTTCCTCAAGCTGC 
GGATCCTCAATGGTCTGCGGCAACGGTGGAG 
NdeI 
BamHI 
LmTBCD LmjF24.2020 CATATGCCTTCACCTCACATGGAGAAGGTGCCA
ATG 
GGATCCTCAGTAGCCGGTCTCCTGCACGAGCGA
CTTG 
NdeI 
 
BamHI 
LmTBCE LmjF03.0770 CATATGCCGTCCCCGTCGTCATCGACG 
GGATCCTTACCGCAACGAGGCGTCCTCGACG 
NdeI 
BamHI 
Tbα- 
tubulin 
Tb927.1.2340 CATATGCGTGAGGCTATCTGC 
GGATCCCTAGTACTCCTCCACATCC 
NdeI 
BamHI 
Tbβ-
tubulin 
Tb927.1.2370 CATATGCGCGAAATCGTCTGCGTTCAG 
CTCGAGCTAGTATTGCTCCTCCTCGTCG 
NdeI 
XhoI 
Lmα-
tubulin 
LmjF13.0280 CATATGATGCGTGAGGCTATCTGC 
GGATCCTTAGTACTCCTCGACGTCC 
NdeI 
BamHI 
Lmβ- 
tubulin 
LmjF33.0794 CATATGCGTGAGATCGTTTCCTGC 
AGATCTCTAGTAGGCCTCCTCtTCCTC 
NdeI 
BglII 
Table 2.1. TBC and tubulin PCR primers 
All primers used for PCR of TBCs and tubulins from T. brucei and L. major in conjunction with 
the GeneDB accession ID and restriction enzymes used for subcloning.  Underlined nucleotides 
are enzyme recognition sites and in lower case are any silent mutations introduced to avoid 
primer self-complementarity.  TbTBCB was the subject of studies by colleagues Rachel Morgan 
and Jennifer Fleming and is included in this list for completeness only. 
 
Blunt-ended PCR products were ligated into pCR-Blunt II-TOPO (Life Technologies) 
and transformed to TOP10 cells.  The product was digested with appropriate restriction 
endonucleases, creating cohesive ends and allowing insertion into pET15bTEV using 
T4 DNA ligase (New England Biolabs).  Final plasmid DNA were transformed to 
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selected competent E.coli cells via the 42°C heat-shock technique (Maniatis et al., 
1982; Sambrook et al., 1989). 
PCR Stage Temperature (°C) Time (s)  
Polymerase activation 95 120  
Denaturation 95 20 Repeated for 
30 cycles Annealing Primer Tm 10 Extension 70 15-20 kb-1 
Final Extension 70 300-600  
Storage 4 ∞  
Table 2.2. PCR parameters 
Summary of PCR parameters used to amplify TBC and tubulin gene sequences from gDNA.  
Primer melting temperatures (Tm) were estimated using OligoCalc (Kibbe, 2007). 
 
2.2.2. Tubulin 
Based on work published by Giles et al. (2009) and GeneDB annotated sequences 
(Logan-Klumpler et al., 2012), genes encoding T. brucei and L. major α- and β-tubulin 
were cloned from gDNA following the same protocols as the TBCs.  Details are 
included in Tables 2.1 and 2.2.  Final gene sequences were inserted into expression 
vectors pET15b-TEV, pET15b-MBP-TEV (modified from pET15b-TEV) and pGEX-
6P-1-TEV (modified from pGEX-6P-1, GE Healthcare).  The latter two vectors 
contained sequences encoding maltose-binding protein (MBP) and glutathione-S-
transferase (GST) fused to the N-terminus of the protein of interest, both cleavable by 
TEV protease.  The MBP fusion construct was based on the pET15b-TEV vector while 
the GST fusion construct maintained its original pGEX-6P-1 backbone with the 
precision protease recognition site replaced with that of TEV protease. 
 
2.2.3. Truncated TBC construct design 
All full-length annotated sequences were examined using several bioinformatic 
approaches including the secondary structure prediction software PSIPRED (Jones, 
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1999), the disorder predictor GlobPlot (Linding et al., 2003) and the crystallisability 
prediction tool XtalPred (Slabinski et al., 2007).  Accompanied by manual inspection of 
multiple sequence alignments (MUSCLE; Edgar, 2004), these programs assisted in the 
design of a number of truncated and globular domain constructs.  For most constructs, 
PCR using the corresponding full-length plasmid as template DNA was followed by 
cloning procedures as discussed previously.  Selected constructs were generated using 
Genscript’s CloneEZ system where primers contained additional bases at the 5'-end 
corresponding to the target vector sequence.  PCR products were inserted directly into 
linearised vector using the CloneEZ recombination enzyme.  All truncated TBC 
constructs are shown in Table 2.3. 
 
2.2.4. Site-directed mutagenesis 
Conservative leucine-methionine mutations were introduced to the LmTBCC C-terminal 
domain construct referred to from this point as LmTBCC152 (LmTBCC residues 152-
335).  Primers to generate L215M and L223M mutants were designed with the aid of 
Agilent Technologies’ QuikChange primer design tool (Novoradovsky et al., 2005) and 
OligoCalc (Kibbe, 2007) (Table 2.3).  PCR was carried out using PFU Ultra HF 
polymerase (2.5 U, Stratagene).  Also included in the PCR mixture were 125 ng sense 
and antisense primers, 0.2 mM each dNTP and 5 ng non-mutated plasmid template.  16 
cycles of 95°C (30 s), 55°C (1 min) and 68°C (1 min kb-1) were followed by treatment 
with dpnI (10 U) and the final sample transformed to XL1 Blue cells.  This process was 
repeated to generate a third construct containing both mutations. 
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Template Construct PCR Primers (5ʹ′  to 3ʹ′) Restriction 
enzyme 
TbTBCA 5-128 CATATGGAGGGCAATGCTGCTAATCGC 
GGATCCTTACGAAACTGCCGCTTGGCCGTC 
NdeI 
BamHI 
 19-128 CATATGGCTGAAGATCCTTTTGTAAAGGCTC 
GGATCCTTACGAAACTGCCGCTTGGCCGTC 
NdeI 
BamHI 
TbTBCC 1-107 CATATGGAGGAAAGGTTTCTTAGAACG 
GGATCCTCAGGATCGGGGCCCCTG 
NdeI 
BamHI 
 1-112 CATATGGAGGAAAGGTTTCTTAGAACG 
GGATCCTCAAGAGGAAAACTTGAAGGATCGG 
NdeI 
BamHI 
 138-308 CATATGGAACCGGAACTTCCTGCAG 
GGATCCTCATACCGCAGCAGCATCC 
NdeI 
BamHI 
 149-308 CATATGGCACGTGACAGAACGCTATG 
GGATCCTCATACCGCAGCAGCATCC 
NdeI 
BamHI 
TbTBCE 1-208 CTCGAGATGGCGAGTCCGGAAGTCAG 
CTCGAGTCAATTCTTGTTAGCTTCGTGAAGGATG 
XhoI 
XhoI 
 44-208 CTCGAGCTTGTTGGGATGGAGAAAACTCG 
CTCGAGTCAATTCTTGTTAGCTTCGTGAAGGATG 
XhoI 
XhoI 
 294-531 CATATGTCCCTCGTGGATTACGCGTATC 
CTCGAGTCAACTCCGAAGGGATGTGTC 
NdeI 
XhoI 
 314-531 CATATGACCATCACAGATGCATGCACACTG 
CTCGAGTCAACTCCGAAGGGATGTGTC 
NdeI 
XhoI 
 436-531 CATATGGCAAGTCACGATGGTACCATGC 
CTCGAGTCAACTCCGAAGGGATGTGTC 
NdeI 
XhoI 
LmTBCA 20-125 CATATGGCGCCGAACGAAAAGACGCTG 
GGATCCTTACGAAACTGCCGCTTGGCCGTC 
NdeI 
BamHI 
LmTBCB 1-138 * GTATTTTCAGGGCCATATGTCTATTGTAAAG 
GTTAGCAGCCGGATCCTTACACTCCAATGCCAG 
NdeI 
BamHI 
 1-151 * GTATTTTCAGGGCCATATGTCTATTGTAAAG 
GTTAGCAGCCGGATCCTTACGCCTCCGTCTTG 
NdeI 
BamHI 
 1-165 * GTATTTTCAGGGCCATATGTCTATTGTAAAG 
GTTAGCAGCCGGATCCTTAGCCGGGTTGGCAAC 
NdeI 
BamHI 
 1-222 * GTATTTTCAGGGCCATATGTCTATTGTAAAG 
GTTAGCAGCCGGATCCTTATACCTGATTAG 
NdeI 
BamHI 
LmTBCC 1-103 CATATGGAGGCGAAGTTCCTCAAGCTGC 
GGATCCTCACGCTGCGCCGCTGCAC 
NdeI 
BamHI 
 1-111 * GTATTTTCAGGGCCATATGGAGGCGAAGTTCCTC 
GTTAGCAGCCGGATCCTCACGCCTTGAGGCGTG 
NdeI 
BamHI 
 152-335 * GTATTTTCAGGGCCATATGAGCAGCACCAACG 
GTTAGCAGCCGGATCCTCAATGGTCTGCGGCAAC 
NdeI 
BamHI 
 164-335 * GTATTTTCAGGGCCATATGTCCACGGGCACG 
GTTAGCAGCCGGATCCTCAATGGTCTGCGGCAAC 
NdeI 
BamHI 
LmTBCC 
152-335 
L215M GCGTGCCATCAGCTGCGAaTGAAGGGCTG        --- 
CAGCCCTTCAtTCGCAGCTGATGGCACGC        --- 
 L223M GCTGCACAAACCTCGATaTgTACGTGTGGTGCGCG  --- 
CGCGCACCACACGTAcAtATCGAGGTTTGTGCAGC  --- 
Table 2.3. TBC truncated constructs and corresponding PCR primers 
All completed truncated TBC clones are listed.  Constructs are named according to the full-
length template amino acid numbering.  Restriction enzyme recognition sites are underlined and 
mutated nucleotides are in lower case.  Constructs marked with * were cloned using the 
CloneEZ system (Genscript). 
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2.2.5. DNA purification and sequencing 
DNA integrity was monitored throughout all stages of cloning by gel electrophoresis in 
1% agarose gels stained with ethidium bromide (approximately 0.2 µg mL-1).  High 
purity plasmid DNA was prepared using the QIAprep spin miniprep kit (Qiagen) and 
digested DNA fragments excised from agarose gels were purified using the QIAquick 
gel extraction kit (Qiagen) according to the manufacturer’s instructions.  An extinction 
coefficient of 0.02 µg mL-1 cm-1 at 260 nm was used to estimate DNA concentration.  
Sample quality was further assessed by ensuring an A260/280 of approximately 1.8 
(values significantly lower than 1.8 may be indicative of protein contamination).  All 
final DNA constructs were verified by DNA sequencing (DNA Sequencing Service, 
University of Dundee).  Where required, additional internal primers were designed to 
collect sequence data along the entire length of the gene of interest. 
 
2.3. Gene expression and protein purification 
2.3.1. Recombinant protein production 
Plasmids containing the target genes were transformed into E.coli BL21 (DE3) Gold or 
BL21 (DE3) pLysS cells for expression.  For proteins produced in LB, each 1 L media 
containing 50 mg L-1 carbenicillin (and 25 mg L-1 chloramphenicol if required) was 
inoculated with 15 mL starter culture and grown in 2 L Erlenmeyer flasks at 37°C in an 
Infors standard shaking incubator (200 rpm) until the optical density (OD) at 600 nm 
reached 0.6-0.8.  Cultures were cooled, expression induced with 0.5-1 mM isopropyl 
thio-β-D-galactoside (IPTG) and growth continued at 18-22°C for 16 h.  For expression 
using AI media, a freshly transformed cell colony was added directly to the broth and 
allowed to grow for 72 h at room temperature with agitation at 200 rpm.  LmTBCD was 
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expressed using ArcticExpress (DE3) cells in LB.  Cultures were grown at 30°C to an 
OD600 of 1-2 then induced with 0.5 mM IPTG and incubated at 12.5°C for 16 h.  All 
cells were harvested by centrifugation at 4000 rcf for 30 min at 4°C and cell pellets 
resuspended in appropriate lysis buffer for storage at -20°C. 
 
2.3.2. Protein purification 
Quantification of TBCA constructs was carried out via the measurement of absorbance 
at 595 nm in Coomassie (Bradford) protein assay reagent (Thermo Fisher Scientific) 
using bovine serum albumin as a reference (based on Bradford, 1976).  Protein presence 
was monitored during purification by both A280 and A215.  All other proteins were 
quantified by the measurement of absorbance at 280 nm and concentration estimated 
using theoretical extinction coefficients (ProtParam; Gasteiger et al., 2005).  Size 
exclusion chromatography columns (GE Healthcare) were all previously calibrated 
using molecular mass standards from Bio-Rad (thyroglobulin, 670 kDa; γ-globulin, 158 
kDa; ovalbumin, 44 kDa; myoglobin, 17 kDa; vitamin B12, 1.35 kDa) and were 
equilibrated in corresponding running buffer prior to use.  All immobilized metal 
affinity columns were pre-loaded with NiCl2 and washed with relevant buffer solution.  
ÄKTA Explorer, Purifier and Prime systems (GE Healthcare) were used throughout and 
all buffers were filter sterilised (0.2 µm) and degassed prior to use.  Standard 
purification buffers are provided in Table 2.4. 
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Buffer Name Buffer 
Lysis 50 mM Tris-HCl pH 7.5, 250 mM NaCl, 20 mM imidazole 
Elution 50 mM Tris-HCl pH 7.5, 250 mM NaCl, 800 mM imidazole 
Gel Filtration 50 mM Tris-HCl pH 7.5, 250 mM NaCl 
Table 2.4. Standard purification buffers 
The composition of standard purification buffers.  Alteration to these standard buffers are 
detailed where appropriate. 
 
Purification of all recombinant native TBCs followed the same general procedure.  
Frozen cells were thawed and resuspended in additional lysis buffer supplemented with 
an EDTA-free protease inhibitor cocktail tablet (Roche) and approximately 10 µg mL-1 
deoxyribonuclease I (DNaseI).  Cells were lysed using a French pressure cell press at 16 
kpsi and lysate was clarified by centrifugation at 37,500 rcf for 30 min at 4°C.  Soluble 
supernatant was filtered (0.2 µm) and loaded onto a 5 mL HisTrap HP column (GE 
Healthcare) for an initial affinity chromatography capture step.  A gradient of 20-800 
mM imidazole was applied.  Eluate containing the over-expressed his-tagged protein of 
interest was treated with TEV protease at 22-30°C for 1-3 h.  Dialysis to remove excess 
imidazole was followed by reverse affinity chromatography.  Cleaved protein no longer 
bound to the column and was therefore separated from any histidine-rich contaminants, 
the protease and the cleaved peptide during this step.  Purification was finalised by size 
exclusion chromatography using a Superdex 75 or Superdex 200 26/60 gel filtration 
column.  Proteins were then dialysed and concentrated using centrifugal concentrator 
filter units with an appropriate molecular weight cutoff (Millipore or Sartorius).  All 
proteins were stored at 4°C and further experiments performed within one week of 
purification.  The mass of all final samples was verified by matrix-assisted laser 
desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF, University of 
Dundee Proteomics Facility) and purity assessed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). 
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2.3.3. Selenomethionine protein preparation 
Selenomethionine-labelled LmTBCA and LmTBCC152 mutant constructs (L223M and 
L215M/L223M double mutant) were prepared following an established protocol (Hall 
et al., 1999).  E.coli B834 (DE3) cells, which are auxotrophic for methionine, were 
transformed with the appropriate expression plasmid and cultured in minimal media 
(Molecular Dimensions).  This media, containing all amino acids except L-methionine, 
was supplemented with 40 mg L-1 selenomethionine (Molecular Dimensions) and 50 
mg L -1 carbenicillin.  Bacteria were cultivated at 37°C to mid-log phase.  Following 
IPTG induction, incubation at 22°C was continued for a further 16 h.  Cells were then 
harvested, lysed and the selenomethionyl-proteins were purified as described for native 
TBCs.  Selenomethionine (SeMet) incorporation was confirmed by MALDI-TOF 
analysis. 
 
2.3.4. TEV protease preparation 
Catalytically active recombinant TEV protease was overproduced (pRK793 expression 
system; Kapust et al., 2001) and purified by similar protocols to those described above.  
Briefly, 1 mM IPTG was used to induce expression in BL21 (DE3) Codon Plus RIL 
cells cultured in LB.  The histidine-tagged enzyme was purified by a single affinity 
chromatography step.  Purified TEV protease was flash cooled in liquid nitrogen in 1 
mg aliquots (typically 2-5 mg mL-1) and stored at -80°C in 50 mM sodium phosphate 
buffer pH 8.0 containing 150 mM NaCl, approximately 250 mM imidazole, 10 % (v/v) 
glycerol, 1 mM dithiothreitol (DTT) and 1 mM EDTA.  1 mg TEV protease was used to 
cleave up to 20 mg tagged target protein. 
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2.3.5. Small scale test expression 
The recombinant expression of TBCs B, D, E and all tubulin constructs was first tested 
on a small-scale.  Typically, cells (BL21 (DE3) GOLD, BL21 (DE3) pLysS or Rosetta 
(DE3) pLysS) containing the relevant expression plasmid were grown in 15-20 mL 
liquid media (LB, AI or NZCYM (Blattner et al., 1977)) at 37°C or ambient 
temperature.  Expression was induced with 0.1-1 mM IPTG for cultures not grown in 
AI media.  After induction, incubation temperature and duration were also varied.  Cells 
were harvested by centrifugation and lysed chemically using BugBuster Mastermix 
(Novagen) according to the manufacturer’s protocol.  Soluble and insoluble cell lysate 
were then analysed by SDS-PAGE and immunoblot if required. 
 
2.3.6. Western blot analysis 
A Western blot was carried out to confirm the presence of target protein, if not apparent 
by SDS-PAGE.  Following separation by SDS-PAGE, proteins were transferred to a 
polyvinylidene difluoride (PVDF) membrane using a Trans-Blot Turbo transfer pack 
and system (Bio-Rad).  The membrane was then blocked using 5 % (w/v) dried 
skimmed milk followed by sequential applications of primary and secondary antibodies.  
Mouse monoclonal antibodies to 6XHis-tag or GST (1-3 µg, Abcam) were used as 
primary antibodies and the secondary antibody was anti-mouse IgG (raised in goat) 
conjugated to horseradish peroxidase (HRP) (0.25-0.7 µg, Sigma-Aldrich).  Dilutions 
and wash steps were performed in phosphate-buffered saline (PBS) supplemented with 
0.05 % (v/v) polysorbate 20.  Pierce ECL Plus Western blotting substrate from Thermo 
Fisher Scientific was used to detect the secondary antibody HRP.  Lumi-film 
chemiluminescent detection film (Roche) was then exposed to the membrane (1-30 
 
 
Part I Tubulin-binding cofactors  Chapter 2: Materials and methods 
32 
minutes) and developed using a Compact X4 automatic X-ray film processor (Xograph 
Healthcare). 
 
2.3.7. Protein identification 
To confirm the identity of recombinant TBC and tubulin proteins and to investigate 
signs of degradation or proteolysis of full-length LmTBCA, TbTBCC and LmTBCC, 
samples were subjected to SDS-PAGE and the protein bands visualised using 
Coomassie-based stain.  Appropriate gel bands were excised and subjected to trypsin 
digestion.  Peptides were identified by reverse phase liquid chromatography on a 4000 
QTRAP LC/MS/MS system (AB SCIEX) and data were analysed using the MASCOT 
search engine (Matrix Science; Proteomics Facility, University of Dundee). 
 
2.3.8. LmTBCC152 size exclusion chromatography 
Approximately 0.4-0.5 mg freshly purified (stored 1-2 days at 4°C) LmTBCC152 was 
passed through a Superdex 75 10/300 size exclusion column pre-equilibrated with either 
standard gel filtration buffer (Table 2.4) or 50 mM MES, 250 mM NaCl pH 6.5 to 
mimic the buffer composition during crystallisation.  A sample of protein prepared 
previously and stored at 4°C for 30 days was passed through the same column in 
standard gel filtration buffer only.  Two further experiments were carried out using 
monomeric and multimeric species immediately after isolation from a Superdex 75 
26/60 column. 
 
 
 
 
 
Part I Tubulin-binding cofactors  Chapter 2: Materials and methods 
33 
2.3.9. Buffer extraction screen 
Full-length LmTBCD and LmTBCE were cultured as described (2.3.1).  Cells were 
distributed equally in a 24-well round-bottomed block (Qiagen), harvested and frozen at 
-20°C.  Approximately 0.15 g cell paste per well was resuspended in 0.75 mL of 
solution containing BugBuster protein extraction reagent (Novagen), DNaseI and one of 
24 buffers originally developed for a protein solubility screen (Fyfe, 2008; Table 2.5).  
Standard lysis buffer was used as a control sample.  As for small-scale expression tests, 
following centrifugation, soluble lysates were assessed by SDS-PAGE and Western 
blot.  
Position Buffer (0.1M) pH Position Buffer (0.1M) pH 
A1 Glycine 3 C1 PIPES 7 
A2 Citric acid 3.2 C2 MOPS 7 
A3 Sodium acetate 4 C3 Sodium/Potassium phosphate 7 
A4 Citric acid 4.5 C4 HEPES 7.5 
A5 Sodium acetate 5 C5 Tris 7.5 
A6 Sodium citrate 5.5 C6 (H)EPPS 8 
B1 Sodium/Potassium phosphate 6 D1 Imidazole 8 
B2 Bis-tris 6 D2 Borate (from acid) 8.5 
B3 MES 6.2 D3 Tris 8.5 
B4 ADA 6.5 D4 Bicine 9 
B5 Bis-tris propane 6.5 D5 CHES 9.5 
B6 Sodium cacodylate 6.5 D6 CAPS 10 
Table 2.5. Buffer extraction screen 
A list of the buffers used in a 24-well protein extraction screen. 
 
2.4. Differential scanning fluorimetry 
2.4.1. Thermal stability buffer screen 
Differential scanning fluorimetry (DSF) was used to examine the potential stabilising 
effects of different buffer conditions.  A thermal stability buffer screen was carried out 
according to methods similar to those described by Niesen et al. (2007).  Protein was 
prepared to a final concentration of 5 µM in 10 mM HEPES, 150 mM NaCl pH 7.5 
supplemented with SYPRO orange fluorescent dye (Life Technologies).  23 buffers, 
 
 
Part I Tubulin-binding cofactors  Chapter 2: Materials and methods 
34 
prepared at 4x stock concentration, were added to the protein-dye mixture to a final 1x 
working concentration in a total volume of 40 µL.  Each reaction was carried out in 
duplicate or triplicate in a thin-walled 96-well ABgene PCR plate (Thermo Fisher 
Scientific) sealed with a transparent adhesive PCR seal (4titude).  Fluoresence readings 
were measured (excitation and emission wavelengths of 492 and 610 nm, respectively) 
using an Mx3005P QPCR system (Stratagene) and the incubation temperature was 
increased from 25°C to 95°C at 1°C min-1.  Data were analysed to calculate protein 
melting temperatures (Tm) using the QPCR system software, MxPro and GraphPad 
Prism (GraphPad Software). 
 
2.4.2. GTP-binding screen 
LmTBCC152 was prepared in 20 mM Tris-HCl pH 7.5, 100 mM NaCl plus SYPRO 
orange dye as for the DSF buffer screening assay described above (2.4.1).  The addition 
of different buffers as potential stabilising agents was replaced with 0-100 µM GTP and 
the same program executed. 
 
2.5. Isothermal titration calorimetry 
The ability of LmTBCC152 to bind GTP was tested via isothermal titration calorimetry 
(ITC).  In brief, 0.2 mM GTP was titrated against 20 µM LmTBC152 in 50 mM PIPES, 
100 mM NaCl pH 7 at 30°C.  Further experimental details of this technique are 
provided in Part II (5.5). 
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2.6. Circular dichroism 
Circular dichroism (CD) was performed on full-length TbTBCA and TbTBCC.  Proteins 
were prepared in compatible buffer (20 mM Tris-HCl pH 7.5, 20 mM NaCl; Kelly et 
al., 2005) and experiments carried out by Sharon Kelly (Protein Characterisation 
Facility, University of Glasgow).  Far UV spectra were recorded on a JASCO J-810 
spectropolarimeter in 0.02 cm pathlength quartz cuvettes with a bandwidth of 1 nm at 
50 nm min-1 and a 0.5 s response time.  The results of 5 scans were averaged and 
secondary structure estimates obtained using the CONTIN algorithm (Provencher and 
Glöckner, 1981; van Stokkum et al., 1990) available on the DICHROWEB server 
(Lobley et al., 2002; Whitmore and Wallace, 2004). 
 
2.7. Crystallisation 
2.7.1. Crystallisation screening 
Sparse-matrix and focussed crystallisation screens were purchased from Molecular 
Dimensions (JCSG+, PGA, MIDAS and Morpheus) and Qiagen (Classics, PEGs, MPD 
and AmSO4).  These suites are each composed of 96 unique pre-mixed conditions 
designed to exploit known crystallisation agents whilst covering a wide chemical space, 
resulting in the highest possible crystallisation hit rates.  60 µL of each solution was 
dispensed into the reservoirs of MRC 96-well polystyrene sitting-drop plates (Molecular 
Dimensions) using a JANUS Automated Workstation (PerkinElmer).  A Phoenix DT 
crystallisation robot (Art Robbins Instruments and Rigaku) was used to dispense two 
0.1-0.2 µL drops of reservoir solution mixed with 0.1-0.2 µL protein at desired 
concentration (typically 5-10 mg mL-1 in the first instance).  Crystallisation plates were 
incubated at room temperature and regular images taken by an automated Minstrel DT 
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imaging system (Rigaku).  Images were inspected using the associated CrystalTrak 
software to identify potential crystallisation hits.  All proteins of satisfactory purity 
were subjected to this screening process and were filtered (0.1 µm) immediately prior to 
use.  Any potential screening hits were subsequently scaled up and further optimised to 
24-well VDX hanging drop plates with 1 mL reservoir volume and 22 mm siliconised 
glass cover slides (Hampton Research). 
 
2.7.2. LmTBCA crystallisation 
Initial crystal hits of the shortened construct LmTBCA20-125 were obtained and 
subsequently reproduced using full length LmTBCA.  Following several rounds of 
optimisation, crystallisation was achieved at 18°C using the hanging-drop vapour-
diffusion method.  Native untagged protein at 4 mg mL-1 in 50 mM Tris-HCl pH 7.5, 
100 mM NaCl was mixed with an equal volume of reservoir solution (0.2 M 
(NH4)2HPO4 and 1.6 M (NH4)2SO4) and crystals appeared within 1-3 days.  SeMet-
LmTBCA crystals were grown using the same technique with protein at 3.8 mg mL-1 
and reservoirs containing 0.3 M LiCl and 1.0 M (NH4)2SO4. 
 
2.7.3. LmTBCC152 crystallisation 
2.7.3.1. Screening hits 
Crystals of poor morphology were first produced in a number of conditions of the PEGS 
suite using native LmTBCC152 at 7.3 mg mL-1 in 20 mM Tris-HCl pH 7.5, 100 mM 
NaCl.  Extensive attempts to optimise these hits were made, of which a selection are 
detailed below. 
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2.7.3.2. General optimisation 
Initial hits were reproduced in both sitting-drop and hanging-drop formats.  General 
optimisation of these hits included varying factors such as protein and precipitant 
concentration via the actual solution concentrations or through the protein:precipitant 
ratio within each drop.  Crystallisation buffer type and pH was varied and protein 
sample buffer was altered according to the results of a DSF buffer screen.  The effect of 
filtering protein samples was examined (Chayen, 2009) as well as the overall incubation 
temperature (4 and 18°C). 
 
2.7.3.3. Reductive methylation 
Reductive methylation of LmTBCC152 lysine residues was carried out according to 
methods described by Kim et al. (2008), based on earlier studies by Rypniewski et al. 
(1993) and Rayment (1997).  This method selectively modifies the amino group of 
lysine residues with the substitution of a terminal methyl group, potentially altering the 
protein surface and crystallisation properties.  In brief, LmTBCC152 at 5 mg mL-1 in 50 
mM HEPES pH 7.5, 100 mM NaCl was treated with multiple additions of 
dimethylamine-borane complex and formaldehyde at 4°C.  The reaction was quenched 
with 1 M Tris-HCl pH 7.5 and the protein solution extensively dialysed against the 
original buffer supplemented with 1 mM DTT.  Precipitated material was removed by 
centrifugation and a sample of the final product was sent for MALDI-TOF analysis to 
assess the degree of methylation. 
 
2.7.3.4. Seeding 
Microseeding techniques were employed, where crystal fragments or sub-microscopic 
crystals were used as nucleants in fresh crystal drops (Bergfors, 2003).  Large clusters 
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of crystalline needles grown by methods described above (2.6.3.1) were transferred to a 
sample of mother liquor in a 1.5 mL microcentrifuge tube.  In the presence of a small 
nylon ball (4-5 mm diameter) such as those used in a traditional French pressure cell 
press (or alternatively, a seed bead purchased from Hampton Research), the crystal 
mixture was vigorously agitated using a vortex mixer for 10-60 s (Luft and DeTitta, 
1999).  Crystallisation drops were prepared as previously with reservoirs containing a 
lower precipitant concentration.  For example, 20 % (w/v) polyethylene glycol 
monomethyl ether (PEG 2000 MME) compared to 25 % (w/v) but a gradient of values 
was always screened.  Seed stock was then introduced to the drop and the tray left 
undisturbed for a minimum of 2 days.  Various tools were used to dispense seed mixture 
including a standard nylon loop, a natural fibre seeding device (Hampton Research) and 
even a human eyelash (kindly supplied by Paul K. Fyfe). 
 
For second and third rounds of experiments, seed stocks were obtained from crystals 
grown as a result of initial seeding.  Seed crystals were always collected immediately 
prior to use.  Crystals of different size and appearance were chosen as seeds.  The level 
of dilution in reservoir solution and time of agitation were also varied.  Additionally, 
seeding tools were passed through a drop containing crystal clusters and directly 
streaked through a fresh drop without any dilution or pulverisation (Stura and Wilson, 
1991). 
 
Other optimisation methods were applied in combination with microseeding efforts.  
Sitting-drops were prepared to screen around the hit condition and 0.05 µL seed mixture 
added using the Phoenix crystallisation robot or drops were streak-seeded.  Commercial 
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sparse-matrix and additive screens were repeated with the addition of seed mixture and 
experiments under oil were also performed in the presence of seed material. 
 
2.7.3.5. Crystallisation under oil 
Standard hanging-drops were prepared with a layer of oil applied over the reservoir 
solution as a method of controlling the rate of vapour diffusion (Chayen, 1997a).  A 
mixture of paraffin and silicone oils (Molecular Dimensions) were used in different 
ratios and barrier depths (Chayen, 1997b).  Experiments similar to the microbatch under 
oil technique (Chayen et al., 1990) were performed following protocols used by D’Arcy 
et al. (2003b, 2004).  A 1:1 mixture of paraffin and silicone oils (6 mL) was dispensed 
over the 72 wells of a polystyrene Terasaki plate (Greiner Bio-One).  1 µL each of 
protein and crystallisation solution were then pipetted under the oil layer and incubated 
at 18°C.  Crystallisation solutions were chosen to screen the hits obtained from vapour-
diffusion experiments and an additional sparse-matrix screen (Qiagen Classics) was also 
prepared in this manner. 
 
2.7.3.6. Additives 
Further crystal optimisation efforts involved the addition of small chemical components 
to screen for improved crystal morphology.  This comprised performing a commercially 
available additive screen (Hampton Research).  Manually prepared sitting drops 
containing equal volumes of LmTBCC152 (7 and 5 mg mL-1) and known crystallisation 
solution (0.1 M MES pH 6.5, 30 % (w/v) PEG 2000 MME) were supplemented with 96 
different additives and crystal growth monitored.  Several other chemicals such as 
dioxane and glycerol were added to the crystallisation mixture (5-15 % (v/v)) while 1-2 
mM GTP and/or DTT were added to the protein sample in a bid to enhance 
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crystallisation.  The incorporation of iodide ions to aid experimental crystal phasing 
power was attempted by adding NaI or KI to reservoir solutions (2-10 mM) or as a 
partial replacement for NaCl in the protein sample buffer (10-100 mM). 
 
2.8. X-ray data collection and processing 
2.8.1. X-ray sources 
These studies were carried out using a number of in-house and synchrotron X-ray 
sources, details of which are provided in Table 2.6. 
Source Location Details Detector 
A In-house Rigaku MicroMax-007 Rotating Anode 
Fixed wavelength (1.5418 Å) 
Rigaku R-AXIS 
IV++ Image-plate 
B In-house Rigaku MicroMax-007 HF Rotating Anode 
Fixed wavelength (1.5418 Å) 
Rigaku R-AXIS 
IV++ Image-plate 
C In-house Rigaku MicroMax-007 HFM Rotating Anode 
Fixed wavelength (1.5418 Å) 
Rigaku Saturn 
944 HG CCD 
D ESRF 
ID23-2 
Synchrotron radiation 
Fixed wavelength (0.8726 Å) 
Rayonix 
MarMosaic 225 
CCD 
E DLS I03 Synchrotron radiation 
Tuneable wavelength (0.6-2.48 Å) 
DECTRIS 
PILATUS 6M-F 
F DLS I04 Synchrotron radiation 
Tuneable wavelength (0.62-2.25 Å) 
ADSC 
QUANTUM 315r 
CCD 
Table 2.6. X-ray sources 
Details of all X-ray sources used.  Also included are any sources used for studies discussed in 
Part II.  DLS, Diamond Light Source, Oxfordshire, UK; ESRF, European Synchrotron 
Radiation Facility, Grenoble, France; CCD, Charge Coupled Device. 
 
2.8.2. X-ray diffraction screening 
All crystals were screened in-house prior to any data collection.  Crystals were first 
harvested in a nylon loop (Hampton Research) and cryoprotected.  LmTBCA crystals 
were passed through a cryoprotectant solution containing 0.2 M (NH4)2HPO4, 1.6 M 
(NH4)2SO4, 25 % (v/v) glycerol and placed directly in a stream of gaseous nitrogen.  
LmTBCC152 crystals were cryoprotected by 40 % PEG 400 (v/v) or a fresh preparation 
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of mother liquor containing 20 % (v/v) glycerol and flash cooled in liquid nitrogen.  A 
number of native LmTBCC152 crystals were tested using a cryoprotectant mixture 
supplemented with 0.2-0.5 M NaI. 
 
LmTBCA crystals were tested using sources A and B (Table 2.6) while LmTBCC152 
crystals were tested using source C.  Crystals mounted on a goniostat and cryogenically 
preserved in a stream of gaseous nitrogen were then exposed to X-rays.  Two diffraction 
images were typically collected at phi angles of 0° and 90° (sources A and B) or 70° 
(source C) with a rotation of 0.5° per image.  Images were inspected, the diffraction 
quality and resolution assessed and the highest standard crystals progressed for further 
data collection. 
 
2.8.3. LmTBCA structure solution 
SeMet and native LmTBCA data were collected at source D (Table 2.6) at a fixed 
wavelength of 0.8726 Å to approximately 2.3 Å and 1.9 Å resolution, respectively.  
SeMet data were indexed and integrated using XDS (Kabsch, 2010).  The symmetry was 
assessed and intensity measurements scaled by POINTLESS and SCALA (Evans, 2006) 
in the CCP4 crystallographic software suite (Collaborative Computational Project, 
Number 4, 1994; Winn et al., 2011).  Selenium sites were identified and density 
modification performed using PHENIX (Adams et al., 2010).  Native data were also 
processed using XDS (Kabsch, 2010) followed by POINTLESS and SCALA (Evans, 
2006).  Phaser (McCoy et al., 2007) was used to perform molecular replacement based 
on the initial SeMet model.  The electron density maps and the structural model were 
inspected and manipulated in Coot (Emsley and Cowtan, 2004; Emsley et al., 2010) and 
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alternated with multiple rounds of refinement performed with REFMAC5 (Murshudov 
et al., 2011).  Solvent molecules were placed based on difference density maps, 
chemical environment and were consistent with the crystallisation mixture composition.  
Overall model quality was assessed using MolProbity (Chen et al., 2010) and validation 
tools within Coot (Emsley and Cowtan, 2004; Emsley et al., 2010). 
 
2.8.4. LmTBCC152 
Multiple native LmTBCC152 diffraction datasets were collected using X-ray sources C 
and E (Table 2.6) at various wavelengths (0.9763 Å, 1.5418 Å and 1.7700 Å).  Data 
were collected from two crystals of SeMet-LmTBCC152-L223M at an experimentally 
derived optimum wavelength of 0.9793 Å (source E, Table 2.6).  Data collection 
strategies were followed according to suggestions from MOSFLM (Leslie, 2006; Battye 
et al., 2011), EDNA (Diamond Light Source) and d*TREK (Rigaku). 
 
Data were indexed and integrated where possible using XDS (Kabsch, 2010) or 
MOSFLM (Leslie, 2006; Battye et al., 2011), as stand-alone packages or via the xia2 
pipeline (Winter, 2010), or HKL-3000 (Otwinowski and Minor, 1997).  Scaling was 
performed using AIMLESS (Evans and Murshudov, 2013). The SHELX program suite 
(Sheldrick, 2008; 2010; Grune, 2008; Pape and Schneider, 2004) and Phaser (McCoy et 
al., 2007) were used in attempts to identify selenium or sulfur atom positions using 
SeMet or native data, respectively.  Phaser (McCoy et al., 2007), MOLREP (Vagin and 
Teplyakov, 1997) and PHENIX (Adams et al., 2010) were used to search for a solution 
by molecular replacement.  Search models were prepared using CHAINSAW (Stein, 
2008) or by the PHYRE2 homology model web server (Kelley and Sternberg, 2009).  
Additionally, any models were inspected in Coot (Emsley and Cowtan, 2004; Emsley et 
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al., 2010) and superimposed with published homologues via the secondary-structure 
matching tool (Krissnel and Henrick, 2004) to guide further model adjustments. 
 
2.8.5. Structural analysis 
All structural figures were prepared with PyMOL (DeLano, 2002) and annotated with 
Adobe Creative Suite 5.  Other programs or webservers used in structural analyses are 
cited where appropriate.  LmTBCA coordinates and structure factors were deposited in 
the Protein Data Bank (Bernstein et al., 1977) with accession code 4cqi. 
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3.1. Tubulin-binding cofactor A 
3.1.1. Protein production 
TbTBCA and LmTBCA are short polypeptides composed of 128 and 125 amino acid 
residues, respectively, with an approximate mass of 14 kDa.  Full-length and truncated 
constructs were generated and soluble protein overproduced in E. coli.  TbTBCA cloned 
from gDNA contained an alanine at position 61 in place of the threonine suggested by 
the annotated database sequence (Logan-Klumpler et al., 2012).  This may be an 
artefact introduced during cloning or due to a gDNA strain variant.  All truncated 
TbTBCA constructs also contained this difference as the full-length gene was used as 
template for amplification.  Both TBCAs are tryptophan-deficient and it was necessary 
to monitor the purification by A215 in addition to the standard A280. Two peaks 
corresponding to full-length TbTBCA were observed on size exclusion 
chromatography.  Elution volumes suggested protein species of approximately 43.8 kDa 
and 26.9 kDa.  The oligomeric state of these species cannot be accurately attributed 
since the experimental and expected masses are quite different.  If taken as accurate, the 
larger species corresponds to a trimeric solution while the smaller 26.9 kDa mass 
suggests an intermediate species of between one and two protein chains.  Although 
numerically closer to a dimeric mass, the predicted non-globular shape of TBCA could 
contribute to a non-standard elution of a monomeric sample. TbTBCA circular 
dichroism experiments confirmed the presence of a highly α-helical protein solution 
(Figure 3.1A), in agreement with known structural details of TBCA folding as a 
compact, non-globular molecule.  A similar elution profile was seen for LmTBCA and 
discrepancies in oligomeric state are also reported for other TBCA homologues 
(Steinbacher, 1999; Guasch et al., 2002; Lu et al., 2010).  A trimeric TBCA has not 
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been reported in the literature, only monomer and dimer (Steinbacher, 1999), and a 1:1 
stoichiometric relationship with β-tubulin has been demonstrated using HsTBCA (Llosa 
et al., 1996).  It is therefore believed that Tb and LmTBCA are mainly monomeric in 
solution under the conditions discussed here with two or more monomers also 
interacting to produce a larger unknown oligomer.  Both species were progressed to 
crystallisation experiments. 
 
An additional unusual feature was seen during the purification of LmTBCA.  The 
presence of a double band on SDS-PAGE remained visible after His-tag cleavage and 
was separated following size exclusion chromatography (Figure 3.1B).  A mass 
difference of approximately 1 kDa differentiated the two species, determined by 
MALDI-TOF mass spectrometry.  However, the sample with smaller mass was seen to 
oligomerise while the sample of expected mass behaved as described above.  The exact 
cause of this remains unclear.  Degradation of the N-terminus was not indicated, as both 
species appeared to possess cleavable His-tags.  Protein ID studies proved to be 
inconclusive.  As stated previously, all protein species were kept separate and 
progressed for additional study where possible.  SeMet-LmTBCA did not display this 
unusual behaviour.  Monomeric SeMet-LmTBCA was purified for crystallisation and 
MALDI-TOF mass spectrometry confirmed the full incorporation of selenomethionine 
in place of the five native methionine residues (Figure 3.1C).  
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Figure 3.1. TBCA purification 
(A) TbTBCA circular dichroism far UV spectra.  (B) LmTBCA SDS-PAGE.  Lane 1, molecular 
weight standards; lane 2, His-tagged LmTBCA; lane 3, LmTBCA following His-tag cleavage; 
lane 4, LmTBCA multimeric species; lane 5, LmTBCA monomeric species.  (C) MALDI-TOF 
spectra indicating a mass difference of 218.6 Da between native LmTBCA (upper panel) and 
SeMet-LmTBCA (lower panel).  This agrees with a theoretical mass difference of 234.5 Da for 
the incorporation of five selenomethionine residues. 
 
3.1.2. LmTBCA crystallisation and structure solution 
Several promising LmTBCA crystallisation conditions were identified in initial sparse-
matrix sitting-drop vapour-diffusion screens.  Only the monomeric solution of expected 
full-length mass produced crystal hits.  The predominant precipitating agent was 
(NH4)2SO4 and diffraction quality native and SeMet crystals were grown under 
conditions described in 2.7.2.  Maximum native crystal size was achieved after 
approximately 3-5 days with dimensions of up to 1.0 x 0.2 x 0.2 mm.  Fewer, smaller 
crystals were obtained of SeMet-LmTBCA (Figure 3.2A).   
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Figure 3.2. LmTBCA crystal and diffraction 
(A) A single SeMet-LmTBCA crystal.  (B) and (C) show X-ray diffraction images from a native 
LmTBCA crystal.  The outermost magenta resolution ring represents 1.8Å resolution. 
 
Data collection and processing details are provided in 2.8.3.  Molecular replacement 
using homologue structures as a search model were unsuccessful.  Instead, phases were 
calculated experimentally by SAD through the production of a SeMet derivative.  
Native and SeMet diffraction data extended to 1.9 Å and 2.3 Å, respectively, and an 
example diffraction image is shown in Figure 3.2B-C.  Crystals were isomorphous in 
space group P3121 with unit cell parameters of a = b = 76.8 Å, c = 39.4-39.5 Å, α = β = 
90° and γ = 120°.  A Matthews coefficient (VM) of 2.36 Å3 Da-1 and a predicted solvent 
content of 50 % (Matthews, 1968; Collaborative Computational Project, Number 4, 
1994) indicated the presence of one LmTBCA molecule per asymmetric unit.  Two 
consecutive SeMet residues, equivalent to Met77 and Met78 in native LmTBCA, were 
useful in validating selenium atom positions through inspection of initial electron 
density maps.  Detailed crystallographic refinement statistics are presented in Table 3.1. 
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 SeMet LmTBCA Native LmTBCA 
Resolution range (Å) 39.5-2.3 (2.4-2.3) 39.4-1.9 (2.0-1.9) 
Space Group P3121 P3121 
Unit cell parameters a=b= 76.8, c= 39.5 Å 
α=β= 90, γ=120° 
a=b= 76.8, c= 39.4 Å 
α=β= 90, γ=120° 
Wavelength (Å) 0.8726 0.8726 
No. Reflections 73555 (10683) 130402 (19204) 
No. Unique Reflections 6205 (878) 10821 (1549) 
Rmerge a (%) 13.8 (61.3) 7.3 (44.8) 
Rpim b (%) 5.9 (26.4) 2.2 (13.2) 
Completeness (%) 100 (100) 100 (100) 
Mean I/σ(I) 19.5 (6.0) 24.9 (6.8) 
Redundancy 11.9 (12.2) 12.1 (12.4) 
Wilson B factor (Å2) 35.3 20.9 
Rwork c (%) - 18.5 
Rfree d (%) - 22.8 
R.m.s.d bonds (Å) - 0.0134 
R.m.s.d angles (°) - 1.586 
Total protein residues - 107 
Total protein atoms - 855 
Average protein B factor (Å2) - 27.3 
DPI e (Å) - 0.138 
Ramachandran plot:   
     Favoured (%) - 96.19 
     Allowed (%) - 2.86 
     Outliers (%) - 0.95 
Additional groups:   
     Solvent (No./Average B (Å2)) - 90/35.0 
     Sulfate (No./Average B (Å2)) - 1/33.4 
     Glycerol (No./Average B (Å2)) - 1/39.6 
Table 3.1. LmTBCA data collection and refinement statistics. 
Values in parentheses correspond to the highest resolution shell.  a. Rmerge = ∑h∑i||(h,i) - <I(h)> 
∑h∑i I(h,i); where I(h,i) is the intensity of the ith measurement of reflection h and <I(h)> is the 
mean value of I(h,i) for all i measurements.  b. Rpim, precision-indicating merging R-factor, is 
Rmerge adjusted by a factor of √(1/n-1) where n is the number of times a given reflection is 
observed.  c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed structure factor amplitude and 
the Fc is the structure-factor amplitude calculated from the model.  d. Rfree is calculated with a 
subset of data that are excluded from refinement calculations (5 %) using the same method as 
for Rmerge.  e. DPI, diffraction-component precision index (Cruickshank, 1999). 
 
3.1.3. LmTBCA structure 
LmTBCA is composed of three α-helices, named here as α1, α2 and α3 progressing 
from the N- to C-terminus.  The helices are in an antiparallel arrangement linked by two 
short loops at opposite ends.  The elongated bundle has a maximum length of 
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approximately 59 Å and is 23 Å at its widest.  α1 and α2 have similar lengths of up to 
56 Å and 52 Å, respectively.  α3 is less than half the length of the full monomer at only 
21 Å.  The model contains residues Glu19 to Ser125.  The first 18 residues could not be 
modelled due to the absence of corresponding electron density.  Ten full helical turns 
make up each of the first two helices and α3 has only four turns.  α1 extends from 
residue Asn22 to Ser60, α2 from Asp63 to Lys99 and α3 from Glu108 to Ala122.  The 
loop linker segments are poorly ordered with respect to the well-organised helices.  A 
bend in α1 and α2 of approximately 20-25° gives an overall curved appearance to the 
molecule.  At the same level, both helices appear to twist, allowing for the incorporation 
of α3 (Figure 3.3A). 
 
Figure 3.3. Sulfate bound to the surface of LmTBCA 
(A) Overall view of a single LmTBCA molecule, represented as red ribbons.  Ala43 and Pro80 
are labelled as approximate positions of the bends in α1 and α2.  Sulfate is bound to the surface 
of α1.  (B) A closer view of the surface sulfate coordinating with Arg45 and Arg49 is shown as 
gold (S) and red (O) sticks.  The arginine residues are also coloured by element (C, grey; N, 
blue) and two water molecules are depicted as red spheres.  Blue mesh represents electron 
density (2Fo-Fc contoured at 2 σ) and magenta dotted lines indicate potential hydrogen bonds. 
 
The surface sulfate seen in Figures 3.3A and 3.3B was modelled in a large unoccupied 
tetrahedral mass of electron density located between two arginine residues (Arg45 and 
Arg49).  Crystals were grown in the presence of ammonium sulfate and the hydrogen 
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bonding pattern seen is suggestive of a tightly bound molecule.   This coordination is at 
the level of the bends in α1 and α2 and may be a consequence of the surface curvature 
or it is possible that the interaction played a role in inducing the helix direction change.  
Such a feature of crystallisation may also be indicative of a natural interaction site, 
where a similar entity may bind at this position in vivo.  A glycerol molecule, used as 
the cryoprotectant, is also bound to the protein, linking Glu41 on α1 and Asp119 on α3 
(not shown). 
 
Despite the growth of crystals using the monomeric sample obtained from size 
exclusion chromatography and the presence of one molecule in the asymmetric unit, 
evidence of a covalent dimer is apparent.  A single disulfide link is observed between 
Cys58 at the C-terminal end of α1 and the same residue of a symmetry-related 
LmTBCA molecule, generated using the crystallographic symmetry operation - x, - x + 
y, - z + 1/3.  Cα atoms are separated by a distance of 7.6 Å and sulfur atoms are 2.2 Å 
apart, an accepted disulfide bond length (Figure 3.4; Richardson, 1981).  Electron 
density agrees with the presence of a covalent bond at this position.  Attempts were 
made to corroborate this observation by subjecting dissolved crystals to SDS-PAGE and 
MALDI-TOF MS.  The reduced environment of SDS-PAGE sample preparation should 
denature a protein sample into its monomeric form.  Here, a shift in mass was seen, 
suggestive of a strong linkage between monomers with only partial denaturation.  
However, due to the location of the bond at the tip of an elongated cylindrical structure, 
the extreme lengthening of the paired molecules resulted in an unusual gel profile (not 
shown).  It was therefore difficult to confirm an accurate molecular mass of the 
crystallised species.  Unfortunately, mass spectrometry analysis did not provide any 
additional knowledge on this matter nor on the presence of the initial 18 amino acids.   
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Residues immediately surrounding Cys58 display higher B factors compared to the rest 
of the molecule due to the poorly ordered side chain atoms.  Mean B factor of Asp55 to 
Pro66 is 56.0 Å2 versus 27.3 Å2 for the protein as a whole.  This is indicative of 
disorder or flexibility with the link at Cys58 stabilising the placement of the α1-α2 
loop.  A cysteine at this position is not conserved throughout TBCAs suggesting it is not 
a critical functional residue.  Nevertheless, the formation of this Cys58-Cys58 disulfide 
bond may have aided in the crystallisation of LmTBCA.  Purification and crystallisation 
solutions were not supplemented with reducing agents.  It cannot be ruled out that the 
linked species was present during purification in low quantity although crystals were 
only obtained using sample originally characterised as a monomer. 
 
Figure 3.4. LmTBCA disulfide bond 
LmTBCA monomer (red) and a symmetry related molecule (orange) are linked by a disulfide 
bond between Cys58 residues with side chain atoms shown as sticks (C, grey; S gold). 
 
A network of hydrogen bonds contributes to maintaining the overall protein shape.  The 
individual helices contain a classical 413 hydrogen bonding arrangement while inter-
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helical hydrogen bonds align the helices with respect to each other.  The bend in α2 
mentioned above is caused by the absence of a backbone hydrogen bond donor from 
Pro80.  This lack of typical α-helical hydrogen bond between Pro80 and Gln76, 
replaced with only a weak hydrogen bond between Pro80 Cδ and Gln76 O, disrupts the 
standard α-helix organisation (Figure 3.5).  A number of hydrogen bonds close to 
Pro80 appear stretched but remain within an accepted length range.  For example, the 
distance from the amide group of Val79 to the carbonyl of Ala75 is 3.5 Å while other 
neighbouring hydrogen bonds are between approximately 2.9 and 3.2 Å.  Notable links 
between α1 and α2 are distributed along the length of the molecule, including salt 
bridges Lys29-Asp92 and Asp39-Arg85 and a hydrogen bond at Glu50-Gln68.  There 
is, however, little direct association between α3 and the two longer helices.   
 
 
Figure 3.5. Backbone hydrogen bonds of LmTBCA α2  
The area highlighted shows a stereo view of helices α1 and α3 as purple ribbons. α2 is depicted 
as pale pink ribbon or as sticks coloured by element (C, grey; O, red; N, blue; S, gold).  Black 
dashed lines represent standard α-helical hydrogen bonds.  Pro80 disrupts this bonding pattern 
allowing the helix to bend.  The magenta dashed line between Pro80 and Gln76, which does not 
represent a hydrogen bond, has a length of 4.20 Å. 
 
 
 
 
 
Part I Tubulin-binding cofactors  Chapter 3: Results and discussion 
54 
3.1.4. TBCA structure comparison and potential for tubulin interaction 
Overall, published TBCA structures (Arabadopsis thaliana TBCA (AtTBCA) PDB 
3mxz, Lu et al., 2010; Homo sapiens TBCA (HsTBCA) PDB 1h7c, Guasch et al., 2002; 
Saccaromyces cerevisiae Rbl2p (ScRbl2p) PDB 1qsd, Steinbacher, 1999) adopt the 
same general conformation as LmTBCA.  Three helices of approximately equal length 
are connected by short loops.  However, the surface curvature is not identical.  A 
proline at the same position as Pro80 is strictly conserved in these species but the 
resultant bend is most pronounced in LmTBCA.  The distortion of α1 is also unique to 
LmTBCA.  ScRbl2p helices α1 and α2 are almost linear and it is the crossover of the 
two lengths that mimics an overall curved appearance.  The apparent effect of the 
proline residue in this case is counteracted by an increased hydrogen bond length at 
what would have become the concave helix surface, producing a less prominent 
direction change.  HsTBCA has an unusual conformation with α2 kinked in the 
opposite direction to that seen in LmTBCA.  The conserved proline then simply returns 
the helix to its original course.  Of the published models, AtTBCA appears the most 
structurally similar to LmTBCA with a root mean square deviation (r.m.s.d.) of 1.8 Å 
when 92 Cα atoms are aligned.  Sequence similarity is also the greatest at about 27 % 
compared to 26 % and 19 % for ScRbl2p and HsTBCA, respectively. 
 
Despite a visual resemblance to LmTBCA, the crystal structure of LmTBCA could not 
be determined via molecular replacement approaches based on any of the published 
homologous structural models.  Elongated, exclusively α-helical proteins have proved 
challenging subjects for molecular replacement in previous studies (Sundaramoorthy et 
al., 2008) including attempts to use ScRbl2p as a model to solve the structure of 
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HsTBCA (Guasch et al., 2002).  The inherent difficulties can be attributed to 
ambiguities in crystallographic rotation and translation, particularly in the direction of 
the helices and the rotation about the helical axes. 
 
Figure 3.6. LmTBCA electrostatic potential 
(A) A van der Waals surface representation of LmTBCA coloured according to electrostatic 
protein contact potential (-5 kTe-1, red to 5 kTe-1, blue) created using PDB2PQR (Dolinsky et 
al., 2004) and APBS (Baker et al., 2001).  (B) The semi-transparent surface of LmTBCA 
coloured by sequence identity to known homologous structures (HsTBCA, ScRbl2p and 
AtTBCA).  Amino acids only present in LmTBCA are coloured red.  Increasing similarity is 
represented by a darkening grey scale with residues identical in all four species shown in black. 
 
LmTBCA α1 and α2 each consist of an abundance of hydrophobic amino acids with 
side chains mainly directed towards the core of the tri-helical bundle.  Surface 
electrostatic potential mapping indicates areas of localised polarity distributed over the 
protein.  The concave exterior, when represented as a van der Waals surface projection, 
is significantly more positively charged in comparison with the rest of the molecule 
(Figure 3.6A) which has an overall calculated pI of 5.2 (ProtParam; Gasteiger et al., 
2005).  The concentration of positive charge is attributed to the solvent-facing arginine 
and lysine residues of α1.  It is also the area of greatest sequence identity with structural 
homologues (Figure 3.6B).  A helical wheel schematic shows the distribution of amino 
acids along α1 and 80 % of positive residues are localised along the surface described 
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(Figure 3.7).  The TBCA binding partner, β-tubulin, is a highly conserved polypeptide 
(Sullivan and Cleveland, 1986) and is largely negatively charged with an overall pI of 
4.6-4.7 (ProtParam; Gasteiger et al., 2005).  Additionally, both α- and β-tubulin C-
terminal tails are negatively charged and are known to bind to other MAPs and cationic 
molecules (Cross et al., 1991; Lefevre et al., 2011).   The concave surface of LmTBCA 
might therefore present a favourable site for β-tubulin interaction. 
 
Figure 3.7. Arrangement of LmTBCA helices 
(A) LmTBCA helices α1, α2 and α3 are shown as violet cylinders linked by pale blue loops 
viewed from above (top) and following rotation by 90° (bottom).  (B) A helical wheel 
projection showing the approximate location of the backbone of all helix residues.  α1 and α3 
amino acids are arranged from N- to C-terminus in a clockwise orientation beginning at Asn22 
and Glu108, respectively (marked with *). α2 reads clockwise starting at Lys99 from the C- to 
N-terminus.  Amino acids with positively charged side-chains are represented as blue circles 
and negatively charged residues are coloured red.  Hydrophobic side-chains are yellow while all 
others are uncoloured.  The three helices are arranged in a similar orientation to (A).  It should 
be noted that due to the curvature of α1 and α2, the distribution depicted above is for guidance 
only and does not infer specific inter-helical interactions.  The helical wheel diagrams are 
adaptations of those produced using the tool by Armstrong and Zidovetzki (2009), available at 
http://rzlab.ucr.edu/scripts/wheel/wheel.cgi. 
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The most apparent variation in TBCA protein sequences is the N-terminal extension 
observed in trypanosomatids (Figure 3.8A).  This region has negligible predicted 
secondary structure and the electron density of LmTBCA provides no evidence of an 
ordered structure.  It is possible that the additional 18 residues may therefore be of little 
functional value and the LmTBCA crystal structure represents a functional unit, directly 
comparable to homologues lacking the extended N-terminus. 
 
LmTBCA lacks a significant hydrophobic surface site characteristic of proteins involved 
in interactions with an unfolded or partially folded partner such as those seen in GroEL 
of the archetypal bacterial protein folding system (Fenton et al., 1994) and members of 
the hsp70 (heat-shock protein of 70 kDa mass) molecular chaperone family (Flynn et 
al., 1991).  This is in agreement with the hypothesis that β-tubulin is already in a folded 
state when initially presented to the tubulin-binding cofactors and the cofactors do not 
contribute to tubulin folding.  Indeed it has been shown that TBCA does not recognise 
denatured β-tubulin (Archer et al., 1998).  Due to the shortage of clusters of exposed 
hydrophobic residues on LmTBCA, it could be argued that the binding event occurs at a 
site different from its polymerisation partner.  When β-tubulin sequences from the same 
organisms as those with published TBCA structures are aligned, sequences are between 
70 % (Scβ-tubulin) and 85 % (Hs and Atβ-tubulin) identical to Lmβ-tubulin.  This 
similarity between polypeptides strongly suggests that the location of binding events 
involving β-tubulin is conserved.  Interactions with the globular surface should then 
require an equivalent level of homology between partner molecule binding sites.  Since 
the overall sequence identity between TBCAs is much lower than that of β-tubulin, 
localised regions of high conservation offer the greatest interaction potential.  β-tubulin 
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sequences diverge mainly at the C-terminal tail, a site implicated in many other 
microtubule-related interactions (for example, Cross et al., 1991 and Lefevre et al., 
2011) and, without detailed structural knowledge, cannot be ruled out as the site of 
interaction with TBCA. 
 
Figure 3.8. TBCA sequence and structure comparison 
(A) Structure-based sequence alignment of LmTBCA and published homologues A. thaliana 
TBCA (3mxz), S. cerevisiae Rbl2p (1qsd) and H. sapiens TBCA (1h7c). Sequence similarity is 
indicated by white text on a grey-scaled background.  Residues highlighted in coloured boxes 
(blue, yellow and purple) are implicated in binding β-tubulin.  Amino acids in orange boxes are 
thought to affect β-tubulin binding but are also located at the ScRbl2p homodimer interface.  
Cys58 is shown as red text and the location of the conserved proline (Pro80) is marked with a 
red triangle.  Sequences were aligned with MUSCLE (Edgar, 2004) and the figure prepared 
using ALINE (Bond and Schüttelkopf, 2009).  (B) Stereoview image of LmTBCA helices α1 
and α2 (red ribbon) with Cα backbone traces of AtTBCA (blue), ScRbl2p (yellow) and 
HsTBCA (purple).  Selected residues are shown as sticks of the same colours, labelled 
according to LmTBCA sequence and numbering.  Residues at the positions of Asp39, Ala43 and 
Glu74 are critical for β-tubulin binding in A.thaliana.  His81 and Ser82 are also thought to play 
a functional role.  In this view, HsTBCA Glu59 (aligns with Glu74 labelled above) appears 
distant from its sister residues but is located at the same position on α2.  Alignment was 
performed using SSM based on Cα atoms of complete PDB chains. 
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Several studies have presented theories of how TBCA interacts with β-tubulin but there 
remains no consensus on the true model, if indeed there is a single mode of action.  
Peptide mapping and competition experiments suggest β-tubulin interacts with broad 
regions on all three helices of HsTBCA (Guasch et al., 2002).  α3 was not considered 
essential but binding activity was diminished when it was removed.  Two specific 
amino acid mutations appeared to influence binding, D66E and C67S.  HsTBCA Asp66 
and Cys67 correspond to His81 and Ser82 in LmTBCA.  The mutation to glutamic acid 
at the position of His81 reduced binding activity but the mutation to serine at the 
position of LmTBCA Ser82 increased the level of HsTBCA-β-tubulin complex 
detected.  These residues are not strictly conserved but their effect on function suggests 
a role in the binding event.  Immediately preceding His81 and Ser82 is the highly 
conserved Pro80 that facilitates the distortion of α2 seen in all known TBCA structures.  
Although not directly involved in molecular contacts with β-tubulin, its conservation 
suggests the importance of the cofactor’s overall shape. 
 
AtTBCA mutagenesis and co-immunoprecipitation studies revealed residues Glu20, 
Tyr24 and Glu57 were critical for binding β-tubulin (Lu et al., 2010).  According to 
sequence and structural alignments, these correspond to Asp39, Ala43 and Glu74 in 
LmTBCA while only Glu57 differs in ScRbl2p, replaced conservatively by Asp57, and 
all three residues remain identical in HsTBCA.  Mutation of each of these individually 
to alanine in AtTBCA resulted in no detection of a TBCA-β-tubulin complex.  Located 
on the C-terminal half of α1 and N-terminal half of α2, this is the region of greatest 
variation between these four structures when the whole molecule is overlaid using 
secondary structure matching procedures (Krissinel and Henrick, 2004).  If a plane were 
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to dissect the protein at the level of the C-terminus, mean Cα deviations are 0.8 Å more 
in the lower portion than in the upper, when viewed in the orientation of Figure 3.3A.  
The negatively charged side chain atoms of Asp39 and Glu74 are exposed on the 
surface of the helix bundle (Figure 3.8B).  The hydrophobic Ala43, however, lies more 
buried and the Cβ atom extends towards α2 unlike the large side-group of AtTBCA 
Tyr24 which projects into solvent on the same surface as Glu20.  The ability of a single 
Tyr-Ala mutation to eliminate binding does indicate a critical functional role but this is 
contradicted by the presence of alanine in native LmTBCA.  Perhaps LmTBCA displays 
lower affinity for β-tubulin as a result or there may be additional or alternative 
contributions made by amino acids elsewhere.  For example, the distinct curvature of 
LmTBCA could present residues along the entire length of the helices, including the 
positively charged region of α1 discussed, towards the binding partner. 
 
Conflicting with the potential binding pattern described, computational docking onto 
the surface of β-tubulin suggests that the homodimeric ScRbl2p interacts via the short 
loops rather than the helices (You et al., 2004).  Helices α1 and α2 instead form the 
dimer interface and a number of the residues discussed above make contacts with or are 
buried by the second molecule (Steinbacher, 1999).  Both monomer subunits are 
predicted to form links with β-tubulin so perhaps these residues are equally important 
for function in ScRbl2p where a dimer must first be formed.  The same study identifies 
the site of β-tubulin most likely to participate as an area that overlaps with the footprint 
of the αβ-tubulin dimerisation site (You et al., 2004).  This corresponds with the ability 
of a TBCA-β-tubulin complex to prohibit premature αβ-tubulin dimer formation since 
α-tubulin and the cofactor cannot bind to β-tubulin simultaneously (Llosa et al., 1996; 
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Fanarraga et al., 1999; Abruzzi et al., 2002).  Alternatively, interaction at an allosteric 
site may require TBCA to induce conformational change to the β-tubulin dimerisation  
surface but there is currently no data to support this.   
 
Of the known TBCA structures, only ScRbl2p is reported to form a homodimeric 
species. Although the dimer interface is notably hydrophilic (Steinbacher, 1999), the 
arrangement of the same few hydrophobic residues forming inter-molecular contacts is 
absent in LmTBCA, AtTBCA and HsTBCA.  LmTBCA displayed some oligomerisation 
during purification but was primarily monomeric in solution.  In the crystal structure, 
contacts between molecules are distributed around the surface and not clustered to 
resemble a dimerisation interface.  The covalent disulfide link made by Cys58 is 
completely different to the configuration of the ScRbl2p dimer.  A 1:1 stoichiometry of 
TBCA:β-tubulin is also described elsewhere (Llosa et al., 1996).  It is therefore unlikely 
that LmTBCA adopts the same functional conformation reported for ScRbl2p but the 
potential for this to occur cannot be dismissed without further evidence. 
 
Several protein structures possess a fold similar to LmTBCA.  As expected, lead results 
from a search for structural relatives using PDBeFold (Krissinel and Henrick, 2004) and 
the Dali server (Holm and Rosenström, 2010) were AtTBCA, ScRbl2p and HsTBCA.  
Details of these and selected subsequent structural neighbours are provided in Table 
3.2.  Inspection of a number of molecules found by PDBeFold suggests that they were 
identified by the incidence of one or more helices of equivalent length to LmTBCA, 
sometimes termed ‘α-ten modules’ due to the presence of ten α-helical turns.  A precise 
functional relationship, if any, is yet to be established but the ability to form protein-
protein complexes appears to be a common theme.  Interestingly, this approach 
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highlighted a number of distant structural neighbours that contain a three-helix bundle 
motif with the function of acting as molecular chaperones.  Indeed, two such proteins 
are actinin, a molecule known to participate in binding to actin, the primary component 
of cytoskeletal microfilaments (Sjöblom et al., 2008) and spectrin, also related to the 
cytoskeleton in eukaryotes (Bennet and Baines, 2001).  Subunits of the prefoldin 
protein-folding complex were also listed.  This fold is therefore acknowledged as a 
binding partner of important cellular elements in systems both outside of and analogous 
to microtubule dynamics.  However, there remains no single conclusive binding pattern. 
 
PDB Description No. aligned 
residues 
RMSD 
(Å) 
Z-score Publication 
3mxz AtTBCA 103 
(97) 
2.7 
(2.04) 
13.5 
(5.3) 
Lu et al., 2010 
1qsd ScRbl2p 97 
(96) 
2.2 
(2.76) 
12.7 
(4.1) 
Steinbacher, 1999 
1h7c HsTBCA 101 
(90) 
3.6 
(2.32) 
12.4 
(4.2) 
Guasch et al., 2002 
1s94 Syntaxin Habc domain (86) (2.27) (3.7) Bracher and 
Weissenhorn, 2004 
4i0x ESAT-6-like protein (73) (2.91) (2.7) N/A 
3k6c Uncharacterised (65) (2.39) (2.8) N/A 
1g73 SMAC 106 3.6 10.1 Wu et al., 2000 
1oxz ARF binding protein 84 2.3 9.3 Zhu et al., 2003 
3fb2 Hsα-spectrin 95 3.2 8.6 N/A 
1u5p Ggα-spectrin 95 3.5 8.4 Kusunoki et al., 2004 
3edv Hsβ-spectrin 95 3.6 8.3 Davis et al., 2009 
2zqm Prefoldin (β)  85 3.3 8 Kida et al., 2008 
2zdi Prefoldin (β) 83 2.7 8 Ohtaki et al., 2008 
1fxk Prefoldin 85 2.5 8 Siegert et al., 2000 
1wlx Hsα-actinin4 97 4.5 5.8 N/A 
1hci Hsα-actinin2 96 3.8 4.6 Ylänne et al., 2001 
Table 3.2. LmTBCA structure similarity search results 
Selected results from structure similarity searches based on LmTBCA chain A.  Results from 
PDBeFold (Krissinel and Henrick, 2004) are shown in parantheses, all others were obtained 
from the Dali-server (Holm and Rosenström, 2010).  Z-scores are a measure of the statistical 
significance of each match and are defined in the associated publications.  A Z-score provided 
by Dali of less than 2 is considered spurious.  Sequence identity of the examples shown was 
calculated as between 29 and 3 %.  SMAC, Second mitochondira-derived activator of caspases; 
Habc, Helix a, b and c; ESAT, Early secreted antigenic target protein; ARF, Adenosine 
diphosphate-ribosylation factor; Gg, Gallus gallus; N/A, no associated publication. 
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3.2. Tubulin-binding cofactor C 
3.2.1. Protein production 
Full-length TbTBCC and LmTBCC were recombinantly expressed and purified in 
soluble form.  The isolated monomeric samples, as suggested by size exclusion 
chromatography, were subject to crystallisation screening but no suitable conditions 
were identified.  TbTBCC circular dichroism analysis indicated the presence of 
correctly folded protein and DSF studies resulted in melting curves also suggestive of a 
folded species.  No buffers in the DSF thermal stability buffer screen provided a 
significant positive shift in protein Tm.  Maximum Tm values were 53.2°C for TbTBCC 
and 50.8°C for LmTBCC, an increase of only 0.7°C and 1.2°C from standard buffers, 
respectively.  Nevertheless, further crystallisation experiments were prepared following 
exchange to those buffers showing the highest Tm and no changes to crystallisability 
were observed. 
 
3.2.2. Degradation and truncation 
Within 7 days of purification, SDS-PAGE and MALDI-TOF analyses indicated protein 
products at a molecular mass smaller than expected for full-length TBCC (both Tb and 
Lm).  These products were not apparent during or immediately following purification 
and were believed to be evidence of degradation or proteolytic activity.  Incubation of 
mass-verified full-length TbTBCC with chymotrypsin resulted in a similar distribution 
of protein fragments (Figure 3.9A).  Peptide identification following further proteolysis 
by trypsin of the two unknown protein bands matched those present in TbTBCC 
(Figure 3.9B), corresponding to an N-terminal fragment of approximately 12 kDa and a 
larger 20 kDa C-terminal region.  The mass of these fragments also coincides with 
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secondary structure and globularity predictions that at least two distinct protein domains 
may be present. 
 
 
Figure 3.9. TbTBCC proteolysis 
(A) SDS-PAGE of TbTBCC.  Lane 1 shows untreated TbTBCC 2 days after initial purification.  
Lane 2 is TbTBCC after addition of chymotrypsin.  The approximate location of full-length 
TbTBCC (black arrow), degradation product I (blue arrow) and degradation product II (red 
arrow) are indicated. (B) Mass spectrometry protein ID results using samples I and II from 
SDS-PAGE.  Matched peptide fragments of degradation products I and II are shown as blue and 
red text, respectively. 
 
As there was no success in obtaining crystals of full length TBCC, this degradation 
event was exploited in order to isolate a more stable protein construct that was 
potentially more likely to crystallise.  Treatment with chymotrypsin had already been 
shown to result in products similar in size to natural degradation and was subsequently 
used to accelerate the process.  The addition of chymotrypsin directly to TBCC prior to 
crystallisation screening produced no crystals.  Size exclusion chromatography 
following limited proteolysis was used to separate the stable protein domains.  It was 
possible to isolate only the larger C-terminal portion in this way.  However, crystal 
growth remained elusive. 
 
Several expression constructs were generated (details in Table 2.3), designed with the 
aid of proteolysis experiments in combination with several sequence-based prediction 
tools (described in 2.2.3).  TbTBCC constructs 1-107, 1-112 and 138-308 and LmTBCC 
construct 152-335 were purified and screened for suitable crystallisation conditions.  
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However, other truncated constructs produced insufficient soluble material or were of 
unsatisfactory purity to attempt crystallisation. 
 
3.2.3. LmTBCC152 crystallisation 
LmTBCC152 was the only truncated construct from L. major that resulted in soluble 
recombinant material purified to an acceptable level.  A high yield of approximately 10-
20 mg final purified product was obtained from 1 L E. coli cell culture.  Initial crystal 
hits were observed in a screen utilising polyethylene glycol (PEG) of different mass as 
the precipitating agent.  Solutions of 0.1 M MES pH 6.5 containing 25 % PEG 2000 
MME, PEG 4000 or PEG 6000 mixed with LmTBCC152 at 7.3 mg mL-1 in 20 mM 
Tris-HCl pH 7.5, 100 mM NaCl produced crystalline material as shown in Figure 3.10. 
 
 
Figure 3.10. Initial LmTBCC152 crystals 
Crystals observed in 0.2 µL sitting-drops (drop diameter approximately 0.5-1 mm).  
Crystallisation solutions contained (A) 0.1 M MES pH 6.5, 25 % (w/v) PEG 2000 MME, (B) 
0.1 M MES pH 6.5, 25 % (w/v) PEG 4000 and (C) 0.1 M MES pH 6.5, 25 % (w/v) PEG 6000. 
 
Due to crystal morphology and size, optimisation was required before X-ray diffraction 
experiments were attempted.  A grid-screen around the original hit conditions in larger 
volume hanging-drop format produced crystals of similar morphology.  These large 
clusters of many fine needle crystals (Figure 3.11A-B) were found to break into smaller 
fragments when disturbed.  In order to slow the speed of crystal nucleation and 
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potentially form fewer individual crystals, both protein and PEG precipitant 
concentrations were reduced (Blow et al., 1994).  However, this resulted in drops that 
either contained similar crystalline material or remained clear.  Experiments prepared 
under an oil layer to slow vapour-diffusion (Chayen, 1999) did not improve crystal 
morphology.  Microseeding to introduce fragments of the sub-optimal initial crystals as 
nucleants in otherwise clear drops (Bergfors, 2003) did show signs of improved crystal 
morphology in our hands (Figure 3.11C-F).  The process involved a large degree of 
trial and error with little logical explanation for the variation in quality of crystal 
growth.  The majority of crystals were obtained following this strategy through 
extensive experiment repetition and grid screening (Cudney et al., 1994). 
 
 
Figure 3.11. LmTBCC152 crystal optimisation 
A selection of crystals of LmTBCC152. Panels (A) and (B) show crystals obtained without 
seeding.  (C)-(G) all show crystals after one or more rounds of microseeding.  (G) was 
photographed under polarised light.  Crystal sizes range from between approximately 0.1 to 0.5 
mm along the longest edge. 
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Other methods of optimisation that were attempted included reductive methylation of 
surface lysine residues (Walter et al., 2006; Kim et al., 2008), which proved unhelpful 
in this case.  A large amount of protein precipitated during the reaction.  A sample of 
the soluble material was analysed by MALDI-TOF but no peaks were observed despite 
positive evidence from SDS-PAGE.  Crystallisation was not carried out using the low 
yield of potentially methylated LmTBCC152. 
 
KI or NaI were included in crystallisation conditions to prevent disruption to already-
formed crystals when soaked with a high concentration of iodide ions to be utilised for 
experimental phase determination.  However, the presence of iodide appeared 
detrimental to crystal growth and crystallisation drops contained a greater amount of 
precipitated material.  Crystals cryoprotected in a solution supplemented with NaI were 
observed to split or partially dissolve prior to cooling.  Alternative additives were found 
to show little or no positive effect on crystallisation.  Samples containing DTT and/or 
GTP crystallised with the same morphology.  ITC and DSF were used to assess the 
potential interaction of LmTBCC152 with GTP but provided no evidence of a binding 
event.  ITC was performed under a limited set of conditions and a non-significant Tm 
change observed in DSF does not necessarily equate to a lack of association (Niesen et 
al., 2007).  Therefore, the ability of these additives to directly associate with 
LmTBCC152 and the level of incorporation within the crystal lattice is still unknown at 
this stage. 
 
One hypothesis for the problematic crystal growth was the possible presence of a non-
homogenous protein solution.  Although the sample collected immediately following 
size exclusion chromatography was believed to be monomeric LmTBCC152, it is 
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possible that oligomerisation was dynamic and a dimer was able to form under certain 
conditions, such as in the crystallisation mixture or simply over a prolonged incubation 
time.  Samples prepared under various conditions were therefore analysed via size 
exclusion chromatography according to 2.3.8 (Figure 3.12).  A small peak at an elution 
volume suggestive of dimer formation was present for all samples.  Long-term storage 
and exchange to the buffer used in crystallisation (MES pH 6.5) also produced 
aggregated material.  It is possible that this may have contributed negatively to 
crystallisation.  However, the predominant species remains monomeric and 
crystallisation experiments were prepared immediately following purification. 
 
Figure 3.12. LmTBCC152 oligomerisation analysis 
Analytical size exclusion chromatography of LmTBCC152 under different buffer conditions and 
sample storage.  The left panel shows the original purification chromatogram.  The right panel 
shows three chromatograms overlaid, each representing a different experiment as detailed in the 
key provided. 
 
SeMet-LmTBCC152 was produced as described in 2.3.3.  LmTBCC152 contains only 
one methionine residue, excluding Met1.  In order to improve possible experimental 
phasing procedures downstream, nucleotides encoding leucine residues were 
conservatively mutated to produce 1-2 additional methionine residues in the protein 
product.  Initial gene constructs were prepared by site-directed mutagenesis (2.2.4).  
Amino acids targeted for mutation were identified based on a multiple sequence 
alignment of TBCC homologues.  Both L215 and L223 are relatively well conserved 
between species and are indeed found as methionine at the equivalent positions in 
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Aspergillus flavus and T. brucei homologues, respectively (Figure 3.13A).  Both the 
L215M-L223M double mutant and the L223M single mutant SeMet proteins were 
crystallised (Figure 3.13B-C).  The L215M-L223M crystals were small and poorly 
formed and only the L223M crystals were subject to X-ray diffraction. 
 
Figure 3.13 SeMet-LmTBCC152 sequence mutation and crystallisation 
(A) An excerpt of a TBCC multiple sequence alignment prepared using BLAST (Altschul et al., 
1997) and ALINE (Bond and Schüttelkopf, 2009).  LmTBCC is shown as blue text from 
residues 203-245.  Boxes on a darkening greyscale highlight sequence identity.  The positions 
of Leu215 and Leu223 are indicated by red triangles.  These residues were mutated to Met for 
the preparation of a SeMet derivative.  (B) L215M-L223M double mutant crystals and (C) 
L223M single mutant crystals. 
 
3.2.4. LmTBCC152 data collection and processing 
Owing to the difficulties in obtaining single diffraction-quality crystals, over 160 native 
and SeMet LmTBCC152 crystals were tested.  A total of 7 datasets were collected and 
processed as described in 2.8.4.  Data from different crystals were indexed either in 
monoclinic space group P21 or orthorhombic P212121.  Corresponding unit cell 
parameters and other representative data processing statistics are listed in Table 3.3. 
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 Native A Native B SeMet C SeMet D 
Resolution range (Å) 46.20-2.3 
(2.38-2.30) 
44.56-2.10  
(2.16-2.10) 
28.23-2.88 
(3.06-2.88) 
28.08-3.40 
(3.67-3.40) 
Wavelength (Å) 1.5418 1.5418 0.9793 0.9793 
Space Group P21 P212121 P21 P212121 
Unit cell parameters 
     a (Å) 
     b (Å) 
     c (Å) 
     β  (°) 
 
36.98 
92.4 
47.74 
108.3 
 
50.78 
67.48 
92.87 
90.0 
 
37.38 
93.05 
47.6 
108.2 
 
50.25 
66.37 
92.96 
90.0 
Solvent content a. (%) 
     1 molecule per ASU 
     2 molecules per ASU 
 
68 
35 
 
68 
37 
 
68 
36 
 
68 
35 
No. Reflections 260105 (6026) 134827 (10463) 15595 (1014) 43592 (8307) 
No. Unique Reflections 12796 (865) 19293 (1558) 5419 (491) 4594 (895) 
Rmerge b (%) 14.1 (59.1) 23.8 (72.8) 18.6 (40.9) 19.1 (38.6) 
Completeness (%) 94.6 (66.0) 100.0 (100.0) 77.2 (43.6) 99.2 (96.7) 
Mean I/σ(I) 20.4 (2.9) 5.8 (2.5) 7.6 (2.8) 10.2 (7.0) 
Redundancy 20.3 (7.0) 7.0 (6.7) 2.9 (2.1) 9.5 (9.3) 
Table 3.3. LmTBCC152 data processing statistics 
Example data processing statistics from two native and two SeMet LmTBCC152 crystals, 
indexed in two possible space groups identified.  a. Solvent content was estimated according to 
Matthews (1968) using a calculated molecular mass of 20476 Da in all cases. b. Rmerge is as 
defined in Table 3.1.  Values in parentheses correspond to the highest resolution shell.  ASU, 
asymmetric unit. 
 
Due to the disparity in symmetry classification, it is possible that the data have been 
indexed in the incorrect space group or translational pseudosymmetry may be present.  
The high Rmerge values shown in Table 3.3 suggest that these data are of low quality, 
even where high redundancy is also a contributory factor.  Growth of single crystals was 
extremely difficult and when achieved, the crystals were often split or cracked (see 
Figure 3.11D as an example).  There may therefore be physical imperfections present 
within the crystal lattice that are not visible through the microscope.  Radiation may 
also have led to additional crystal damage, particularly as LmTBCC152 has a high 
overall content of sulfur-containing amino acids (12 cysteine and 2 methionine).  These 
are known to be susceptible to radiation-induced structural changes (Burmeister, 2000) 
owing to their relatively large absorption coefficient (Garman, 2003).  Radiation 
damage-induced phasing (RIP; Ravelli et al., 2003) could not be applied as any ‘after’ 
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data (data obtained after X-ray burn) were unusable. 
 
Attempts to solve the structure by MR, sulfur-SAD or via the combined MR-SAD 
approach using highly redundant data collected in-house, processed in space group P21, 
were not successful.  Nor was a solution obtained using data merged from multiple 
crystals.  Similar experiments performed using native orthorhombic data were equally 
unproductive.  MR search models included an NMR model of HsTBCC C-terminal 
domain (PDB 2yuh, Saito et al., unpublished) and the N-terminal domain of HsRP2 
(PDB 2bx6, Kühnel et al. (2006); 3bh6 and 3bh7, Veltel et al. (2008)).  Aligned regions 
of these proteins share only approximately 20-25 % sequence identity with 
LmTBCC152.  Tests were performed using the entire aligned region, following 
truncation to remove potential flexible regions or with side chain atoms removed as a 
polyalanine model.  Molecular replacement is believed to have proved unsuccessful for 
similar reasons as for LmTBCA (3.1.4).  LmTBCA is predominantly α-helical while 
LmTBCC152 structure predictions and homologues identified based on sequence 
suggest that it is composed of β-strands in a helical arrangement, a β-helix (Yoder et al., 
1993).  
 
SeMet data collected at the absorption peak wavelength, as indicated by an energy scan 
(Figure 3.14A), appeared to provide sufficient anomalous signal (not shown) but 
several software packages for phase determination by SAD failed to identify the 
locations of selenium atoms.  As mentioned, the crystals also appeared highly sensitive 
to synchrotron radiation.  Diffraction visibly deteriorated over the experiment duration 
to such an extent that additional data could not be collected at the inflection or remote 
wavelengths for the application of MAD phasing.  An increasing Rmerge and B factor, 
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decreasing reflection intensity as well as discolouration of the cryo-cooled sample by 
the X-ray beam (Figure 3.14B) may also be indicative of radiation effects (Garman, 
2010). 
 
Figure 3.14. SeMet-LmTBCC152 energy scan and radiation effects 
(A) Energy scan of a SeMet-LmTBCC152 (L223M) crystal showing the selenium peak and 
inflection X-ray energies and associated anomalous scattering factors, ƒʹ′ and ƒʹ′ʹ′.  This figure 
was generated by Chooch (Evans and Pettifer, 2001).  (B) A native LmTBCC152 crystal in the 
X-ray beam showing a vertical path of radiation-induced discolouration. 
 
3.2.5. TBCC sequence and homologue-based structure analysis 
Based on the protein sequence, LmTBCC152 is most similar to other known or putative 
TBCCs and is also predicted to share structural similarity with the protein RP2.  This 
protein is encoded by the retinitis pigmentosa 2 gene in H. sapiens and is implicated in 
diseases causing retinal degeneration.  Consisting of two structural domains, the N-
terminal region is homologous to the C-terminal domain of TBCC (Bartolini et al., 
2002).  RP2 has been shown to function as a GTPase-activating protein (GAP) for Arl3 
(ADP-ribosylation factor-like 3) (Kühnel et al., 2006; Veltel et al., 2008).  TBCC has 
also been proposed to possess GAP activity in the hydrolysis of GTP bound to β-tubulin 
prior to release of the αβ-tubulin heterodimer from the TBC-tubulin supercomplex 
(Tian et al., 1999).  Crystal structures of RP2 in complex with its Arl3 partner and GTP 
analogues can therefore help to inform on the location of the nucleotide site and the 
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potential interaction of TBCC with β-tubulin.  A solution structure of the HsTBCC C-
terminal domain (PDB 2yuh) has no associated publication and together with the RP2 
homologue structures (PDB 2bx6, Kühnel et al., 2006; PDB 3bh6, 3bh7, Veltel et al., 
2008) comprise the limited structural details available for the C-terminal domain of 
TBCC.  The N-terminal region of HsTBCC has also recently been determined by NMR 
(PDB 2l3l, Garcia-Mayoral et al., 2011).  An alignment of the full-length LmTBCC and 
HsTBCC sequences with the homologous domain of HsRP2 is shown in Figure 3.15A.  
The regions of HsTBCC with known structure are highlighted.  There are several 
regions where sequence is maintained between these proteins.  In particular, as also 
evident in the section of a larger alignment shown in Figure 3.13A, the arginine at 
position 214 and neighbouring residues are strictly conserved throughout species in 
TBCC proteins and RP2.  This arginine has been shown to severely affect the rate of 
Arl3 GTP hydrolysis when mutated in RP2 (Veltel et al., 2008) and is also key in the 
function of other GAPs (Scheffzek et al., 1997).  Other amino acids important for 
catalytic function include Gln212, Glu234 and Phe290 (numbered according to 
LmTBCC sequence).  This strict conservation between species strongly suggests 
conservation of function and further emphasises the role of TBCC as a GTPase-
activating protein.  HsTBCC has indeed been shown to partially replace RP2 
functionality where the reduced activity was justified by a lower affinity for Arl3 as a 
protein partner (Veltel et al., 2008).  Studies have also demonstrated that TBCC and 
TBCD are together required for the hydrolysis of GTP by β-tubulin and stimulate 
release the αβ-tubulin heterodimer (Tian et al., 1997).  TBCD does not appear to 
display a motif or fold common to any known GAPs, suggesting it may be TBCC 
adopting the more classical GAP role. 
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Figure 3.15. LmTBCC homologue sequence alignment and structural model 
(A) Full-length LmTBCC aligned with HsTBCC and the N-terminal domain of HsRP2 (residues 
38-204).  Sequences were aligned using MUSCLE (Edgar, 2004) and annotated using ALINE 
(Bond and Schüttelkopf, 2009).  The secondary structure of LmTBCC predicted by PSIPRED 
(Jones, 1999) is shown as blue cylinders (α-helices) and arrows (β-strands) and the crystallised 
portion is indicated by blue markers.  Regions of HsTBCC with NMR structures available are 
surrounded by a green border.  Green triangles highlight residues perturbed by tubulin and 
peptides in interaction studies (Garcia-Mayoral et al., 2011).  Selected important amino acids 
for HsRP2 GAP activity are shown by black stars while the red star indicates the strictly 
conserved catalytic arginine (Veltel et al., 2008). (B) Structural models of the LmTBCC N- and 
C-terminal domains generated by PHYRE2 (Kelley et al., 2009).  A zoomed view also shows 
the important catalytic residues of HsRP2 (PDB 3bh7) as cyan sticks, labelled according to 
LmTBCC, and their interaction with GDP and AlF4- when complexed with Arl3 (not shown). 
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Structural homology models of the two individual LmTBCC domains were prepared 
using the PHYRE2 webserver (Kelley and Sternberg, 2009).  Displayed in cartoon form 
in Figure 3.15B, the N-terminal domain is based on the same domain of HsTBCC 
(approximately 70 % model confidence with 86 % sequence coverage) while the C-
terminal domain is based on the homologous region of HsRP2 (100 % model 
confidence with 78 % coverage).  HsRP2 complexed with Arl3 contains a molecule of 
GDP residing at the interface between the two proteins.  The catalytic arginine and other 
important residues described above are shown in Figure 3.15B when superimposed on 
the structural model of the LmTBCC C-terminal domain.  Additional residues of Arl3, 
including Gln71 (not shown), act to position the water molecule required for hydrolysis 
and further contacts are made between the protein surfaces.  This could therefore 
explain the difficulties in detecting a binding event between LmTBCC and GTP as the 
partner protein may be necessary and the nucleotide does not bind, or has a low affinity, 
to TBCC alone.  Nor does there appear a suitable pocket on the putative model of 
LmTBCC152 for the nucleotide to bind. 
 
Secondary structure predicted from sequence alone (PSIPRED; Jones, 1999) shown in 
Figure 3.15A presents some inconsistencies with that of the models.  For example, the 
initial α-helix of LmTBCC is predicted to span from Ala3 to Leu48.  However, the 
model depicts a break in this helix, also described in HsTBCC where at least the first 30 
amino acids are highly flexible and have no fixed orientation.  These residues are 
among those that Garcia-Mayoral and coworkers (2011) also found were perturbed 
during NMR experiments in the presence of a β-tubulin peptide or the αβ-tubulin 
heterodimer.  The broad range of residues, noted by green triangles in Figure 3.15A, 
suggests that a large surface area of the domain interacts with tubulin and/or a large 
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conformational change takes place.  The N-terminal tail may therefore become ordered 
upon complex formation as seen in other unstable microtubule binding proteins (Al-
Bassam et al., 2002). 
 
Although the predicted α-helical configuration of the LmTBCC N-terminal region could 
be described as visually similar to that of LmTBCA (3.1), it is difficult to align the 
sequences or structures accurately.  Pairwise sequence alignement by MUSCLE (Edgar, 
2004) suggests an identity of approximately 17 % but caution should be exercised in 
this analysis.  Alignment of the ‘maintained’ amino acids structurally is problematic due 
to the differences in α-helix lengths.  Perhaps the helical region performs a similar role 
to TBCA but equally it may be required to interact with another component of the 
supercomplex and based on these limited comparisons, it is not possible to infer specific 
common functional capabilities.   
 
The link between the TBCC N- and C-terminal domains is predicted to be disordered, 
suggesting that the connection is flexible.  A similar feature is seen in TbTBCB where 
the two domains were also modelled separately (Fleming et al., 2013).  It is also clear 
that TBCC is composed of two distinct units.  Preliminary small-scale pull-down trials 
using his-tagged N-terminal domain (LmTBCC1-111 or TbTBCC1-107) and untagged 
LmTBCC152 or TbTBCC138 did not identify an interaction (data not shown).  Indeed, 
the propensity of full-length TBCC to cleave without the intentional addition of a 
protease enzyme is indicative of the individual nature of the domains. 
 
There is currently no knowledge of how the cofactors are arranged in the supercomplex 
with α- and β-tubulin or details of their molecular interactions.  Due to the proposed 
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function of TBCC as a GTPase-activator, catalysing β-tubulin GTP hydrolysis, we can 
postulate that the C-terminal domain of LmTBCC interacts with β-tubulin through the 
surface where the strictly conserved arginine finger resides.  The equivalent region of 
RP2 is revealed as the interface between RP2 and Arl3 so this part of the conserved 
protein fold is known to be receptive to protein-protein interactions and has a 
complementary surface charge distribution.  Complex structures of RP2 containing 
GDP can therefore inform on the possible position of the β-tubulin nucleotide with 
respect to LmTBCC.  A crude superimposition of the GDP molecules in the RP2-Arl3-
GDP complex and in β-tubulin (PDB 1tub (Nogales et al., 1998) and a more recent 
PDB 4ihj (Prota et al., 2013) were both examined) results in a series of structural 
clashes, particularly with the β-tubulin α-helices α5, α11 and α12 (Nogales et al., 
1998).  Using secondary structure matching procedures (Krissinel and Henrick, 2004) to 
align β-tubulin with Arl3 reveals a potential association (Figure 3.16).  107 Cα atoms 
were aligned between Arl3 and β-tubulin, mainly localised to the initial 242 β-tubulin 
amino acids.  Overall sequence identity was poor at approximately 7 % but the aligned 
secondary structure appears to agree.  GDP of β-tubulin is more buried than when 
bound to Arl3 where it is exposed on the surface and readily susceptible to the action of 
RP2.  In this representation, the nucleotide guanine is rotated by up to 90° and the 
superimposed side chain of Arg214 is no longer within acceptable contact distance.  
The functional residues may therefore reposition to access the required catalytic 
orientation (Bourne, 1997).  As a simplified, approximate model, exact contact details 
cannot be reliably extracted and more complex molecular modelling strategies could 
provide a more accurate prediction in the absence of experimental data.  However, this 
is the first structural representation proposed for the interaction between TBCC and β-
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tubulin.  This representation includes only the LmTBCC C-terminal domain but there 
remains potential for placement of the N-terminal region that agrees with proposed 
interactions with residues located at the β-tubulin C-terminus (Garcia-Mayoral et al., 
2011). 
 
Figure 3.16. Potential configuration of LmTBCC C-terminal domain and β-tubulin 
(A) HsArl3 (yellow; PDB 3bh7 Veltel et al., 2008) with Hsβ-tubulin (purple; PDB 4ihj, Prota et 
al., 2013) residues 2-242 superimposed by secondary structure matching.   The alignment 
(right) shows the secondary structure of the highlighted regions of β-tubulin and Arl3 more 
clearly.  Boxed portions of sequence indicate the 107 structurally aligned residues (SSM; 
Krissinel and Henrick, 2004).  HsRP2 from the RP2-Arl3 complex is shown in cyan with the N-
terminal domain highlighted. (B) A semi-transparent van der Waals surface representation of 
the potential configuration of the LmTBCC152 model (blue) and β-tubulin (purple).  β-tubulin 
was aligned with Arl3 of the RP2-Arl3 complex as shown in (A) and the model of LmTBCC 
was generated by PHYRE2 (Kelley and Sternberg, 2009).  β-tubulin GDP is indicated at the 
interface as red sticks and β-tubulin is in the same orientation in both (A) and (B). 
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3.2.6. Addendum: LmTBCC152 structure solution 
During the preparation of this thesis, the expression system for native and SeMet-
LmTBCC152 (L223M), crystallisation conditions and information retrieved from 
previous data collection experiments were passed to Paul K. Fyfe and a student, Alex 
Finney.  New data collected at Diamond light source were processed using XDSGUI 
(Kabsch, 2010) and four selenium sites successfully identified by the PHENIX (Adams 
et al., 2010) pipeline.  The majority of the model was automatically built using data 
extending to 2.0 Å resolution.  The solution was obtained using monoclinic data 
indexed in space group P21 with unit cell dimensions of a = 37.64, b = 93.24, c = 48.28 
Å and the angle, β = 108.4°.  Two molecules were present in the asymmetric unit 
corresponding to a crystal solvent content of approximately 35 % (Matthews, 1968).  
Data were obtained from a single crystal, performed using a helical collection strategy 
to minimise radiation damage.  Similar data processing problems were initially 
encountered as described above and due to ‘crystal slippage’ caused by the intentional 
collection strategy. 
 
As expected, the TBCC C-terminal domain primarily adopts a β-helix formation.  
Figure 3.17A shows the overall structure of LmTBCC152.  It has an r.m.s.d. of 2.4 Å 
and 2.0 Å when aligned with 131 Cα atoms of the HsTBCC C-terminal solution 
structure (PDB 2yuh) and 121 Cα atoms of the HsRP2 N-terminal domain (PDB 3bh7), 
respectively.  The homology model described above (3.2.5) also displayed an r.m.s.d. of 
approximately 2.0 Å when 120 Cα atoms are aligned and the superimposed structures 
are shown in Figure 3.17B.  Structure is highly maintained over the β-helix (coloured 
blue) with larger deviations apparent in the flanking loop regions (red and orange).  This 
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may have contributed to the difficulties obtaining the correct solution by molecular 
replacement using a search model containing this segment while the β-helix alone was 
not sufficient. 
 
Figure 3.17 LmTBCC152 overall structure 
(A) Cartoon diagram of the crystal structure of LmTBCC152.  The N- and C-terminal residues 
of the model, Gly158 and Ser325, are labelled.  (B) The LmTBCC152 structure overlaid with 
the PHYRE2 homology model.  LmTBCC152 is coloured pale blue and red while the homology 
model is coloured dark blue and orange.  The blue regions of both models consist of Gly158 to 
Phe241.  N- and C-terminal residues of the homology model are labelled Ser152' and Thr320', 
respectively. 
 
3.3. Tubulin-binding cofactors B, D and E 
3.3.1. TBCB 
Crystal structures of the TbTBCB N-terminal ubiquitin-like (Ubl) domain and C-
terminal CAP-Gly domain were recently determined by colleagues (Fleming et al., 
2013; PDB accession codes 4b6w and 4b6m, respectively).  LmTBCB and TbTBCB 
protein sequences are approximately 60 % identical.  LmTBCB was therefore over-
expressed as full-length and extended domain constructs in attempts to bridge the link 
and identify the relative orientations of the individual domains.  Despite the production 
 
 
Part I Tubulin-binding cofactors  Chapter 3: Results and discussion 
81 
of soluble protein material, no crystals were obtained to progress the structural 
knowledge of TBCB. 
 
3.3.2. TBCD 
TBCD is the largest of the cofactors with a mass of approximately 150 kDa.  Genes 
encoding TBCD were cloned into expression vectors from T. brucei and L. major 
gDNA.  The final LmTBCD translated sequence was identical to that annotated in 
databases (see Table 2.1 for database details).  However, a number of nucleotides were 
replaced in TbTBCB.  This may be a result of T.brucei strain variation but it is also 
possible that mutations were introduced experimentally.  Initial small-scale test 
expressions showed little obvious soluble protein material of the expected molecular 
mass.  A buffer extraction screen was carried out to assess whether different lysis 
buffering systems improved the soluble yield of protein following gene expression 
under identical conditions.  Western blot analysis indicated the presence of small 
amounts of His-tagged sample and several buffers appeared to increase the level 
detected (Figure 3.18A).  Protein ID was validated as LmTBCD with 56 % peptide 
coverage when searched against the L.major sequence database (Figure 3.18B).  1 L 
cells were cultured following the same protocol as the small-scale test and progressed to 
standard purification methods using one buffer identified (0.1 M borate pH 8.5) 
throughout purification.  Protein of expected molecular mass was then visible by SDS-
PAGE.  However, additional studies including size exclusion chromatography and DSF 
suggested the sample was highly aggregated or improperly folded and so, unsuitable for 
crystallography at this stage. 
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Figure 3.18 LmTBCD purification 
(A) Western blot of LmTBCD buffer extraction screen and SDS-PAGE of LmTBCD following 
affinity chromatography.  Only soluble samples using buffers C1-D6 are shown (listed in Table 
2.5).  Buffer D2, indicated by a black star in the lane highlighted by a red box, consisted of 0.1 
M borate pH 8.5.  The horizontal band along the top of the image is believed to be aggregated 
LmTBCD material.  On SDS-PAGE, the lane indicated by a black star contains soluble 
LmTBCD following capture by affinity chromatography.  Lane S contains molecular weight 
standards that apply to both the Western blot and SDS-PAGE images. (B) Protein ID results 
from an excised SDS-PAGE gel slice.  Sequence given in red text indicates peptides matched to 
LmTBCD with an overall coverage of 56 %. 
 
3.3.3. TBCE 
All gene expression studies carried out to produce T. brucei and L. major TBCE have 
resulted in insoluble material.  Full-length and truncated domain constructs have 
produced no measurable soluble protein using a bacterial expression system.  TBCE is 
predicted to consist of two domains similar to TBCB with the N- and C-terminal 
domains reversed.  Despite the ability to produce soluble recombinant TBCB, there 
remain some unknown features preventing the correct production of TBCE in E. coli.  
Protein refolding experiments performed by others have also shown no success and 
TBCE may only be obtained through isolation from a native source or gene expression 
using a eukaryotic cell host (Kortazar et al ., 2006). 
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3.4. Tubulin 
According to a number of reports, soluble tubulins have been produced recombinantly 
in E.coli (Oxberry et al., 2001; MacDonald et al., 2001; 2003; 2004; Fennell et al., 
2006; Giles et al., 2009).  Published expression protocols to produce α- and β-tubulin 
from T. brucei were therefore followed (MacDonald et al., 2003; Giles et al., 2009) and 
additional fusion-tag constructs generated.  In all cases, protein product was observed at 
the correct molecular mass but no soluble material was detected (Figure 3.19).  The 
advantage of obtaining soluble tubulin recombinantly versus a native source is that the 
α- and β-tubulin monomers could be produced individually in the absence of other 
MAPs.  Structural or interaction studies may then have been possible to interrogate 
TBC function.  However, despite several positive reports, the procedure has not been 
successful in our hands.  Tubulin undergoes a series of post-translational modifications 
(Janke and Kneussel, 2010) and indeed a complex folding process in vivo and it should 
not be possible to accurately reproduce these using a bacterial expression system.  As 
such, recombinant tubulins are prone to aggregation or accumulation in inclusion bodies 
(MacDonald et al., 2003). 
 
A small sample of porcine assembly-competent tubulin was obtained from Rachel E. 
Morgan (originally purchased from Cytoskeleton, Inc).  An initial crude assessment was 
made of the ability of the sample to form polymerised microtubules in the absence of 
any TBCs.  Microtubule concentration is proportional to absorbance at 340 nm so when 
monitored over time (up to 1 h), the formation of microtubules through the 
polymerisation of αβ-tubulin heterodimers can be assessed (Shelanski et al., 1973; Lee 
and Timasheff, 1977).  The addition of ligands that may disrupt the polymerisation 
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reaction will therefore alter the standard absorbance curve.  However, further 
development of the assay would be required in order to pursue this as one avenue for 
studying the effects of TBCs on tubulin polymerisation and may represent some 
promising future work. 
 
Figure 3.19 Tubulin PCR and test expression 
(A) PCR products of α- and β-tubulin from T. brucei and L. major gDNA.  Lane 1, Tbβ-tubulin; 
lane 2, Lmβ-tubulin; lane 3, Tbα-tubulin; lane 4, Lmα-tubulin.  Length is indicated in nucleotide 
base pairs (bp).  (B) Lmβ-tubulin test expression of His-, GST- and MBP-tagged constructs, 
cultured in LB at the temperatures indicated.  Lanes numbered 1 contain the insoluble pellet 
fraction following chemical lysis and lanes numbered 2 contain soluble samples.  Large bands 
are observed in several insoluble lanes at the expected mass of the corresponding tagged β-
tubulin product. 
 
3.5. Part I summary and concluding remarks 
The structure of recombinant TBCA from L. major is presented.  This monomeric 
protein has a compact architecture consisting of three α-helices arranged in an anti-
parallel bundle.  A proline residue mid way along α2 distorts one of the longest helices, 
giving the molecule a curved surface.  When compared with structural homologues, this 
helical bend is found to be more prominent in LmTBCA and is uniquely accompanied 
by a similar bend in α1 where there is no equivalent proline.  The resultant concave face 
is described as convex in related proteins.  With the function of capturing excess free β-
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tubulin in microtubule dynamics, potential binding sites are discussed.  Amino acids 
conserved between species that have been described as functionally important 
elsewhere may also be implicated in binding in LmTBCA.  However, some contrasting 
areas of sequence are apparent in LmTBCA.  For example, a tyrosine in AtTBCA is 
reported to be vital for β-tubulin binding through studies involving a Tyr-Ala mutation.  
Alanine is native at this position in LmTBCA, raising questions regarding the implied 
functional properties of the residue.  Meanwhile, a cluster of exposed positively charged 
amino acids on the concave surface of LmTBCA could favourably bind to the highly 
negative β-tubulin.  Although we have not performed functional experiments using 
LmTBCA to confirm binding analogous to any of those already reported, accurate 
details of the interaction would be best identified by the elucidation of a β-tubulin-
TBCA complex crystal structure. 
 
Tubulin-binding cofactor C from T. brucei or L. major is a two-domain protein that 
when produced recombinantly degrades into two separate parts, each of which appeared 
relatively stable in isolation.  Although the full-length protein and the N-terminal 
domain could not be crystallised, crystals of the C-terminal domain of LmTBCC, 
composed of residues 152-335, have been generated and X-ray diffraction data 
collected from native crystals and a selenomethionine-derivative.  Unfortunately, the 
crystallographic phase problem could not be solved using these data.   
 
The TBCC C-terminal domain construct, LmTBCC152, is predicted to adopt a similar 
conformation to a homologue protein, HsRP2.  An arrangement of at least ten β-strands 
form an overall β-helix with an additional, more flexible region neighbouring the helical 
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surface.  A solution structure of the equivalent domain of HsTBCC consists of multiple 
positions for these residues.  A potential site of interaction with β-tubulin as a GTPase 
activator is also discussed.  It has since been shown through the successful solution of 
the LmTBCC152 structure by a colleague using crystals of SeMet-LmTBCC152 
(L223M) reproduced following the procedures outlined in this thesis that the protein is 
indeed organised as predicted.  Detailed examination of the newly established crystal 
structure is required and assessment of the GTP hydrolysing properties of LmTBCC is 
an exciting opportunity for future work. 
 
Structural details of T. brucei TBCB have recently been described by colleagues 
(Fleming et al., 2013).  Cofactors D and E, however, remain elusive and additional 
efforts to obtain soluble protein are necessary for progression in this area but these 
studies lay the foundations for such research.   
 
Overall, Part I of this thesis provides reproducible gene expression protocols and an 
initial examination of the structural details of trypanosomatid TBCs.  Extending from 
these results will allow the molecular interactions between tubulin subunits and 
cofactors to be further explored. 
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4.1. Pteridine reductase 1 
Part II of this thesis presents studies on the enzyme, pteridine reductase 1 (PTR1; EC 
1.5.1.33).  An overview of enzyme function and inhibition is provided as well as an 
introduction to isothermal titration calorimetry, a biophysical technique employed 
alongside the structural and kinetic evaluation of potential PTR1 ligands. 
 
4.1.1. Overview of function 
 
Figure 4.1. PTR1 substrates and products 
PTR1 catalyses the two-stage reduction of biopterin or folate to the 7,8-dihydro- and 5,6,7,8-
tetrahydro-forms.  All reductions are accompanied by NADPH oxidation to NADP+, providing 
a hydride to the carbon atoms at positions 7 and 6, marked with *.  All chemical structures 
throughout this thesis were prepared using MarvinSketch (ChemAxon). 
 
PTR1 is a member of the NADPH-dependent short-chain dehydrogenase-reductase 
superfamily (SDR) and is unique to trypanosomatid parasites.  The primary function of 
PTR1 is catalysis of the two-stage reduction of biopterin to 5,6,7,8-tetrahydrobiopterin 
via the 7,8-dihydrobiopterin intermediate (Bello et al., 1994; Nare et al., 1997a).  
Pterins are pteridine derivatives; a pyrimidine and pyrazine fused ring system with 
 
 
Part II Pteridine reductase 1  Chapter 4: Introduction 
89 
additional amino and keto groups at positions 2 and 4, respectively (Figure 4.1).  
Trypanosomatid parasites are pterin auxotrophs, employing a pathway that includes 
PTR1 in the salvage of pterins from the host.  The function of reduced pterins in 
trypanosomatids is not fully characterised but they are required for parasite growth 
(Bello et al., 1994) and implicated in metacyclogenesis (Cunningham et al., 2001), the 
production of nitric oxide and resistance to oxidative stress (Nare et al., 1997b). 
 
In addition to the reduction of unconjugated pterins (biopterin), PTR1 also displays the 
ability to reduce conjugated pterins (folate) to the dihydro- and active tetra-hydro forms 
(Bello et al., 1994; Nare et al., 1997a; Figure 4.1).  Tetrahydrofolate is normally 
produced via the reduction of folate and dihydrofolate by the enzyme, dihydrofolate 
reductase (DHFR; EC 1.5.1.3).  DHFR is present in humans with the folate substrate 
obtained through diet (vitamin B9) but PTR1 is absent and tetrahydrobiopterin is 
sourced via the biosynthesis from GTP.  Reduced folates are utilised most notably as 
cofactors in the biosynthesis of 2'-deoxythymidine-5'-monophosphate (dTMP) from 2'-
deoxyuridine-5'-monophosphate (dUMP) via the enzyme thymidylate synthase (TS; EC 
2.1.1.45).  In trypanosomatids, DHFR exists as a bifunctional enzyme fused with 
thymidylate synthase, DHFR-TS. 
 
The catalytic mechanism of PTR1 is similar to that of other SDRs and has been 
described elsewhere (Gourley et al., 2001; Figure 4.2).  The first reduction step 
involves donation of a hydride from the NADPH cofactor to substrate at C7, generating 
NADP+.  A protonated aspartic acid residue does not directly interact with the substrate 
but donates a hydrogen bond to a strictly conserved active site tyrosine that provides a 
proton to substrate N8 and is stabilised by a nearby lysine residue during the transition, 
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which also helps to orient the cofactor.  The second reduction step occurs at positions 5 
and 6 of the dihydro- substrate and hydride is transferred from the nicotinamide C4 to 
substrate C6.  An activated water molecule replaces tyrosine as the proton donor to N5 
while the cofactor pyrophosphate and an ideally placed arginine residue assist in the 
temporary enolisation of the substrate keto group. 
 
Figure 4.2. PTR1 mechanism 
The PTR1 mechanism, modified from Gourley et al. (2001) with permission, showing the first 
(A) and second (B) reduction steps to produce the dihydro- and tetrahydro- forms of biopterin 
or folate.  R represents the same groups provided in Figure 4.1 and the cofactor phosphate is 
shown as AH.  In Trypanosoma brucei PTR1, amino acids depicted correspond to Arg14, 
Asp161, Tyr174 and Lys178. 
 
4.1.2. Pteridine reductase 1 inhibition 
Molecules targeting folate synthesis and metabolism are in clinical use in the treatment 
of bacterial infections, certain cancers as well as malaria.  In particular, DHFR is the 
target of such drugs (Blakley, 1995; Kompis et al., 2005), affecting DNA synthesis by 
limiting the supply of dTMP.  The presence of PTR1 in trypanosomatid parasites 
provides a bypass mechanism (Hardy et al., 1997; Nare et al., 1997a) for the reduction 
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of folates when DHFR is inhibited by traditional antifolates and is therefore detrimental 
to their effectiveness in these organisms (Nare et al., 1997a; Luba et al., 1998).  In 
Leishmania parasites, PTR1 is the only enzyme known to reduce biopterin and has been 
shown to be essential for cell growth in vitro by gene knockout studies where growth 
was successfully rescued by the provision of reduced pterins (Bello et al., 1994; Nare et 
al., 1997b).  Additionally, the loss of T. brucei cell viability and virulence resulted from 
knockdown studies by RNA interference in the bloodstream form of the parasite 
(Sienkiewicz et al., 2010).  PTR1 therefore represents an interesting target for the 
development of potential therapeutic agents in the fight against diseases caused by 
trypanosomatid parasites such as human African trypanosomiasis, Chagas disease and 
Leishmaniasis (Ong et al., 2011).  A single molecule that can target both PTR1 and 
trypanosomatid DHFR-TS or an inhibitor specific to PTR1 for use in combination with 
known antifolates are both desirable prospects (Nare et al., 1997b).  Or indeed, there 
may be potential for effective therapies to target this candidate alone. 
 
Figure 4.3. Methotrexate chemical structure 
Methotrexate (4-amino-N10-methyl-pteroylglutamic acid; MTX) has a highly similar structure to 
folate and the differences are highlighted red.  See Figure 4.1 for the chemical structures of 
folate and reduced folates. 
 
The archetypal antifolate, methotrexate (MTX) is shown in Figure 4.3.  The chemical 
structure of MTX is highly similar to that of folate, differing at position 3 and 4 of the 
pteridine moiety and with an additional methyl group in the aminobenzyl region (shown 
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in red in Figure 4.3).  While able to inhibit PTR1, MTX is less effective against this 
enzyme than it is against DHFR-TS (IC50 1.1 µM against LmPTR1 and 0.005 µM 
against LmDHFR-TS; Hardy et al., 1997) and resistance can be generated by 
Leishmania parasites (Hardy et al., 1997; Nare et al., 1997a).  L. major parasites 
displayed a high sensitivity to MTX in PTR1 knockout studies (Bello et al., 1994) and 
upregulation of PTR1 expression is one possible mechanism of MTX resistance, 
emphasising that current antifolate drugs are inadequate for the treatment of diseases 
caused by trypanosomatid parasites. 
 
4.1.3. Structural knowledge 
Crystal structures of PTR1 from L. major (LmPTR1) and T. brucei (TbPTR1) have been 
published using diffraction data extending to 1.75 Å and 2.2 Å resolution, respectively 
(Gourley et al., 2001; Dawson et al., 2006).  Additional insight is provided by ternary 
complex crystal structures containing cofactor and substrate or inhibitor of LmPTR1 
(Gourley et al., 2001; McLuskey et al., 2004; Schüttelkopf et al., 2005; Cavazzuti et al., 
2008) and TbPTR1 (Mpamhanga et al., 2009; Tulloch et al., 2010; Spinks et al., 2011).  
Collectively, these structures have afforded an understanding of cofactor and substrate 
binding, informed a potential mechanism of action and presented possible modes of 
inhibition. 
 
Sequence similarity between PTR1 from different trypanosomatid species is high.  For 
example, TbPTR1 and LmPTR1 share approximately 50 % identical amino acids and 
are over 80 % similar when conservative substitutions are considered.  This is reflected 
by a high conservation of overall protein structure, described in more detail in Chapter 
6, but there are several notable active site differences with some inhibitors displaying 
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different affinities for the orthologous enzymes, including MTX (Ki 0.152 µM and 
0.039 µM for TbPTR1 and LmPTR1, respectively; Dawson et al., 2006).  This includes 
a tryptophan-histidine (TbTrp221-LmHis241) and cysteine-leucine exchange 
(TbCys168-LmLeu188) and differences in a loop known to line the substrate-binding 
region of the active site (Dawson et al., 2006).  These sequence disparities may be 
sufficient to demand inhibitors with specificity for a single orthologue and, coupled 
with the potential of ligands to adopt distinctive orientations within the PTR1 active 
site, it is essential to characterise new inhibitors structurally to confirm the mode of 
binding.  Furthermore, molecules have yet to be produced with sufficient inhibitory 
effect against a trypanosomatid PTR1 together with the appropriate physicochemical 
properties and efficacy to allow progression to later stages of drug development, 
underlining the need for additional rational design efforts. 
 
4.2. Isothermal titration calorimetry 
4.2.1. Practical overview 
Virtually all molecular binding events are accompanied by an exchange of heat (Freyer 
and Lewis, 2008).  Isothermal titration calorimetry (ITC) is a label and immobilisation-
free technique that can be used to characterise the thermodynamics of those binding 
interactions.  Modern calorimeters are highly sensitive, detecting heat changes as little 
as 0.1 µcal (0.4 µJ) and the change in heat is directly proportional to the amount of a 
particular reaction that has occurred (Wiseman et al., 1989).  
 
The studies presented here have been carried out using a power compensation 
isothermal titration calorimeter, containing two identical cells maintained at the same 
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temperature throughout the course of the experiment.  In the case of a ligand:protein 
titration, multiple successive injections of a set volume of ligand are added to protein 
held within the experimental cell.  When a binding event occurs, the change in heat is 
sensed and power (typically recorded in µcal sec-1) is adjusted accordingly to maintain 
the constant temperature with respect to the unmodified reference cell (Leavitt and 
Freire, 2001).  In an exothermic reaction where heat is evolved, power is consequently 
reduced and results in a downward peak on the raw data panel (Figure 4.4A).  Large 
heat changes are expected on initial injections when all protein binding sites are 
available for complex formation.  Subsequent injections result in smaller heat changes 
as fewer titrant molecules are able to bind to a protein partner.  Finally, when saturation 
occurs, only the effects of dilution and mixing are observed.  A single continuous 
injection is indeed possible but not employed during this project.  Two drawbacks of 
ITC are the relatively low throughput and high reagent consumption levels although 
instruments with greater automation and reduced sample volume capabilities are 
becoming available to allow application of the technique earlier in the drug discovery 
pipeline (Weber and Salemme, 2003). 
 
4.2.2. Thermodynamic profile 
A thermodynamic profile of an interaction can be obtained from a single ITC 
experiment (Wiseman et al., 1989).  This includes the direct measurement of the 
association (or binding) constant, Ka, the stoichiometry of the interaction, N, and the 
change in enthalpy caused by the binding event, ΔH.  Indeed, calorimetry is the only 
method able to measure enthalpic changes directly (Freire et al., 1990; Ladbury, 2010).  
With knowledge of the universal gas constant, R, and the temperature, T, calculation of 
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the dissociation constant, Kd, the change in entropy, ΔS, and the observed free energy of 
binding, ΔG can be accomplished using Equations 4.1 and 4.2. 
 
   ΔG = ΔH-TΔS =  -RTlnKa   (Equation 4.1) 
   Kd = 1/Ka     (Equation 4.2) 
 
Enthalpy is the change in energy as heat and is positive for endothermic reactions or 
negative in exothermic reactions, reflecting both the breakage and formation of non-
covalent bonds.  Entropy is traditionally described as a measure of the disorder or 
randomness in a system and is the subject of the second law of thermodynamics that 
states the universe tends towards maximum disorder.  Increased disorder is reflected by 
a greater ΔS value (often reported as the term from Equation 4.1, -TΔS) and appears 
driven by desolvation events associated with hydrophobic interactions and loss of 
conformational freedom on complex formation, both of ligand and protein.  The free 
energy is an overall measure of the spontaneity of a reaction and, as Equation 4.1 
states, is dependent on the enthalpic and entropic events as are the affinity descriptors, 
Ka and Kd. 
 
In order to accurately determine these thermodynamic properties from one experiment, 
the final curve (isotherm) produced must be the optimum shape.  This is signified by the 
unitless parameter, c, defined as the product of the association constant and the total 
number of binding sites (Figure 4.4B; Wiseman et al., 1989; Pierce et al., 1999; 
Broecker et al., 2011).  In a tight-binding system, low macromolecule concentrations 
are necessary or the curve may be too sharp, producing errors in the derived Ka.  
Conversely, for a weaker binding interaction, the full sigmoidal curve may not be 
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observed and the experimental ΔH will not reflect the accurate value, nor can the 
entropic contribution to the overall free energy be extracted.  A window of 
approximately 1-1000 represents an ideal c value (Wiseman et al., 1989) while a more 
conservative upper limit of 500 (Turnbull, 2011) or an optimum of approximately 40 
(Broecker et al., 2011) are also recommended.  It is therefore imperative that 
experimental parameters are appropriate and in some cases, a compromise between 
optimum theoretical sample concentrations and achieving measurable signal must be 
met (Biswas and Tsodikov, 2010). 
 
Figure 4.4. The ITC isotherm 
(A) An experimental ITC isotherm.  The upper panel displays the raw data.  Each peak 
represents a single injection of titrant.  The lower panel shows the integrated peaks to which the 
best-fitting curve is modeled.  Ka, N and ΔH are measured directly.  (B) Schematic to emphasise 
the shape of the binding isotherm determined by the unitless parameter, c.  This figure is a 
modified version of that in Wiseman et al., 1989. 
 
4.2.3. ITC and crystallography 
Drug discovery programs have traditionally focussed on improving the affinity of 
inhibitors (Leavitt and Freire, 2001).  Other important properties of an inhibitor 
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molecule must also be considered (Ladbury et al., 2010).  This includes the mechanism 
of inhibition, pharmacokinetic profile as well as production concerns such as simplicity 
and cost.  Contributing to an appreciation of such properties, structural information can 
be utilised to build a structure-activity relationship (SAR) and guide chemical 
optimisation (Congreve et al., 2005; Hunter, 2009) while an experimentally derived 
thermodynamic profile can provide insight into a binding system that predictions, 
structural models or measurements of potency alone do not (Salemme et al., 1997; 
Weber and Salemme, 2003; Chaires, 2008).  Ligands with identical affinities can have 
drastically different enthalpic and entropic contributing components (Cooper et al., 
2001; Li et al., 2008).  While interpretation may not be trivial (Cooper et al., 2001; 
Chaires, 2008), it is essential to consider the thermodynamic parameters and to relate 
them to high resolution structures to understand any correlation between binding 
energetics and structure (Leavitt and Freire, 2001; Ladbury, 2010).  As such, an 
approach exploiting multiple biophysical techniques is important to heighten the overall 
insight of a ligand-binding event and aid in the design of effective inhibitors. 
 
4.3. Aims 
With a combined use of crystallography, a kinetic inhibition assay and ITC, we aim to 
characterise the atomic details of PTR1-ligand interactions and identify molecular 
features that have the greatest contribution to affinity.  While structural data are 
available for PTR1 in a number of ligand complexes, previous experiences 
demonstrated that crystals of the L.major enzyme suffered from poor reproducibility, 
typically produced only medium resolution X-ray diffraction and were often of a form 
not optimal for inhibitor studies (W.N.Hunter, personal communication).  We therefore 
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looked to the L. donovani and T. brucei enzymes to provide an improved model for 
inhibitor studies.  TbPTR1 then provides the basis for work undertaken as part of a 
collaboration to examine a series of novel potential inhibitory compounds with a view 
to establishing SAR for the series, to identify new interaction features and contribute to 
future inhibitor design efforts.  The use of thermodynamic binding profiles has not yet 
been utilised in a wide inhibitor study for this enzyme and we set out to assess the value 
of the technique and to generate ligand binding profiles to guide inhibitor optimisation.  
PTR1 therefore not only represents a useful target to investigate inhibitors from a drug 
design perspective but also an interesting model to examine protein-ligand interactions. 
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5.1. General materials and methods 
All general materials and methods are as provided in Part I Chapter 2.  In this chapter, 
any protocol modifications or additional details specific to studies involving the enzyme 
pteridine reductase 1 (PTR1) are described.   
 
5.2. PTR1 ligands 
PTR1 cofactors NADP+ and NADPH were purchased from Melford and all pterin 
substrates were obtained from Schircks Laboratories.  Non-commercial potential PTR1 
ligand molecules were synthesised by Judith Huggan and Abedawn Khalaf (University 
of Strathclyde, Glasgow) or obtained from the Center for Organic and Medicinal 
Chemistry, Research Triangle International (North Carolina, USA).  Ligands were 
prepared in 100 % (v/v) dimethyl sulfoxide (DMSO) to 100 mM based on dry weight.  
The insolubility of any compound at this concentration was established following the 
application of sonication and heat (42°C).  Solubilised compounds were stored in glass 
vials at -20°C and 10-fold serial dilutions (in DMSO) made as working stocks. 
 
5.3. Gene expression and protein purification 
5.3.1. Leishmania donovani PTR1 
A plasmid containing the gene encoding PTR1 from L. donovani, originally cloned 
from gDNA, was obtained from W.N.Hunter.  The gene of interest was subcloned into 
pET15b-TEV using restriction endonucleases NdeI and BamHI to allow the hexa-
histidine tag of the protein product to be cleavable by TEV protease.  BL21 (DE3) 
GOLD cells transformed with this plasmid were cultured in LB as described in 2.3.1.  
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Purification was also similar to that described in 2.3.2 using buffers containing 50 mM 
Tris-HCl pH 7.7, 200 mM KCl and 20-800 mM imidazole.  No size exclusion 
chromatography step was performed.  Cleaved LdPTR1 was exchanged to a solution of 
20 mM Tris-HCl pH 7.7 and concentrated to 5-10 mg mL-1. 
 
5.3.2. Trypanosoma brucei PTR1 
The T. brucei PTR1 expression plasmid, pET15b-TbPTR1 was obtained from 
W.N.Hunter (Dawson et al., 2006).  Recombinant expression was carried out as for 
LdPTR1 above.  TbPTR1 was then purified by a single affinity chromatography step in 
standard buffers (Table 2.4).  Tagged protein was exchanged using a PD-10 desalting 
column (GE Healthcare) to 20 mM Tris-HCl pH 7.5 for crystallisation or 50 mM Tris-
HCl pH 7.5, 250 mM NaCl, 20 % (v/v) glycerol for kinetic experiments.  Following 
concentration to 15-20 mg mL-1 in a centrifugal concentrator with 100 kDa molecular 
mass limit, aliquots of TbPTR1 were flash cooled in liquid nitrogen and stored at -80°C 
until required.  For ITC, TbPTR1 was freshly prepared and stored at 4°C in 20 mM 
sodium citrate pH 3.7 for a maximum of 7 days. 
 
5.4. Spectrophotometric assay 
Inhibition of TbPTR1 activity was carried out according to an established 
spectrophotometric assay (Dawson et al., 2006).  In brief, 1 mL samples containing 30 
µg TbPTR1 (0.96 µM) , 20 µM dihydrobiopterin and 0-1 mM compound of interest in 
20 mM sodium citrate pH 3.7 were warmed to 30°C in acrylic cuvettes (Sarstedt).  Each 
reaction was started by the addition of 100 µM NADPH.  The decrease in absorbance at 
340 nm was monitored for 120 s using a Shimadzu UV-2450 spectrophotometer 
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coupled to UVProbe (Shimadzu).  Dihydrobiopterin stocks were prepared in 0.1 M 
NaOH to 10 mM and stored at -20°C.  Fresh NADPH was dissolved in water to 10 mM 
immediately prior to each set of approximately 50 measurements.  DMSO to a final 
concentration of 1 % (v/v) was present throughout.  All potential inhibitors were 
initially assessed in duplicate at 10 µM and 50 µM.  Compounds showing inhibition of 
greater than 60-70 % at 50 µM were assayed in triplicate at a range of concentration 
points (9-12) to produce a full dose-response curve.  Mean PTR1 inhibition (%) was 
plotted against the log compound concentration and a sigmoidal curve fit using four-
parameter non-linear regression in SigmaPlot (Systat Software).  IC50 values were 
extracted and Ki values calculated using the Cheng-Prusoff equation for competitive 
inhibition where Ki  = IC50 / (1 + [S]/Km) (Cheng and Prusoff, 1973).  Note that this 
assumes stoichiometry of 1:1 and that all inhibitor binding reactions are reversible.  
Substrate Km was used as published (10.9 µM; Dawson et al., 2006). 
 
5.5. Isothermal titration calorimetry 
ITC experiments were all carried out using a VP-ITC system (MicroCal, GE 
Healthcare) controlled by the software, Origin5 (OriginLab).  20-100µM TbPTR1 was 
prepared in the 1.5 mL sample cell and titrated with 0.1-1 mM compound.  Compounds 
were prepared from 100 mM stocks, diluted to the desired concentration using buffer 
identical to that of the protein sample.  Both samples in 20 mM sodium citrate pH 3.7 
were supplemented with 1 mM NADP+ and DMSO to a final concentration of 5 % 
(v/v).  An initial injection of 2 µL to remove any residual air from the syringe was 
followed by 29-39 injections of 6-8 µL titrant at 3 minute intervals (0.5 µL s-1 injection 
rate).  The injection needle also acted as a stirring paddle, mixing the sample cell 
 
 
Part II Pteridine reductase 1  Chapter 5: Materials and methods 
103 
contents at 300 rpm.  Heat evolved due to the addition of compound was measured as 
the change in power required to maintain the sample cell at 30°C with respect to the 
reference cell.  The baseline was determined automatically and manually adjusted 
where necessary.  Raw data peaks were integrated and iteratively fit to the OneSite 
curve model.  No values were fixed in the first instance.  The association constant (Ka), 
stoichiometry (N) and change in enthalpy (ΔH) were extracted from the best-fitting 
curve and the entropic change (ΔS) calculated.  For a number of compounds, the ligand 
concentration input values were retrospectively adjusted to reflect a 1:1 stoichiometry.  
Control titrations were performed when possible in the absence of protein by injecting 
compound into buffer alone and the resultant integrated heats subtracted from the main 
experiment data.  A standard titration of 30 injections of 0.5 mM MTX (8 µL) into 40 
µM TbPTR1 was performed to verify the activity and quantitation of each fresh protein 
preparation.  Each experiment was repeated 2-3 times and all analyses were carried out 
using Origin5. 
 
5.6. LdPTR1 crystallisation and structure solution 
Crystals of LdPTR1 were grown by hanging-drop vapour diffusion at 18°C.  
Crystallisation drops contained an equal volume of 5 mg mL-1 LdPTR1 in 20 mM Tris-
HCl pH 7.7, 1 mM NADP+, 20 mM DTT and 1 mM MTX mixed with 0.1 M MES pH 
6.5, 1.6 M (NH4)2SO4 and 10 % (v/v) dioxane. 
 
A nylon loop was used to harvest suitable crystals that were then passed through a 
cryoprotectant solution containing 40 % (v/v) PEG 400 and cooled to -173°C in a 
stream of nitrogen gas.  Crystals were screened for diffraction in-house using X-ray 
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source A (Table 2.6).  The best diffracting crystal was manually annealed (the 
cryostream was physically blocked for 5-10 s) and diffraction data collected at source F 
(Table 2.6). 
 
Diffraction data were integrated using MOSFLM (Leslie, 2006) and scaled in SCALA 
(Evans, 2006).  Molecular replacement by Phaser (McCoy et al., 2007) was performed 
using a single monomeric chain of the published L. major PTR1 structure as the search 
model (PDB 1e7w; Gourley et al., 2001).  Coot (Emsley and Cowtan, 2004; Emsley et 
al., 2010) was used to manipulate the structural model and in the placement of solvent 
molecules.  Refinement was carried out using REFMAC5 (Murshudov et al., 2011). 
 
5.7. TbPTR1-ligand co-crystallisation and structure solution 
TbPTR1 was crystallised in the presence of cofactor and ligand of interest following 
published methods (Tulloch et al., 2010).  A mixture of 4-6 mg mL-1 TbPTR1, 1 mM 
NADP+, 20 mM DTT and 1 mM compound was incubated on ice for 1 h prior to 
crystallisation.  The solution was centrifuged to remove any insoluble material.  1-2 µL 
protein-ligand solution was then mixed with 1 µL crystallisation solution containing 
1.7-2.7 M NaOAC and 20-50 µM sodium citrate pH 4.5-5.0.  Drops were suspended on 
siliconised glass coverslips above reservoirs containing the latter solution at 18°C. 
 
Crystals grown in an excess of 2.6 M NaOAC were placed in a nylon loop and flash-
cooled directly in liquid nitrogen.  Otherwise, a solution of 3 M NaOAC was used to 
cryoprotect the TbPTR1-ligand co-crystal prior to cooling to -173°C.  Diffraction data 
were collected in-house or at Diamond light source (sources A, B, C, E and F, Table 
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2.6).  Data were collected to 1.7-2.4 Å resolution and typically covered approximately 
180 degrees of rotation.  X-ray images were integrated using XDS (Kabsch, 2010) or 
MOSFLM (Leslie, 2006; Battye et al., 2011) and scaled in SCALA (Evans, 2006) or 
AIMLESS (Evans and Murshudov, 2013).  Molecular replacement was performed by 
MOLREP (Vagin and Teplyakov, 1997) or data were refined directly against the 
TbPTR1 tetrameric starting model using REFMAC5 (PDB 2c7v; Dawson et al., 2006; 
Murshudov et al., 2011).  Electron and difference density map inspection and model 
manipulation with Coot (Emsley and Cowtan, 2004; Emsley et al., 2010) was combined 
with multiple further refinement cycles.  Non-crystallographic symmetry restraints were 
not applied and geometry restraint weightings were manually adjusted in later 
refinement calculations.  The subset of data used to calculate Rfree was maintained in all 
structure analyses.  Cofactor and solvent molecules were added to the model in Coot 
(Emsley and Cowtan, 2004; Emsley et al., 2010) from the associated monomer library 
(Vagin et al., 2004).  Simple amino acid modifications were incorporated in the same 
manner.  Novel ligands were drawn using JME Molecule Editor (Ertl, 2010) and 
coordinates generated using PRODRG (Schüttelkopf and van Aalten, 2004).  Geometry 
restraints were obtained from PRODRG (Schüttelkopf and van Aalten, 2004) or eLBOW 
(Moriarty et al., 2009) and each ligand placed according to difference density Fourier 
maps.  For compounds SDG 33 and SDG 65, two conformations were modelled and 
refined, each with occupancy set to 0.5. 
 
It should be noted that a script known colloquially as BigRedButton, written by Paul K. 
Fyfe, was developed using feedback from usage with these data and proved especially 
useful for initial data and model assessment.  This script called on xia2 (Winter, 2009) 
to process data with XDS (Kabsch, 2010) then MOLREP (Vagin and Teplyakov, 1997) 
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and REFMAC5 (Murshudov et al., 2011), producing interpretable maps and an initial 
model directly from X-ray images.  The TbPTR1 active site was visualized and ligand 
presence quickly evaluated before proceeding with further data collection or more 
comprehensive data processing procedures. 
 
Structural analysis was carried out using programs described in 2.8.5 and additional 
software are cited directly where applicable. 
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6.1. Leishmania donovani pteridine reductase 1 
6.1.1. Protein production, crystallisation and structure solution 
Recombinant LdPTR1 was produced as described in 5.3.  Following initial 
crystallisation screening in sitting-drop format, optimised crystals formed by hanging-
drop vapour diffusion within 2-3 days at 18°C (5.6).  Crystals grew only in the presence 
of cofactor, NADP+, and inhibitor, MTX.  Maximum crystal size was approximately 0.1 
x 0.1 x 0.05 mm.  Attempts to crystallise apo-LdPTR1 under these conditions, or to find 
new suitable conditions, were unsuccessful.  Initial X-ray diffraction was improved by 
annealing the crystal.  Further details of data collection and subsequent structure 
refinement statistics are provided in section 5.6 and Table 6.1.  Crystals display space 
group C2221 with unit cell lengths of a = 107.51 Å, b = 126.44 Å and c = 87.51 Å.  A 
Matthews coefficient (VM) of 2.49 Å2 Da-1 (Matthews, 1968) corresponded to a crystal 
solvent content of approximately 50 % and the presence of two LdPTR1 subunits per 
asymmetric unit.  The structure of LdPTR1, assigned PDB accession 2xox, was 
determined to 2.5 Å resolution by molecular replacement using a published LmPTR1 
structure as the search model (PDB 1e7w; Gourley et al., 2001). 
 
Figure 6.1. LdPTR1 crystal and diffraction 
(A) LdPTR1 crystal. (B) An example diffraction image (2.5 Å resolution at the image edge). 
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Resolution range (Å) 32.0-2.5 (2.6-2.5) 
Space Group C2221 
Unit cell parameters a = 107.51, b = 126.44, c = 87.51 Å 
α = β = γ = 90° 
Wavelength (Å) 0.973 
No. Reflections 144562 (21139) 
No. Unique Reflections 21006 (3022) 
Rmerge a (%) 9.9 (42.1) 
Rpim b (%) 4.1 (17.1) 
Completeness (%) 99.9 (100.0) 
Mean I/σ(I) 11.0 (3.4) 
Redundancy 6.9 (7.0) 
Wilson B factor (Å2) 47.7 
Rwork c (%) 22.8 
Rfree d (%) 28.5 
R.m.s.d bonds (Å) 0.019 
R.m.s.d angles (°) 1.766 
Total protein residues 458 
Total protein atoms 3201 
Average protein B factor (Å2) 43.4 
DPI e (Å) 0.396 
Ramachandran plot:  
     Favoured (%) 95.2 
     Allowed (%) 4.6 
     Outliers (%) 0.2 
Additional groups:  
     Solvent (No./Average B (Å2)) 24 / 38.0 
     Sulfate (No./Average B (Å2)) 2 / 53.4 
Table 6.1. LdPTR1 data collection and refinement statistics 
Values in parentheses correspond to the highest resolution shell (2.6–2.5 Å).  a. Rmerge = 
∑h∑i||(h,i) - <I(h)> ∑h∑i I(h,i); where I(h,i) is the intensity of the ith measurement of reflection 
h and <I(h)> is the mean value of I(h,i) for all i measurements.  b. Rpim, precision-indicating 
merging R-factor, is Rmerge adjusted by a factor of √(1/n-1) where n is the number of times a 
given reflection is observed.  c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed structure 
factor amplitude and the Fc is the structure-factor amplitude calculated from the model.  d. Rfree 
is the same as Rwork except calculated with a subset, 5 %, of data that are excluded from 
refinement calculations.  e. DPI, diffraction-component precision index (Cruickshank, 1999). 
 
6.1.2. LdPTR1 overall structure 
This crystal form of LdPTR1 has two subunits in the asymmetric unit (A and B, Figure 
6.2A).  These subunits are highly conserved structurally with an r.m.s.d. of 0.51 Å when 
212 Cα atoms are overlaid.  Unless otherwise indicated, LdPTR1 subunit A was used 
for all further structural analysis.  PTR1 is a tetrameric enzyme and this is generated by 
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the symmetry operation –x, y, -z + ½ (a 21 screw axis parallel to c).  Each monomer 
presents as a classical Rossmann fold (Rao and Rossmann, 1973; Gourley et al., 2001).  
Seven parallel β-strands are sandwiched between two sets of three α-helices (Figure 
6.2B).  Several loops have residues that could not be modelled, located at β3-α3, β4-α4 
and β6-α6 in addition to extreme N- and C- terminal residues.   
 
 
Figure 6.2. LdPTR1 overall structure 
(A) A cartoon depiction of the LdPTR1 tetramer.  Subunits A and B alone comprise the 
crystallographic asymmetric unit.  Coloured according to chain, β-strands are shown as arrows 
and α-helices as cylinders.  (B) An LdPTR1 monomer.  β-strands are shown as cyan arrows and 
are labelled 1-7.  Helices α1-α6 are labelled (blue ribbons) while potential 310 helices in loops 
α4-β5, β5-α5 and α6-β7 are unlabelled.  Breaks in the yellow coloured loops are signified by 
black, blue and red coloured asterisks.  A sulfate ion is shown as sticks in the active site (S, 
yellow; O, red).  Secondary structure features were assessed using STRIDE (Frishman and 
Argos, 1995; Heinig and Frishman, 2004). 
 
6.1.3. A disordered LdPTR1 active site 
Amino acids that create the PTR1 active site are strictly conserved between LdPTR1 
and LmPTR1 (Gourley et al., 2001).  Sequence comparisons also show that these 
residues are highly similar to those involved in binding the cofactor, substrate and 
product in TbPTR1 (Dawson et al., 2006).  In contrast to LmPTR1 and TbPTR1, 
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however, the LdPTR1 structural model presented displays a poorly ordered active site 
region.  The electron density does not indicate the presence of NADP+ or MTX, despite 
their presence in excess during crystallisation.  MTX is a known inhibitor of PTR1 with 
a Ki of 39 ± 19 nM and 152 ± 16 nM against the L. major and T. brucei enzymes, 
respectively (Dawson et al., 2006). 
 
Figure 6.3. Sulfate bound in the LdPTR1 active site 
A sulfate ion (yellow and red sticks) is bound to LdPTR1, making multiple contacts with 
conserved β2-α2 loop residues, His38, Arg39 and Ser40, shown as sticks coloured by element 
(C, grey; N, blue; O, red).  Potential hydrogen bonds are indicated as orange dashed lines with 
lengths of 2.7-3.6 Å.  The Fo-Fc difference density omit map, calculated by omitting sulfate 
from the final model, is shown as green mesh contoured at 3.5 σ,. 
 
A sulfate ion was modelled into a tetrahedral mass of electron density close to the short 
β2-α2 loop (Figure 6.3).  The density did not extend beyond the spatial radius of the 
single sulfate molecule.  In LmPTR1 and TbPTR1, the cofactor adenine 2'-phosphate 
group is located in the same polar cavity that is formed by the β2-α2 loop and the turn 
connecting β1 and α1.  The sulfate forms hydrogen bonds with three main chain 
amides, His38, Arg39 and Ser40, and the hydroxyl side group of Ser40.  These three 
residues are identical in LmPTR1 and form similar contacts with the cofactor phosphate.  
Owing to the high concentration of ammonium sulfate (1.6 M) required to obtain these 
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LdPTR1 crystals, sulfate appears to have displaced any NADP+ that may otherwise have 
been bound in solution. 
 
During the catalytic cycle, NADPH must first bind, followed by substrate.  Product and 
oxidised cofactor then dissociate sequentially.  The same mechanism of binding is 
described for inhibitors (Luba et al., 1998; Gourley et al., 2001).  The location of the 
sulfate in this LdPTR1 model restricts the access of NADP(H) and thus, the ability for 
an additional ligand molecule to join the binary complex.  Critical residues Phe113 and 
Arg17 are amongst those found disordered in LdPTR1.  Phe113, in the missing β4-α4 
loop, is normally involved in stabilising the ligand position within the catalytic site.  It 
is required to form π-stacking interactions along with the cofactor nicotinamide and 
ligand (Gourley et al., 2001; Dawson et al., 2006).  The disordered side chain of Arg17 
affects the binding of the cofactor pyrophosphate (McLuskey et al., 2004).  Other key 
catalytic residues are Asp181, Tyr194 and Lys198.  Tyr194 is oriented similar to other 
published PTR1 structures.  However, Asp181 is in the relocated β5-α5 loop while 
weak electron density suggests the placement of the Lys198 side chain is unsuitable to 
form stabilising interactions previously observed with either the cofactor ribose or 
neighbouring residues Ser111 and Asn147 (Gourley et al., 2001; Schüttelkopf et al., 
2005). 
 
6.1.4. LdPTR1 and LmPTR1 structure comparison 
Overall, LdPTR1 and the LmPTR1 model used for molecular replacement share over 90 
% sequence identity.  This is translated to an r.m.s.d of 1.3 Å when 202 Cα atoms are 
aligned in Coot (Emsley and Cowtan, 2004; Figure 6.4).  There are, however, several 
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important differences between the crystal structures.  Residues 227-254 remain 
unmodelled in this structure of LdPTR1, which includes the substrate-binding loop 
(Tulloch et al., 2010).  Additionally, a short α-helix between β6 and α6 is also 
unaccounted for in this region.  In LmPTR1, a total of seven α-helices are present, with 
residues 235-244 forming α6.  Indeed, secondary structure prediction by the PSIPRED 
server (Buchan et al., 2010) suggests that residues 235-243 should form an α-helix in 
LdPTR1. 
 
Figure 6.4 LdPTR1 and LmPTR1 backbone comparison 
A stereo diagram of LdPTR1 (blue) and LmPTR1 (grey) backbone traces overlaid.  The sulfate 
bound to LdPTR1 is shown as orange sticks while NADPH and methotrexate bound to LmPTR1 
are coloured yellow and red, respectively.  The substrate-binding loop of LmPTR1, absent in 
this structure of LdPTR1, is highlighted orange.  The β5-α5 loop is repositioned in LdPTR1 
(highlighted in cyan) with respect to the LmPTR1 loop (black).  
 
As mentioned briefly, the loop connecting β5 and α5 displays a large change in position 
between LmPTR1 and LdPTR1.  Distances of up to 16 Å are observed for residues 
topologically equivalent to LdPTR1 Val180-Gly190.  The repositioned loop overlaps 
with both the cofactor nicotinamide and the pteridine-like moiety of MTX.  A binary 
complex of LmPTR1 with NADPH (PDB 2bfo; Schüttelkopf et al., 2005) displays the 
same overall conformation as the ternary complex used in comparisons.  The same 
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loops are also relocated with respect to TbPTR1 complexed with NADP+ and MTX 
(PDB 2c7v; Dawson et al., 2006) which shares approximately 53 % amino acids to 
LdPTR1.  It is possible that the placement of this loop in the active site prevented 
complex formation.  Equally, the lack of ligand may have allowed for an increase in 
flexibility in the region and the loop is able to adopt a different position within the 
vacant active site.  Further inhibitor studies were unfortunately not possible based on 
this crystal form. 
 
6.2. Trypanosoma brucei pteridine reductase 1 
6.2.1. Compound details 
 
 
Figure 6.5. Compound scaffolds 
(A) The majority of compounds tested were built around two pyrrolopyrimidine derivatives 
with substitutions made at the R1, R2 and R3 groups (positions 4, 5 and 6).  (B) Chemical 
structure of trimetrexate, 5-methyl-6-[(3,4,5-trimethoxyphenyl)aminomethyl]quinazoline-2,4-
diamine. 
 
Compounds were synthesised by collaborators at the University of Strathclyde (named 
SDG; Strathclyde Dundee Glasgow) and the Research Triangle Institute (trimetrexate).  
Based on a scaffold previously known to make important interactions with key amino 
acids (Tulloch et al, 2010), a variety of chemical substitutions were made at three 
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positions of two pyrrolopyrimidine scaffolds (Figure 6.5A).  A number of the assessed 
compounds fall outwith this framework but all of those detailed structurally are derived 
from the two core scaffolds.  A single exception is the known DHFR inhibitor, 
trimetrexate (TMQ; Figure 6.5B).  SDG compound structures are provided in 
Appendix A. 
 
6.2.2. Spectrophotometric assay 
All SDG compounds soluble to 100 mM in 100 % (v/v) DMSO were screened in 
duplicate at two concentration points, 10 µM and 50 µM, against 30 µg mL-1 TbPTR1 
(0.96 µM).  30 compounds that failed to dissolve adequately at the desired 
concentration were immediately rejected from further experiments and a total of 102 
compounds were assessed.  Inhibition was calculated as a percentage where 0 % 
inhibition was measured in the absence of inhibitor.  Background NADPH oxidation 
was subtracted from all measurements.   
 
As described in 5.4, compounds displaying at least 60-70 % inhibition of TbPTR1 at 50 
µM were analysed across a range of concentrations, typically from 0.025 µM to 100 
µM.  Ki values are provided for 54 compounds in Table 6.2 and two representative 
dose-response curves are shown in Figure 6.6.  All reported Ki values were obtained 
under the experimental conditions described in 5.4, based on no prior knowledge of 
structural binding modes and assume reversible competitive inhibition with a 
stoichiometry of 1:1.  The Ki of MTX was measured as 0.17 µM in agreement with the 
published value of 0.15 µM (Dawson et al., 2006).  Kinetic results are discussed in 
more detail in 6.2.6 and Table 6.2 is referred to throughout this chapter. 
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Compound R1 R2 R3 Ki (µM) 
--- Scaffold I --- 
SDG 4 NH2 CN Br 3.32 ± 0.13 
SDG 5 a NH2 CN C6H4COH 0.20 ± 0.01 
SDG 7 NHCH3 H CO2C2H5 9.88 ± 0.10 
SDG 10 NHCH2C6H11 CN H 1.62 ± 0.02 
SDG 23 NC4H8S CN H 8.75 ± 0.16 
SDG 32 NC4H8 H H 4.17 ± 0.07 
SDG 33 NC4H8S H H 8.64 ± 0.09 
SDG 53 NC4H8 CCC6H5 H 0.19 ± 0.01 
SDG 65 NH2 C6H4CH3 H 0.32 ± 0.01 
SDG 67 NH2 C6H5 H 0.40 ± 0.01 
SDG 68 NH2 C6H4F H 0.48 ± 0.01 
SDG 69 NH2 CN H 4.87 ± 0.06 
SDG 72 NC4H8 CN H 0.80 ± 0.02 
SDG 73 a NC4H8 CN C6H4COH 0.20 ± 0.01 
SDG 74 b NH2 CN CHCHC6H5 0.16 ± 0.01 
SDG 76 NH2 CN CCC6H5 0.24 ± 0.01 
SDG 77 b NH2 CN CHCHC6H5 0.34 ± 0.01 
SDG 80 NH2 CH2CH2C6H5 H 0.26 ± 0.01 
SDG 82 NH2 CN CHCHC6H4CH3 0.27 ± 0.01 
SDG 84 NH2 CN CH2CH2C6H5 0.35 ± 0.01 
SDG 100 NH2 C6H5 C6H5 0.59 ± 0.01 
SDG 106 NHC6H11 C6H4F H 0.56 ± 0.01 
SDG 107 NHC6H11 C6H5 C6H5 0.20 ± 0.01 
SDG 112 NH2 C6H5 C6H4F 0.24 ± 0.01 
SDG 114 NH2 C6H4F C6H4F 0.30 ± 0.01 
SDG 120 N(CH3)CH3 C6H5 C6H5 0.29 ± 0.01 
SDG 122 NH2 C6H4OCH3 C6H4F 0.58 ± 0.01 
SDG 123 N(CH3)CH3 C6H4OCH3 C6H4F 0.30 ± 0.01 
SDG 127 NH2 C6H5 C6H4Br 0.14 ± 0.01 
SDG 130 NH2 C6H5 C6H4CH2CH 
(CH3)CH3 
0.58 ± 0.01 
SDG 132 NH2 C6H5 C6H4SO2CH3 1.28 ± 0.02 
SDG 134 NH2 C6H5Cl C6H5F 0.29 ± 0.01 
--- Scaffold II --- 
SDG 57  - CH3 H 7.33 ± 0.13 
SDG 60  - C6H4CH3 H 1.21 ± 0.03 
SDG 61  - C6H4F H 1.26 ± 0.01 
SDG 62  - C6H5 H 1.18 ± 0.01 
SDG 70  - CH2NHC6H4OCH3 H 7.08 ± 0.06 
SDG 71  - CH2NHC6H4Cl H 2.53 ± 0.06 
SDG 75  - CN CH2CH2C6H5 0.12 ± 0.01 
SDG 81  - CH2CH2C6H5 H 0.27 ± 0.01 
SDG 99  - C6H5 C6H5 1.17 ± 0.02 
SDG 102  - CH3 C6H5 1.06 ± 0.02 
SDG 111  - C6H5 C6H4F 0.51 ± 0.01 
SDG 113  - C6H4F C6H4F 0.76 ± 0.02 
SDG 115  - C6H4Cl C6H4Cl 0.25 ± 0.01 
SDG 126  - C6H5 C6H4Br 0.23 ± 0.01 
SDG 128  - CH2CH2C6H5 C6H5 0.95 ± 0.02 
SDG 133  - C6H4Cl C6H4F 0.47 ± 0.01 
Table 6.2. (Part 1) 
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Compound R1 R2 R3 Ki (µM) 
--- Scaffold I* --- 
SDG 54 c NC4H8 H H 4.23 ± 0.06 
SDG 85 d NH2 CO2C2H5 C6H5 0.77 ± 0.02 
SDG 88 d NH2 CO2C2H5 C6H5SCH3 1.08 ± 0.04 
SDG 89 d NH2 CONHC6H4Cl H 1.09 ± 0.02 
SDG 91 d NH2 CONHC6H4C2H5 H 0.97 ± 0.02 
SDG 93 d NH2 CONHC6H4SCH3 H 0.68 ± 0.01 
Table 6.2. TbPTR1 inhibition 
SDG compounds are categorised by scaffold and listed according to name.  Crystal structures 
were obtained of TbPTR1 containing compounds highlighted in grey rows.  Scaffold I* consists 
of compounds that contain an additional modification to scaffold I, distinct from the R-group 
substitutions.  a. SDG 5 and SDG 73 were subsequently discovered to bind covalently to 
TbPTR1 under the conditions used for crystallisation and values here were calculated assuming 
reversible inhibition. b. SDG 77 is the (Z)-isomer of SDG 74 (E).  c. NHOCF3 replaces position 2 
NH2 of scaffold I.  d. O replaces position 7 NH of scaffold I. 
 
 
Figure 6.6. TbPTR1 inhibition 
Inhibition of TbPTR1 by SDG 100 (open circles) and SDG 127 (closed circles).  Each data 
point represents the mean of three replicates and error bars denote the standard deviation of the 
same three measurements. 
 
6.2.3. Ligand co-crystallisation and structure determination 
Recombinant TbPTR1 was obtained in high yield following the protocol described in 
5.3.2.  Crystallisation experiments were prepared (5.7) in order to co-crystallise the 
histidine-tagged protein in the presence of the oxidised cofactor, NADP+, and 
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compound of interest.  Compounds that displayed TbPTR1 inhibition greater than 
approximately 60 % at 50 µM were considered for crystallisation.  A cut-off value was 
not strictly imposed and individual compound structure was also taken into account.  
For example, a single molecule was commonly selected to represent a group of highly 
similar compounds.  Crystals grew to their maximum size within 1-3 days (Figure 6.7). 
 
Figure 6.7. TbPTR1 ligand co-crystals 
A selection of TbPTR1 crystals viewed under polarised light.  These crystals were all grown in 
the presence of NADP+ and selected inhibitors and range in size up to approximately 0.1-0.5 
mm along the longest dimension. 
 
Diffraction data were collected to 1.7-2.4 Å resolution from 32 TbPTR1-inhibitor co-
crystals.  Of these, 23 novel ternary complex structures have been successfully 
determined.  The remaining 9 datasets gave poor quality electron density into which 
ligands could not be satisfactorily modelled or questionable novelty and ambiguities in 
the chemical structure were observed.  In particular, electron density for SDG 77 was 
inconsistent with the expected structure and SDG 54 appeared identical to that of SDG 
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32, perhaps as a product of degradation.  Additionally, the high-resolution crystal 
structure of TMQ bound to TbPTR1 was solved using data extending to 1.3 Å 
resolution alongside that of pemetrexed, cryomazine and the 2,4-diamino pyrimidine 
derivative, PY848, which were determined by Alice Dawson and Lindsay B. Tulloch. 
 
All crystals were isomorphous in monoclinic space group P21.  Four molecules were 
present in the asymmetric unit and together these comprise the functional PTR1 
tetramer.  Each subunit was treated individually and non-crystallographic symmetry 
restraints were not applied during refinement.  For the high-resolution TMQ complex, 
anisotropic thermal parameters were included in refinement calculations.  Data 
collection and refinement statistics are provided in Table 6.3.  Structure factors and 
coordinates are deposited in the Protein Data Bank (Bernstein et al., 1977).  Selected 
features observed in these structures are discussed. 
 
6.2.4. TbPTR1-inhibitor complex structural features 
6.2.4.1. Overall structure and active site organisation 
All TbPTR1 models adopt the same conformation as described (Dawson et al., 2006).  
Briefly, the Rossmann-fold repeat is displayed with a seven-stranded β-sheet flanked on 
either side by three α-helices.  A seventh α-helix is present, connected to the substrate-
binding loop (α6-β6).  A number of loop regions could not be modelled in their entirety 
due to a lack of sufficient electron density.  The missing residues vary between 
structures and in some cases between subunits of the same tetramer but are generally 
found in the β4-α4 and α4-β5 loops.  All published PTR1 structures also appear poorly 
ordered at the β4-α4 loop, indicating an inherent flexibility in the region. 
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A single subunit is shown in Figure 6.8, depicting the secondary structure and location 
of the substrate and inhibitor binding site.  The tetramer is similar to that shown for 
LdPTR1 in Figure 6.2A.  R.m.s.d between all four chains is consistent, at 
approximately 0.29 ± 0.09 Å when 248-252 Cα atoms are aligned (individual values 
were calculated using SSM (Krissinel and Henrick, 2004) in Coot (Emsley and Cowtan, 
2004; Emsley et al., 2010)).  Due to this high level of structural conservation, analysis 
has been carried out using subunit A unless otherwise specified. 
 
Figure 6.8. TbPTR1 monomer architecture 
(A) A monomer of TbPTR1 shown as red and orange ribbons with a semi-transparent van der 
Waals surface and (B) rotated to show the active site from above.  This figure was prepared 
using TbPTR1 from the SDG 60 ternary complex but shows NADP+ and folate from PDB 3bmc 
(Tulloch et al., 2010) in the catalytic site.  Gaps in two loops are linked by coloured asterisks 
(*).  The substrate-binding loop between β6 and α6 is coloured blue, cofactor yellow and folate 
black (with blue N and red O).  The side-chain of Phe97 is displayed as red sticks to show the π-
stacking of the NADP+, folate and phenylalanine ring systems.  (B) depicts the approximate 
orientation of the enzyme used to prepare subsequent figures. 
 
In all instances, NADP+ is bound within the active site, creating the right environment 
for interactions with inhibitor molecules (Dawson et al., 2006).  Key hydrogen bonds 
contributing to position the cofactor in TbPTR1 include those between the adenine 
moiety and the side chain carboxyl of Asp62; Ser95 amide and the adenine ribose O; the 
adenine 2' phosphate and His35, Asn36 and Ser37 amides and Ser37 hydroxyl groups 
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located on β2-α2; both α- and β-phosphates and Arg14 through the side chain amide 
and amino atoms; the nicotinamide ribose and the amino group of Lys178; Ser207 
amide and Leu208 carbonyl groups with the nicotinamide N7 (not shown).  While the 
adenine moiety lies more buried in the elongated cleft, the extended cofactor forms the 
floor of the catalytic site, creating additional positions for substrate or inhibitor 
interaction, particularly at the nicotinamide ribose and phosphate groups (Figure 6.9).  
The association of cofactor with members of the SDR family are well characterised 
(Duax et al., 2003) and the sequential binding of ofactor then substrate in PTR1 is 
conserved (Luba et al., 1998). 
 
Figure 6.9. Organisation of the TbPTR1 active site 
(A) A surface representation of TbPTR1 with cofactor and substrate, folate, bound (PDB 3bmc) 
showing key residues that create the active site pocket.  Potential hydrogen bonds are depicted 
as magenta dotted lines and all atoms are coloured according to atom type: O, red; N, blue; S, 
gold; P, orange; C, yellow (NADP+), cyan (TbPTR1) or black (folate).  Phe97 is not labelled.  
(B) The active site with folate removed and key hydrogen donor or acceptor groups circled blue 
or red, respectively.  Scaffolds I and II are shown opposite and possible hydrogen donor or 
acceptor groups are designated D or A, respectively.  Arrows on the schematic also indicate the 
intended direction of R1, R2 and R3 substitutions.  
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The vacant active site of TbPTR1 is approximately 30 x 22 x 15 Å (Dawson et al., 
2006) before NADP+ is bound.  Both cofactor and folate are shown in the active site in 
Figure 6.9A (PDB 3bmc; Tulloch et al., 2010).  MTX and other molecules designed to 
prevent PTR1 activity are competitive inhibitors so it is necessary to generate 
interactions equivalent or surplus to those made with substrate.  Amino acids important 
for positioning substrate or MTX include Ser95, which donates a hydrogen bond to 
Asn127 and is able to accept hydrogen bonds from a ligand at both the main chain 
carbonyl and side chain hydroxyl groups.  Tyr174 is able to share hydrogen bonds with 
nitrogen-based groups of the pterin moiety and is also positioned close to Asp161 and 
Lys178, together comprising what is often considered the catalytic triad.  The p-
aminobenzoyl (pABA) and γ-glutamate tail of both folate and MTX make no additional 
hydrogen bonds with TbPTR1 and are directed out of the active site cavity.  The region 
of the active site at the opposite side to the cofactor (at the right of most figures 
presented here, indicated in Figure 6.9B) contains sub-pockets that are not exploited by 
either substrate or MTX, representing an ideal area for inhibitor development.  
Scaffolds I and II (Figure 6.5) were previously shown to successfully generate key 
contacts with cofactor and catalytic residues (Tulloch et al., 2010) and were therefore 
subject to further modification with new interactions identified.  Figure 6.9B shows the 
TbPTR1 active site with folate removed and highlights several amino acids and cofactor 
groups that these scaffolds were intended to share hydrogen bonds with.  Hydrogen 
bond donor or acceptor groups were assigned based on previous knowledge of active 
site interactions and most of the designated groups of scaffolds I and II are 
complementary to those of the active site if binding occurs in the orientation shown and 
no other protonation events occur.  Regions of the active site to be explored by chemical 
substitutions at R1, R2 and R3 are also indicated. 
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Figure 6.10. TbPTR1 active site containing NADP+ and 24 inhibitors 
(A) To display the range of inhibitors assessed structurally, all 24 ligands are overlaid on a 
surface representation of the TbPTR1 active site based on the ternary complex with SDG 60.  
Five amino acids have been removed for clarity (Phe97, Pro210, Ala212, Met213 and Glu217).  
NADP+ is shown as yellow sticks.  All other atoms are coloured according to element (C, grey; 
N, blue; O, red; S, gold; F, pale blue; Br, brown).  (B) Difference density omit maps of all 
inhibitors, represented by blue mesh.  Fo-Fc maps were calculated with the molecule removed 
from the final model and contoured at 3 σ (TMQ at 4 σ).  (i) and (ii) indicate the primary and 
secondary molecules observed in the active site while (A) and (B) indicate molecules bound to 
subunits A or B.  SDG 5 and SDG 73 are shown linked to Cys168. 
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When all 24 compounds with crystal structures are superimposed in the TbPTR1 active 
site (Figure 6.10A), it is clear that the core scaffold position appears well conserved 
and the widely dispersed appearance of the R-group substituents demonstrates the range 
of molecules assessed.  Corresponding omit maps are also provided for each compound 
(Figure 6.10B).  In most cases, the inhibitor shows the same binding pose in all four 
subunits in the asymmetric unit and it is only necessary to describe a single example.  
However, we have observed ligands that adopt two orientations at partial occupancy and 
these will be described alongside other features of ligand binding. 
 
6.2.4.2. Ligand orientation 
Substrate molecules all bind in the same orientation, shown by the TbPTR1 structure in 
a complex with folate (PDB 3bmc; Tulloch et al., 2010; Figure 6.9) and by LmPTR1 
structures complexed with biopterin, dihydro- and tetra-hydrobiopterin (PDB 2bf7, 
1e92, 2bfp; Gourley et al., 2001; Schüttelkopf et al., 2005).  The core pterin moiety lies 
coplanar with the nicotinamide and the side chain of Phe97 in a π-π stack with the 2-
amino group donating hydrogen bonds to Ser95.  The substrate 4-carbonyl is then 
directed towards Pro210 of the substrate-binding loop.  MTX and a number of other 
inhibitor molecules adopt a different orientation to maximise hydrogen bonding 
capabilities with the 4-amino group positioned to donate a hydrogen bond to Tyr174, 
taking the place of substrate N8.  Of the 24 ligand-complex structures here, only SDG 
80 and TMQ adopt the MTX-like orientation.  The pyrrolo-pyrimidine core of SDG 80 
aligns in the same way as the pteridine of MTX.  The ethylphenyl group then extends 
towards Trp221, deeper into the hydrophobic cavity than the MTX pABA group which 
is directed to solvent.  The partner of SDG 80 based on scaffold II binds according to 
the substrate orientation (PDB 3jqb, Tulloch et al., 2010) and is shown schematically in 
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Figure 6.11.  This published ligand is SDG 81 and the binding orientation was 
confirmed1.  The change in orientation replicates that seen between folate and MTX 
where a similar chemical substitution is made.  There does not appear to be any 
conformational changes imposed on active site amino acids to accommodate either SDG 
80 or SDG 81 and of all other SDG models studied, the NH2:N:NH pattern of scaffold I 
and II positions 2:1:7 appears to favour the substrate-binding orientation. 
 
 
Figure 6.11.  SDG 80 and SDG 81 (3jqb) adopt different orientations 
Schematic depicting SDG 80 bound in the MTX-like orientation (left) while the ligand from 
PDB 3jqb (SDG 81) adopts the substrate-like orientation (right).  Ligands are shown as large 
circles coloured by residue (C, black; N, blue; O red) with purple bonds.  Nearby residues and 
NADP+ have orange bonds.  Water molecules (cyan circles) have been filtered and are only 
shown if at least two contacts are made.  Potential hydrogen bonds are depicted as green dashed 
lines and hydrophobic interactions represented by red curves.  This figure was prepared using 
LigPlot+ (Wallace et al., 1995) and all contacts were calculated automatically by the associated 
HBPLUS (McDonald and Thornton, 1994). 
 
1The crystal structure of SDG 81, published by Tulloch et al. (2010), was inadvertently re-
determined.  Further details are therefore not presented. 
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TMQ has a quinazoline core and lacks a nitrogen at position 8 (equivalent to N7 in 
pyrrolopyrimidines) to favourably interact with Tyr174 if it were bound in the substrate 
orientation.  In the MTX orientation, the 4-amino group is optimal to provide this 
contact.  All previous ligands based on scaffold II also adopt the substrate-like 
orientation (Tulloch et al., 2010).  When all R-groups were represented by H, relatively 
poor inhibition of both TbPTR1 and LmPTR1 resulted, indicating that additional 
substitutions are required. 
 
SDG 65, with an amino group at R1 of scaffold I, presents as a dual conformer adopting 
the MTX-like orientation with half occupancy in subunit A.  It also appears to bind in 
the substrate-like orientation at half occupancy while it has been modelled solely in this 
orientation in all other subunits.  It is possible that the highly similar SDG 67 and SDG 
68 are also able to bind in this manner but electron density suggested a preference for 
the substrate-like binding mode.  McLuskey et al. (2004) found a similar feature in the 
L. major ternary complex with 2,4,6-triaminoquinazoline (TAQ) where multiple 
orientations were displayed by the inhibitor.  Again, this may indicate that additional 
substitutions are necessary to drive a single binding mode.  For example, addition of 
bulky groups at the R3 position may be one way to ensure the substrate-like orientation 
is adopted as large clashes would be expected to prohibit binding in any other 
orientation. 
 
Interestingly, SDG 23 binds in an unexpected orientation that is neither substrate nor 
MTX-like.  Rather, the pyrrolopyrimidine ring system is flipped by 180° from the 
traditional substrate-like position (Figure 6.12). The 2-amino group of SDG 23 is 
directed towards Asp161, sharing a hydrogen bond with a side chain OD atom.  Tyr174 
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can still make contact with the N and NH at positions 1 and 7 but the entire core is more 
distant from the cofactor.  Only a weak water-mediated hydrogen bond connects the 
inhibitor to the NADP+ phosphate and Ser95 (mean NH-H2O distance is 3.6 Å) while a 
hydrogen bond remains with the nicotinamide ribose (mean distance 3.1 Å).  A water 
molecule in place of the amino group that forms hydrogen bonds with the cofactor α-
phosphate and Ser95 has previously been seen in the L. major enzyme complexed with 
trimethoprim, a DHFR inhibitor containing a pyrimidine-2,4-diamine core 
(Schüttelkopf et al., 2005). 
 
Figure 6.12. SDG 23 binds in an unfavourable orientation 
TbPTR1 is shown as a semi-transparent van der Waals surface.  Phe97 was removed prior to 
surface generation and is shown as thin lines here for clarity.  Selected active site residues, 
NADP+ and SDG 23 are shown as sticks, coloured by atom using the same colour scheme as 
Figure 6.9 except SDG 23 C atoms are shown here in grey.  Potential hydrogen bonds shared 
with SDG 23 are shown in magenta and the water molecule with hydrogen bonds to Ser95 and 
cofactor is shown as a red sphere. 
 
The alternative orientation of SDG 23 was likely brought about by the large 
thiomorpholine group at position 4, clashing with residues of the substrate-binding loop, 
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including Pro210.  However, SDG 33 contains the same group and adopts the substrate-
like orientation inducing movement of those residues.  This therefore implies that it is 
the combination of R1 thiomorpholine and R2 carbonitrile in SDG 23 that prohibits the 
intended substrate-like interactions while not containing the ideal organisation to exploit 
the MTX orientation.  Compounds that bind in this manner, making only water-
mediated hydrogen bonds with the cofactor phosphate and Ser95, are typically weak 
inhibitors, including SDG 23 (Ki 8.75 µM).  Understanding the features that cause this 
suboptimal placement is important for improving inhibitor design.  The core framework 
employed here has never been structurally assessed with an R1 substitution larger than 
an amino group.  It has been demonstrated that while the active site can accommodate a 
thiomorpholine (SDG 33), pyrrolidine (SDG 32, SDG 53 and SDG 73), N4,N4-dimethyl 
(SDG 120) or an N4-cyclohexane group (SDG 106 and SDG 107) and bind in substrate-
like orientation, the coincident R2 constituent can influence the ultimate binding mode.  
In particular, the inability to accommodate a large thiomorpholine substitution at the R1 
position in combination with an R2 carbonitrile in order for substrate-like binding is 
highlighted.   
 
6.2.4.3. The substrate-binding loop 
The substrate-binding loop is flexible, particularly between residues 205-213.  It has 
already been shown in LdPTR1 that the absence of ligand in the catalytic site likely 
affects the placement of this loop and in TbPTR1, we observe that this loop shows some 
degree of disorder even where both cofactor and inhibitor appear bound in an ordered 
manner.  In most cases, only the most prevalent conformation of the loop is modelled.  
However, in some complexes, there are likely two (or indeed more) possible positions 
of this loop.  Care should be taken in the analysis of such placement, as there are likely 
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multiple conformers where the loop has not been adequately stabilised.  Despite this, it 
is clear that scaffold I compounds with R1 substituents other than NH2 result in 
relocation of this loop.  For example, SDG 53 illustrates that a pyrrolidine group at R1 
coupled with an extended inflexible hydrophobic R2 group directed towards Trp221 
forces the loop and part of β6 to be displaced (Figure 6.13). 
 
Figure 6.13. Substrate-binding loop displaced by SDG 53 
A stereo image demonstrating the different positions of the substrate-binding loop between 
TbPTR1 complexed with SDG 53 (cyan ribbon) and folate (PDB 3bmc, black).  NADP+ is 
displayed as yellow sticks while SDG 53 and selected active site residues are coloured by atom 
(C, cyan or grey; N, blue, O, red; S, gold). 
 
6.2.4.4. Subunit variation and conformational changes 
While non-crystallographic symmetry restraints were not imposed during structure 
refinement (5.7) and the TbPTR1 tetramer chains are typically well conserved 
structurally (6.2.4.1), there are some local variations observed.  This is mainly restricted 
to the placement of flexible amino acid side-chains, particularly involving exposed 
surface residues or disordered loops.  Active site residues generally adopt a fixed 
conformation but have been shown to adjust position to accommodate certain ligands.  
For example, the substrate-binding loop often appears disordered (described in 6.2.4.3) 
and Trp221 on the border of the active site has been displaced by inhibitors 
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(Mphamhanga et al., 2009).  Here, SDG 128 causes an unusual repositioning of Phe97 
(Figure 6.14).  As described, Phe97 usually forms a stacked arrangement with the 
cofactor nicotinamide and the substrate pterin moiety (Figure 6.8).  In subunits A, C 
and D of the SDG 128 ternary complex, the R2 phenethyl group is able to fold back, 
almost creating a second stack over the R3 phenyl group.  Phe97, whilst still aligned 
over the core scaffold, is displaced by up to 2.5 Å to overlay only the 6-membered 
pyrimidine ring and no longer appears coplanar with both cofactor and ligand.  Subunit 
C displays a less prominent relocation than A and D while in subunit B, Phe97 remains 
in the same position as all other PTR1 complexes.  The R2 phenethyl in subunit B is 
instead extended towards the hydrophobic pocket formed by Leu209, Met213 and 
Trp221.  The extended conformation is also accompanied by a small adjustment of the 
substrate-binding loop.  
 
Figure 6.14. Active site Phe97 displaced by SDG 128 
In three out of four subunits, Phe97 is displaced by a phenethyl substitution at R2. NADP+ is 
shown as yellow sticks.  Subunit A active site residues and inhibitor are coloured pale blue 
while the equivalent residues and ligand of subunit B are coloured dark blue.  Phe97 is shown in 
both cases as thin lines of the same colours. 
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6.2.4.5. Two inhibitors binding in a single active site 
In two structures, there is evidence of multiple inhibitor molecules binding in the same 
active site.  SDG 33 shows well defined electron density for two molecules per subunit 
and the same applies to SDG 32 in subunits A and D.  Both SDG 32 and SDG 33 are 
low molecular weight compounds with mass of 203 and 235 Da, respectively.  As such, 
they could be classified within the category of ‘fragments’ (Carr et al., 2005).  Both 
SDG 32 and SDG 33 are weak inhibitors of TbPTR1 in the low micromolar range (4.17 
µM and 8.64 µM, respectively; Table 6.2).  However, as fragments, their potency is 
desirable as potential starting molecules (Rees et al., 2004).  The mode of binding of the 
second molecule can therefore be particularly useful in the design of further compounds 
expanding on the core template.  The distinct poses adopted by SDG 33 are shown in 
Figure 6.15.  The first, or primary, pose assumes the classic substrate-like orientation.  
The R1 thiomorpholine group is present in two conformations, each of half occupancy, 
in subunits A and B.  In one conformer, the group is directed towards Arg14, potentially 
acting as a weak hydrogen bond acceptor while the other conformer, as in subunits C 
and D, is modelled with the sulfur aimed out of the cavity.  The secondary pose adopted 
by SDG 33 displays a more ordered placement than that of SDG 32 (see omit maps in 
Figure 6.10B) and lies almost perpendicular to the primary molecule in what is usually 
seen as a cavity containing water molecules or in some cases, DTT.  Separated by less 
than 4 Å, the angle between the ring planes of both molecules is approximately 90° and 
is indicative of favourable edge-face π-interactions while the molecule at the secondary 
site can also interact with the side chain of Phe171 in the same manner.  The 2-amino 
group of the secondary SDG 33 lies within favourable hydrogen bonding distance to 
both the backbone carbonyl of Gly205 and the carboxylate of Asp161.  In structures of 
both the folate and MTX-bound enzyme, this position is occupied by an ordered water 
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molecule.  Indeed, during the first reduction step in the enzyme mechanism (Figure 
4.2), Asp161 likely acquires a proton from solvent that is passed on to substrate by 
Tyr174.  Here, the side chain of Asp161 also shares a hydrogen bond with SDG 33 N1 
while a water molecule hydrogen bonds to the 7-NH group.  The ordered R1 
thiomorpholine group extends to facilitate hydrophobic interactions with residues in the 
β6-α6 substrate-binding loop and does not cause any significant conformational change 
to nearby amino acids. 
 
Figure 6.15. Two SDG 33 molecules bound in the TbPTR1 active site 
The TbPTR1 active site is represented as described in Figure 6.12.  The primary SDG 33 
molecule is labelled (i) and is present in two conformations.  The secondary SDG 33 molecule 
(ii) is shown sharing hydrogen bonds with Asp161, Gly205 and a water molecule.  Also shown 
is Phe171 as thin cyan lines, forming a border to the secondary binding site. 
 
This secondary binding location has been occupied by an inhibitor molecule on two 
previous occasions (Mpamhanga et al., 2009).  However, only in one subunit were two 
inhibitor molecules bound simultaneously, displaying only partial occupancy.  The main 
site molecule also did not form all of the well-characterised key hydrogen bonds in 
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either the standard substrate or MTX-like orientations.  The ability to bind 
simultaneously in both the substrate-like orientation and at this secondary site is 
therefore displayed for the first time by SDG 33 and to some extent, SDG 32.  It is 
possible that the second molecules are permitted to bind due to the high 
compound:enzyme ratio present in the crystallisation mixture (at least five-fold excess).  
However, compounds binding solely in the second site have been shown by 
Mpamhanga et al. (2005) to inhibit TbPTR1 activity (apparent Ki 0.4 µM, measured 
under different assay conditions).  Therefore, binding in this orientation may indeed 
contribute to inhibition and kinetic values provided for SDG 33 may be inappropriate.  
This perhaps also contributes to the difference between the apparent potency of SDG 33 
and SDG 32, where the second molecule is less ordered.  Nevertheless, other fragment-
sized molecules crystallised with PTR1 generally do not display the same ability to bind 
at multiple locations indicating that the properties of SDG 33 are indeed favourable and 
demonstrates a desirable area to optimise a single molecule capable of exploiting the 
otherwise vacant secondary site in combination with the primary catalytic region. 
 
6.2.4.6. Covalent interactions and modifications 
A cysteine residue, Cys168, at an opening to the catalytic site is often susceptible to 
covalent modifications.  Oxidation to sulfenic acid is regularly observed (in at least one 
subunit of complexes with SDG 53, 57, 68, 82, 99, 120 and 126) and it has been found 
to form covalent links with DTT (in at least three subunits of complexes with SDG 65, 
67 and 99) or cacodylate (Dawson et al., 2006).  A unique observation presented is the 
covalent attachment of two inhibitors to TbPTR1 via Cys168 (Figure 6.16A).  SDG 5 
and SDG 73 both contain a 3-formylphenyl group attached to scaffold I at position 5 
(R3).  The pyrrolopyrimidine core binds in the substrate orientation as described for 
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other molecules in the series.  The R3 phenyl ring is rotated by approximately 30° with 
respect to the main scaffold in order to present the reactive formyl group to contact 
Cys168 where, following nucleophilic attack by the deprotonated thiol, they are linked 
by a covalent bond. 
 
Figure 6.16. SDG 5 is a covalent inhibitor of TbPTR1 
(A) SDG 5 is shown covalently attached to Cys168, surrounded by selected active site residues 
and NADP+.  All atoms are coloured as previously except His267ʹ′ and Ala268ʹ′ from subunit D, 
represented by orange C atoms.  These two residues are shown to highlight the proximity for 
their potential involvement in the covalent linkage mechanism. (B) A sequence alignment of 
TbPTR1 and LmPTR1.  Conserved amino acids are shown as white text on a black background.  
Selected conserved active site residues are highlighted by blue boxes while the TbPTR1 β6-α6 
substrate binding loop is surrounded by a teal box. The non-conserved Cys168 and partially 
conserved C-terminal residues are highlighted red and orange, respectively.  TbPTR1 secondary 
structure according to Dawson et al. (2006) is shown as teal cylinders (α-helices or η-turns) and 
arrows (β-strands). 
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In drug development, there is a reluctance to utilise molecules that bind covalently to 
their target.  Non-specific binding leading to toxicity is the major concern and as such, 
compounds that risk generating high toxicity are often avoided at the early stages of the 
development process.  Covalent inhibitors do not automatically fail to meet the criteria 
of traditional drug-like models such as Lipinski’s ‘rule of five’ (Lipinski et al., 2001).  
Many commonly used drugs are in fact covalent modifiers including aspirin (Roth et 
al., 1975; Tóth et al., 2013) and β-lactam antibiotics (Sainsbury et al., 2011).  Indeed, it 
is estimated that almost one third of enzymes targeted by marketed drugs (21 out of 71 
enzymes targeted by 317 FDA approved drugs in 2005, USA) undergo a covalent 
modification (Robertson, 2005), but rarely are they designed with this intended 
mechanism of action (Singh et al., 2011).  An advantage of purposely designing 
covalent dugs includes the potential lower dose requirement.  If highly specific, toxicity 
can then also be lower than anticipated.   
 
The potential reactivity of TbPTR1 Cys168 was previously postulated by Dawson et al. 
(2006) to be enhanced by the proximity of His267 and the carboxyl terminus of Ala268 
from a neighbouring subunit (subunit D), an arrangement similar to that seen in cysteine 
proteases (Tyndall et al., 2005) where the basic histidine side chain is able to 
deprotonate the thiol group.  Cys168 is not conserved between PTR1 of different 
species (Figure 6.16B).  The equivalent residue in LmPTR1 is Leu184 so compounds 
SDG 5 and SDG 73 may result in poorer inhibition of the L. major enzyme where the 
functional groups would clash.  SDG 5 and SDG 73 are the first covalent inhibitors of 
recombinant TbPTR1 described.  Therefore, if covalent modification were the intended 
route for PTR1 inhibitor development, these structures demonstrate that Cys168 of 
TbPTR1 can be exploited.  Alternatively, this reactive group tethered to Cys168 could 
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be utilised in the development of more potent inhibitors similar to an approach 
employed in fragment-based drug discovery (Erlanson et al. 2004). 
 
6.2.5. Isothermal titration calorimetry 
ITC was attempted with the majority of compounds in Table 6.2.  Suitable isotherms 
were achieved for seven SDG inhibitors.  The major problem encountered causing this 
attrition rate involved compound solubility.  The same buffer system as the inhibition 
assay was used and although optimisation may have allowed measurement of an 
increased number of samples, the derived thermal parameters would not have been 
comparable (Pierce et al., 1999; Olsson et al., 2008).  Additionally, some titrations 
resulted in low heat changes  with noisy background dilution effects (such as SDG 23 
and SDG 53). 
 
Two example thermodynamic profiles are provided in Figure 6.17.  Data obtained from 
ITC are listed in Table 6.4 and shown graphically in Figure 6.18.  All ITC experiments 
were performed using fresh TbPTR1 preparations and based on the measured 
stoichiometry of a control titration using MTX, the quantification of active enzyme was 
confirmed to be within an acceptable range (N = 1 ± 0.1).  Consequently, the only 
variable causing large changes in N should be the preparation of ligand.  Excluding 
SDG 32 and 33, all crystal structures presented demonstrate 1:1 stoichiometry and have 
been analysed on that basis.  Ligand concentrations were therefore retrospectively 
adjusted to normalise the variation in experimental N values and produce a value of N = 
1.  Both experimental and adjusted data are provided in Table 6.4 and all further 
analyses have been carried out using the adjusted values.  Data for SDG 32 and SDG 33 
titrated against TbPTR1 are not included here.  The N values obtained were 
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approximately 0.7 and 0.6, respectively, and the crystal structures of these inhibitors 
show evidence of two molecules in the active site (6.2.4.5) so it is not appropriate to 
assume N = 1.  As mentioned, two molecules binding in the active site may be a 
crystallographic artefact but equally, the particularly low stoichiometric value is 
suggestive of an unusual interaction, introducing additional complications to 
interpretation.  ITC experiments where two ligand molecules bind to a single protein 
monomer should in theory return N = 2 and the isotherm show signs of two separate 
thermal events where a two-site binding model could be applied in the curve-fitting 
procedure.  Here, perhaps the primary and secondary molecules’ affinity for TbPTR1 do 
not differ to a large enough extent to distinguish the interactions. 
 
Figure 6.17. TbPTR1 ITC isotherms 
Representative thermodynamic profiles of MTX (left) and SDG 68 (right) titrated against 
TbPTR1-NADP+.  The upper panels show the raw data and the lower panels show the curve of 
best fit following peak integration. 
 
All isotherms displayed an acceptable c value of between 5 and 250 (Table 6.4).  The 
optimum c for accurate data extraction can be considered to be approximately 40 
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(Broecker et al., 2011) while others suggest a far wider range of 1-1000 (Wiseman et 
al., 1989).  In the case of MTX, with the highest c of approximately 230, performing the 
titration using a lower inhibitor concentration to produce a lower c may also have 
resulted in lower and perhaps immeasurable heat exchange.  While, for isotherms with c 
< 10, the availability of ligand and solubility at higher concentrations were prohibitive. 
	   	   	   	   	   	   	   	   	  
  
N Kd          (µM) 
ΔG                 
(kJ mol-1) 
ΔH                
(kJ mol-1) 
 -TΔS                
(kJ mol-1) c 
LE      
(kcal mol-1 
HA-1) 
Ki           
(µM) 
Biopterin 0.71 ± 0.02 3.88 ± 0.32 -31.41 ± 0.21 -66.11 ± 1.60 34.69 ± 1.53 7.4 0.44  - 
  1.00 ± 0.01 5.48 ± 0.29 -30.53 ± 0.15 -46.97 ± 1.15 16.44 ± 1.28 7.4 0.43   
DHB 0.82 ± 0.07 5.35 ± 0.96 -30.66 ± 0.42 -63.24 ± 2.93 32.58 ± 2.51 6.2 0.43  - 
  1.00 ± 0.01 6.22 ± 0.29 -30.36 ± 0.21 -50.10 ± 1.75 19.73 ± 1.94 6.5 0.43   
MTX 1.08 ± 0.02 0.19 ± 0.04 -39.04 ± 0.50 -51.67 ± 1.47 12.64 ± 1.93 231.3 0.28 0.17 
  1.00 ± 0.01 0.18 ± 0.04 -39.17 ± 0.51 -55.40 ± 2.29 16.23 ± 2.76 230.8 0.28   
SDG 57 1.33 ± 0.01 1.95 ± 0.23 -33.15 -29.71 ± 0.38 -3.44 41.0 0.66 7.33 
  1.00 ± 0.01 1.46 ± 0.17 -33.88 -39.62 ± 0.50 5.74 41.2 0.67   
SDG 60 1.10 ± 0.03 0.61 ± 0.01 -36.05 ± 0.02 -35.02 ± 0.82 -1.03 ± 0.84 53.8 0.48 1.21 
  1.01 ± 0.00 0.56 ± 0.00 -36.31 ± 0.00 -38.70 ± 1.20 2.40 ± 1.20 54.5 0.48   
SDG 65 1.07 ± 0.03 0.38 ± 0.02 -37.23 ± 0.16 -31.09 ± 0.64 -6.14 ± 0.53 111.6 0.49 0.32 
  1.00 ± 0.03 0.36 ± 0.03 -37.38 ± 0.21 -33.09 ± 1.12 -4.29 ± 0.91 111.3 0.50   
SDG 67 1.45 ± 0.04 1.10 ± 0.11 -34.60 ± 0.25 -25.53 ± 0.94 -9.07 ± 1.14 53.2 0.49 0.40 
  1.01 ± 0.01 0.76 ± 0.06 -35.51 ± 0.19 -36.73 ± 1.92 1.21 ± 2.11 53.2 0.50   
SDG 68 1.14 ± 0.02 1.18 ± 0.21 -34.42 ± 0.48 -27.55 ± 0.35 -6.87 ± 0.82 39.6 0.46 0.48 
  1.00 ± 0.01 1.04 ± 0.17 -34.75 ± 0.45 -31.40 ± 0.85 -3.35 ± 1.29 39.5 0.46   
SDG 106 1.33 ± 0.04 4.12 ± 1.28 -31.31 ± 0.79 -23.18 ± 1.14 -8.13 ± 1.93 13.5 0.31 0.56 
  1.00 ± 0.00 3.13 ± 1.04 -32.01 ± 0.85 -30.61 ± 0.76 -1.40 ± 1.62 13.5 0.32   
SDG 132 0.90 ± 0.02 4.27 ± 0.76 -31.18 ± 0.47 -25.89 ± 0.79 -5.30 ± 1.20 8.7 0.28 1.28 
  0.98 ± 0.01 4.69 ± 0.82 -30.94 ± 0.47 -23.72 ± 1.02 -7.23 ± 1.38 8.6 0.27   
Table 6.4. ITC thermodynamic data 
Thermodynamic parameters obtained from ITC of seven SDG inhibitors (two scaffold I and five 
scaffold II, as indicated), MTX and substrates, biopterin and dihydrobiopterin (DHB).  All 
values are the average of 2-3 independent experiments and corresponding standard deviations 
are shown.  SDG 57 was a single experiment only and reported errors are those produced by 
curve-fitting procedures and not provided for the entropic value.  Experimental values are 
reported in white rows, adjusted values are shaded grey.  Ligand efficiency per heavy atom 
(HA) was calculated using ΔG in kcal mol-1 (1 J = 4.184 cal).  Ki values from Table 6.2 are 
provided for reference.  
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Figure 6.18. TbPTR1 ligand thermodynamics 
Thermodynamic data extracted from ITC isotherms, converted to the SI units, kJ mol-1.  All 
values are the average of 2-3 independent experiments and corresponding standard deviations 
are shown.  SDG 57 was a single experiment only and reported errors are those produced by 
curve-fitting procedures and not provided for the entropic value.  ΔG, ΔH and -TΔS are 
experimental values while ΔGʹ′, ΔHʹ′ and -TΔSʹ′ indicate the adjusted values of Gibbs’ free 
energy, enthalpy and entropy, respectively.  Kd values from Table 6.4 and R-group details of the 
SDG compounds are also provided. 
 
Overall, a bimodal distribution is observed where ligand binding produces either a 
positive or negative change in entropy coupled with a negative free energy of binding 
and change in enthalpy.  In terms of favourable binding, greater negative values of ΔG, 
ΔH and -TΔS are often considered most desirable (Holdgate, 2001).  The enthalpic and 
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entropic changes of all ligands in Figure 6.18 and Table 6.4 are widely distributed 
(largest ΔΔH and Δ-TΔS are 31.68 and 26.96 kJ mol-1, respectively) whereas ΔG 
fluctuates relatively little (largest ΔΔG 8.81 kJ mol-1).  This is due to high enthalpy-
entropy compensation resulting from the opposing ΔH and -TΔS values of some 
ligands.  The relationships between the thermodynamic parameters obtained from all 
ITC experiments are shown in Figure 6.19.  The expected logarithmic relationship 
between ΔG and Kd is clearly demonstrated by the ligands, which range in affinity from 
0.18 to 6.22 µM (Figure 6.19A).  However, the scattered distribution of ΔH and -TΔS 
values is apparent (Figure 6.19B-C) and is not evident from experiments measuring 
potency alone.  Additionally, while ΔG remains relatively stable with respect to the 
wide-ranging ΔH, the entropic penalty of ligands with favourable ΔH is shown in 
Figure 6.19D compared with the lower, more favourable, entropic contribution 
produced by ligands binding with poorer enthalpy.  These relationships further highlight 
the apparent effect of entropy-enthalpy compensation in this set of ligands. 
 
The compensatory effect may be a consequence of the hydrophobic properties of the 
SDG compound R-group substitutions compared with those of substrate or MTX.  
Hydrophobic interactions between two species tend to generate a favourable increase in 
the disorder of a system as water molecules arranged in an ordered manner around the 
individual hydrophobic groups are distributed into bulk solvent on binding (Ladbury 
and Chowdhry, 1996; Bronowska, 2011).  The ordered intramolecular bonds between 
solvent first need to be broken and can contribute to the poor simultaneous enthalpic 
change.  In contrast, biopterin, DHB and MTX all display relatively large positive -TΔS 
values.  The polar groups attached to the pterin moiety are not surrounded by the same 
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ordered system of water molecules as a hydrophobic group and so, desolvation on 
binding is not entropically driven.  In general, the net strength of the bonds formed to 
produce a favourable enthalpic contribution can also be accompanied by a greater loss 
of conformational freedom of both ligand and protein, giving a poor change in entropy 
(Leavitt and Freire, 2001).  This compensatory effect can be difficult to overcome 
(Cooper et al., 2001).  Improvements to entropy or enthalpy alone can compromise the 
highly favourable counterpart as demonstrated by the SDG compounds, which display a 
more favourable change in entropy but a reduced enthalpy when compared with 
substrates or MTX. 
 
Figure 6.19. ITC thermodynamic relationships 
Relationships between thermodynamic properties of ten ligands titrated against TbPTR1.  (A) – 
(C) show Kd versus ΔG (blue), ΔH (red) and -TΔS (grey).  (D) shows the relationship between 
ΔH and both ΔG (blue circles) and -TΔS (grey squares). 
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6.2.5.1. Ligand efficiency 
Ligand efficiency (LE) is the average contribution to the overall ΔG by each non-
hydrogen atom (or ‘heavy atom’, HA) and was calculated using the experimental free 
energy of ligand binding based on the idea of Kuntz et al. (1999) where LE = - ΔG/HA 
(Table 6.4).  ΔG is directly related to Ka  (thus, Kd) via the relationship ΔG = -RTlnKa 
where R is the universal gas constant (8.314 J K-1 mol-1 or 1.987 cal K-1 mol-1) and T is 
the temperature (K).  As such, the LE calculated using Kd as suggested by Hopkins et al. 
(2004) is identical.  In the absence of Kd or ΔG data for the majority of SDG 
compounds, the Ki or IC50 can therefore be used in their place (Hopkins et al., 2004) 
and are provided later.  Comparisons of the experimentally derived LE of the 7 SDG 
inhibitors are indeed in close agreement with the alternative values. 
 
SDG 57 is the smallest inhibitor in the series with only an additional methyl group at R2 
of scaffold II and at 0.67 kcal mol-1 HA-1 (2.80 kJ mol-1 HA-1), LE is higher than that of 
the other inhibitors tested, biopterin and DHB.  The crystal structure of SDG 57 bound 
to TbPTR1 confirms that although the overall affinity is relatively low (Kd 1.46 µM), 
the majority of atoms participate in the key contacts with active site residues.  Addition 
of more complex R-groups must then also favourably interact with active site residues 
to maintain the high LE.  However, the lower LE values of much larger ligands like 
MTX and SDG 132 suggest that this is not always the case and highlights the need for 
optimisation. 
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6.2.5.2. The effect of minor ligand changes 
In order to assess the effect of different chemical substitutions on the thermodynamics 
of binding, it is important to first understand whether the observed differences are in 
fact significant.  Holdgate (2001) suggests ΔΔH or ΔΔG of ≥ 4 kJ mol-1 or a change in -
TΔS of ≥ 8 kJ mol-1 is significant.  While differences to this extent are observed, it is 
mainly between SDG ligands that also display the largest structural differences such as 
SDG 57 and SDG 132.  Interpreting such differences is fraught with difficulties as there 
are many factors contributing to the observed changes.  Small chemical substitutions 
therefore allow for the most reliable thermodynamic interpretations.  While the 
introduction of a minor structural difference may not produce such enhanced 
thermodynamic effects, overall changes can still be used to gauge potential trends.  
SDG 65, 67 and 68 are all very similar compounds, differing by the addition or type of 
a single heavy atom.  To aid in these comparisons, the seven SDG compounds studied 
by ITC are shown in Figure 6.20.  Table 6.5 provides values for the change in 
thermodynamic parameters of SDG 65 and SDG 68 with respect to SDG 67. 
 
Figure 6.20. SDG compounds studied by ITC 
The chemical structures of SDG 57, SDG 60, SDG 65, SDG 67, SDG 68, SDG 106 and SDG 
132.  SDG 57 and SDG 60 are scaffold II compounds, all others are scaffold I and atom 
numbering is as shown in Figure 6.5. 
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 Kd ΔG ΔH -TΔS LE 
SDG 67 0.76 -35.51 -36.73 1.21 0.50 
 ΔKd ΔΔG ΔΔH Δ  -TΔS ΔLE 
SDG 65 -0.40 -1.87 3.64 -5.50 0.00 
SDG 68 0.28 0.76 5.33 -4.56 -0.04 
Table 6.5. Thermodynamic comparisons: SDG 67, 65, and 68. 
Thermodynamic parameters of SDG 67 are taken from Table 6.4.  All units are as provided 
previously, omitted here for simplicity.  The observed change in these values are provided for 
SDG 65 and SDG 68, highlighted cyan if the change is more favourable or red if the parameter 
becomes less favourable with respect to SDG 67. 
 
SDG 65 and SDG 68 contain methyl and fluoride groups, respectively, extending from 
the R2 phenyl group of SDG 67.  LE values of 0.50 and 0.46 kcal mol-1 HA-1 coupled 
with the direct comparison of affinity (Kd = 0.36 and 1.04 µM, respectively) suggest 
that the methyl substitution is more favourable.  Indeed, the ΔG and -TΔS values of 
SDG 65 are improvements to those of SDG 67.  However, the more favourable entropic 
contribution of both SDG 65 and SDG 68 is accompanied by an enthalpic penalty.  Both 
compounds display greater hydrophobicity and a larger surface area than the phenyl 
group alone, and may account for these effects.  The increased length given by the 
methyl and fluoride R2 substitutions allow for an increased propensity to form van der 
Waals interactions with Trp221.  While the compensatory differences produced by SDG 
68 are detrimental to affinity, SDG 65 has the highest overall affinity for TbPTR1 of 
these three compounds with no effect on ligand efficiency. 
 Kd ΔG ΔH -TΔS LE 
SDG 60 0.56 -36.31 -38.70 2.40 0.48 
 ΔKd ΔΔG ΔΔH Δ  -TΔS ΔLE 
SDG 65 -0.20 -1.07 5.61 -6.69 0.02 
Table 6.6. Thermodynamic comparisons: SDG 60 and 65. 
Thermodynamic parameters of SDG 60 are taken from Table 6.4.  All units are as provided 
previously, omitted here for simplicity.  The observed change in these values are provided for 
SDG 65, highlighted cyan if the change is more favourable or red if the parameter becomes less 
favourable with respect to SDG 60. 
 
A pairwise comparison of only SDG 65 and SDG 60 (Table 6.6) provides an interesting 
observation.  These compounds are partners belonging to scaffold I and II, respectively.  
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While exchanging the carbonyl of SDG 60 to the R1 amino group of SDG 65 results in 
an overall increase in affinity through improvements to -TΔS and ΔG, there is a 
significant loss in favourable enthalpy.  There is little change in the hydrophobicity, 
suggested by cLogP values of 1.9 and 2.1 (calculated using Molinspiration, 
Cheminformatics, 2013) to account for such changes.  When the inhibitors are analysed 
based on the same binding orientation, it is possible that the amino group of SDG 65 
forms weaker hydrogen bonds with nearby water molecules or the carbonyl of SDG 60 
can accept a hydrogen bond donated by Arg14.  A ‘moderate’ hydrogen bond has been 
estimated to have a dissociation energy in the range of 17-62 kJ mol-1 (Steiner, 2002).  
But, ΔH reflects the net change of all non-covalent bonds and it is still extremely 
difficult and inappropriate to assign changes in ΔH to the breakage or formation of a 
single hydrogen bond, particularly when the strength of each bond is effectively 
unknown.  Alternatively, this pattern of thermodynamic changes can signify an 
alteration in binding mode (Holdgate, 2001).  While the crystal structures show both 
inhibitors adopt the substrate binding orientation, there is evidence that SDG 65 can 
also assume the MTX-like orientation in one subunit.  The only obvious difference 
between poses is the loss of an ordered water molecule.  This may account for the loss 
in enthalpy while entropy is gained from the water returning to bulk solvent.  However, 
precise details of specific water molecules are difficult to assess even with guidance of 
crystallographic models (Davis et al., 2003). 
 Kd ΔG ΔH -TΔS LE 
SDG 68 1.04 -34.75 -31.40 -3.35 0.46 
 ΔKd ΔΔG ΔΔH Δ  -TΔS ΔLE 
SDG 106 2.09 2.74 0.79 1.95 -0.14 
Table 6.7. Thermodynamic comparisons: SDG 68 and 106. 
Thermodynamic parameters of SDG 68 are taken from Table 6.4.  All units are as provided 
previously, omitted here for simplicity.  The observed change in these values are provided for 
SDG 106, highlighted cyan if the change is more favourable or red if the parameter becomes 
less favourable with respect to SDG 68. 
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SDG 68 and SDG 106 (Table 6.7) both contain the same R2 group and comparisons 
can inform on the effect of the large N 4-cyclohexyl group extending from R1.  It is clear 
that not only is affinity compromised but, while perhaps not considered significant, 
there are no thermodynamic advantages to the addition of this group.  Structural data are 
available for both inhibitors and, as discussed in 6.2.4.2 and 6.2.4.3, although the 
TbPTR1 active site can accommodate such a substitution at R1, binding can induce 
some conformational changes, particularly the substrate-binding loop.  It is difficult to 
pinpoint a single cause for the observed thermodynamic effects as the substitution is 
larger than a single atom but we can speculate that this conformational change is costly 
and may indeed be the source of the reduced affinity.  A similar relationship is seen 
between SDG 67 and SDG 132, where all parameters are significantly less favourable 
when the complex R3 group is added.  However, limited conclusions can be drawn as 
other substitutions at this position may be thermodynamically favourable. 
 Kd ΔG ΔH -TΔS LE 
SDG 57 1.46 -33.88 -39.62 5.74 0.67 
 ΔKd ΔΔG ΔΔH Δ  -TΔS ΔLE 
SDG 60 -0.90 -2.43 0.92 -3.34 -0.19 
Table 6.8.  Thermodynamic comparisons: SDG 57 and 60. 
Thermodynamic parameters of SDG 57 are taken from Table 6.4.  All units are as provided 
previously, omitted here for simplicity.  The observed change in these values are provided for 
SDG 60, highlighted cyan if the change is more favourable or red if the parameter becomes less 
favourable with respect to SDG 57. 
 
Comparing scaffold II compounds SDG 57 and SDG 60 (Table 6.8) gives a pattern 
analogous to that of SDG 67 and SDG 65 (Table 6.5).  The addition of a more 
hydrophobic group at R2 produces favourable entropic changes while a small 
detrimental change in enthalpy results.  Again, the net effect is an improvement in 
affinity but in this case, the additional group is larger than a methyl attachment and 
ligand efficiency is compromised. 
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Overall, even with both thermodynamic and structural data for six SDG compounds (no 
crystal structure is available for SDG 132), it remains extremely difficult to understand 
the precise underlying cause of the thermodynamic events.  In particular, the 
contributions made by water must be considered and these are not always fully apparent 
in crystal structures.  These studies have made efforts to characterise some of the 
observed effects produced by small changes to ligand structure and show that the 
entropic change produced on ligand binding has been improved.  Although the SDG 
compounds are not enthalpically optimised compared to substrates and methotrexate, 
the improved entropic contributions do reduce the effect of enthalpy-entropy 
compensation and the resultant free energy values are comparable.  Improving ΔS may 
be considered relatively easy compared with that of ΔH by the addition of bulky or 
hydrophobic groups (Ladbury et al., 2010; Ferenczy and Keserű, 2012) but solubility 
can be compromised if this strategy is overused.  Optimisation of enthalpy has been 
shown to directly lead to improved inhibitors in other systems, such as HIV protease 
inhibitors (Ohtaka et al., 2004; Chaires, 2008).  Here, future improvements should 
therefore focus on enhancing the enthalpy of binding by these scaffolds.  It is more 
difficult to design and synthesise compounds that possess the ideal bond lengths and 
properties to make specific hydrogen bonds to improve enthalpy and these are often 
obtained fortuitously (Ladbury et al., 2010).  One prospect is to perhaps mimic the 
apparent enthalpically favourable position 6 group of biopterin and DHB substrates in 
addition to the entropically favourable hydrophobic R3 phenyl system utilised in these 
SDG inhibitors.  Or, to exploit the hydrogen bonding capabilities of Asp161 and 
Gly205 as shown by SDG 33 may improve enthalpy whilst a hydrophobic R2 
substitution can generate favourable entropy. 
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6.2.6. Overall analysis 
With one exception, all molecules in Table 6.2 obey the guidelines often used to predict 
oral bioavailability, Lipinski’s (2001) ‘rule of five’ (≤ 500 Da, ≤ 5 hydrogen bond 
donors, ≤ 10 hydrogen bond acceptors, cLogP ≤ 5).  Containing substitutions at all three 
R-groups of scaffold I, SDG 107 is one of the best inhibitors of the series (Ki 0.2 µM) 
but violates the guidelines with a cLogP of 5.4.  Changes in enthalpy, entropy and free 
energy of those studied by ITC are also within the range typical of drug-like molecules 
(-80 to 20 kJ mol-1, -60 to 40 kJ mol-1 and -50 to -30 kJ mol-1, respectively; Holdgate, 
2001).  The value of efficiency indices such as LE are being recognised and 
implemented within drug discovery strategies to guide the optimisation of a chemical 
series alongside conventional parameters such as potency (Abad-Zapatero, 2007).  Here, 
LE has been monitored and while penalties were paid by some compounds, the overall 
LE was maintained above approximately 0.3 kcal mol-1 HA-1 even with relatively large 
phenyl substitutions (Figure 6.21A).  A molecule containing 25 non-hydrogen atoms 
with 1 nM potency (Ki) would have an LE of approximately 0.5 kcal mol-1 HA-1 (Abad-
Zapatero, 2007) and although there is still room for improvement, some SDG 
compounds boast an LE of greater than 0.5 (Figure 6.21A). 
 
cLogP, the calculated octanol-water partition coefficient, values for each compound 
were predicted based on contributions from individual chemical groups using 
Molinspiration (Cheminformatics, 2013) and indicates the compound lipophilicity  The 
same method for cLogP calculation is employed by the ZINC compound database 
(Irwin et al., 2012), widely used in virtual screening approaches.  While there appears to 
be little correlation between Kd and cLogP (Figure 6.21B), this is based on a very low 
sample number from a set of compounds that displayed poor solubility.  Indeed, the low 
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solubility of those not suitable for ITC was perhaps dominated by their higher 
lipophilicity.  Ki values also appear widely distributed with respect to cLogP but the 
compounds with the poorest potency of this series are also the least lipophilic.  
Conversely, all compounds with a cLogP of greater than 2.5 also have an apparent Ki of 
less than 1.5 µM, suggesting that hydrophobic substitutions improve overall potency.  
This is further confirmed by the structural observations showing hydrophobic R2 and 
R3 groups extending from the catalytic centre to make favourable hydrophobic contacts 
with peripheral active site residues. 
 
Of all compounds studied, those belonging to scaffold I with an R1-amino group 
typically displayed greater potency than the equivalent scaffold II compound where all 
other substitutions were identical.  The trend between Ki and ΔG of scaffold I 
compounds appears to resemble that between Kd and ΔG (Figure 6.21C).  The two 
scaffold I compounds, SDG 57 and SDG 60, appear as outliers.  It may be inappropriate 
to draw conclusions from only two data points but at this stage, we cannot completely 
rule out that these two scaffold II compounds were to some extent themselves reduced 
by TbPTR1 during the spectrophotometric assay.  If true, these compounds are able to 
block substrate binding but NADPH oxidation can still occur through hydride donation 
to the pyrrolopyrimidine C5 and an artificially low inhibition rate is observed.  ITC was 
performed in the presence of oxidised cofactor, NADP+, and only the effect of titrated 
ligand binding is measured.  Many scaffold II compounds displayed reasonable TbPTR1 
inhibition but the possibility of inhibitor reduction may suggest that scaffold I 
compounds are more valuable for further study. 
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Figure 6.21. Ligand efficiency, LogP and kinetic relationships 
(A) Ligand efficiency according to SDG compound number and coloured according to scaffold 
(scaffold I, green; scaffold II, purple; other, grey circles). (B) Calculated LogP values (cLogP) 
are plotted against the Ki values of all compounds in Table 6.2 (coloured as in (A)) and the Kd 
of ligands in Table 6.4 (scaffold I, orange; scaffold II red triangles).  (C) The relationship 
between ΔG  and Ki (scaffold I and MTX, green circles; scaffold II, purple circles) or Kd (orange 
triangles, also shown in Figure 6.19). 
 
The scaffolds alone are weak inhibitors of PTR1 (Tulloch et al., 2010) and the addition 
of only a methyl group at R2 also results in relatively poor inhibition (SDG 57).  An 
additional phenyl substituent at either R2 (SDG 62) or R3 (SDG 102) immediately 
improves the inhibitory effect.  Additional chemical modifications were therefore 
introduced to instigate and identify further improvements. 
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Substitutions larger than NH2 can be made at R1 with an improvement in potency (for 
example, SDG 122 to SDG 123 and SDG 100 to SDG 120 or SDG 107) but can force 
the ligand into a suboptimal position that cannot form key hydrogen bonds directly with 
cofactor or Ser95, resulting in weak affinity and poor heat exchange on ITC (SDG 23). 
 
The use of halogen substituents such as a 4-bromophenyl group at R3 produced one of 
the highest inhibition rates of both scaffolds (SDG 126 and SDG 127).  Addition of 
fluorine at the same position had a lower effect (SDG 111 and 112) but still improved 
the potency over the non-halogenated compounds (SDG 99 and 100).  Combining the 
R3 4-fluorophenyl with the same group at R2 (SDG 114) had a small detrimental effect 
where replacement with a 3-chlorophenyl (SDG 133 and SDG 134) partially regains the 
potency.  Additional groups beyond the R2 phenyl generally showed no overall 
advantage over the ring substitution alone (including SDG 111 to SDG 113, SDG 112 
to SDG 114, SDG 67 to SDG 68) except in the case of SDG 65 where a methyl addition 
did enhance affinity through an improvement in entropy although the scaffold II 
equivalent behaved marginally better without this addition (SDG 62 compared to SDG 
60).  While the R2 4-fluorophenyl of SDG 68 reduced overall affinity, the entropic 
contribution was more favourable than the phenyl alone so should not be ruled out.  The 
use of 4-chlorophenyl groups at R2 and R3 (SDG 115) resulted in greater inhibition 
than the equivalent 4-fluoro substituents (SDG 113) but it is not known which chloro- 
group had the greatest effect.  Conventionally, halogen components are utilised to 
improve ADMET properties (absorption, distribution, metabolism, excretion and 
toxicity) to ultimately aid in producing a drug-like molecule with good bioavailability 
(Bronowska, 2011).  More recent applications suggest that halogenated ligands can 
inform structure based design studies through optimisation of halogen bonds (Lu et al., 
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2009; Xu et al., 2011) that form based on the anisotropic distribution of charge 
surrounding the atom (Kolář et al., 2013), analogous to hydrogen bonds (Auffinger et 
al., 2004).  While it is possible that the presence of non-covalent attraction between the 
bromo-group of SDG 126 or SDG 127 and His267' or Cys168 carbonyl may support the 
observed inhibitory improvements, it is likely primarily attributed to the ability of the 
large bromine atom to fill the cavity lined by Tryp221, Cys168 and Met213. 
 
While extension from a phenyl group at R2 may not be favourable in most cases other 
than SDG 65, lengthening the distance of the phenyl from the core scaffold by either an 
ethyl (SDG 80) or an ethynyl (SDG 53) extension did appear to improve inhibition.  
The crystal structures show that for SDG 53, inhibition was enhanced through 
interactions with the hydrophobic pocket bordered by Leu209, Met213 and Trp221 that 
is better reached by the longer extension.  SDG 80, however, adopts the MTX-like 
orientation and the ethylphenyl group does not fill the pocket to the same degree, 
possibly contributing to the slightly lower observed potency.  SDG 53 contains a 
pyrrolidine substitution at R1, preventing the MTX-like orientation through clashes 
with Tyr174 and Asp161 while SDG 80 would share a hydrogen bond with Tyr174 in 
either orientation.  A combined R1-pyrrolidine and R2-phenethyl has not yet been 
investigated. 
 
Compounds with a carbonitrile substituent at R2 generally inhibited TbPTR1 well.  
While this group alone only slightly improved inhibition from a methyl (SDG 69), 
additions at R3 made significant improvements.  In the spectrophotometric assay, SDG 
74 and SDG 75 appeared to be the best performing compounds of scaffold I and II, 
respectively, where the simultaneous R3-styryl partially fills the pocket generated by 
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Met163, Cys168, Trp221 and also bordered by His267' from subunit D.  Similar to the 
R2 phenyl substituent, it appears that a longer extension of the phenyl group is 
beneficial at R3.  However, the potency drops marginally when either a rigid 
phenethynyl (SDG 76) or a flexible phenethyl group (SDG 84) replaces the styryl. 
 
When the two main scaffolds are not strictly obeyed, such as replacement of the 
scaffold I 7-NH with O (SDG 85, SDG 88, SDG 89, SDG 91, SDG 93), inhibition did 
not improve beyond approximately 0.7 µM (Ki) but extensive R-groups were not 
examined.  Structural data are not available to examine the binding of these compounds 
due to difficulties generating diffraction-quality crystals but we can speculate that the 
MTX-like pose would be adopted.  The O in place of the scaffold I 7-NH may assume 
the binding position of the substrate 4-carbonyl while the R1-amino group is situated to 
donate a hydrogen bond to Tyr174. 
 
To conclude, these studies have shown that hydrophobic groups extending to interact 
with Trp221 not only improve potency but do so by enhancing the favourable entropic 
contribution to binding.  SDG 32 and SDG 33 highlight that a second site where 
hydrogen bond donors close to Asp161 and Gly205, replacing an ordered water 
molecule, can be utilised in a single molecule that simultaneously fulfils the well-
characterised primary binding features.  This strategy in combination with a 
hydrophobic extension may then improve the enthalpic change on binding which is 
compromised when entropy alone is optimised.  Indeed, multiple substitutions on the 
framework employed here can be advantageous, particularly with extended phenyl 
groups and there remains potential for substitutions at all three R-groups with early 
attempts appearing promising (SDG 107 or SDG 123, no structure available).  The 
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physical properties of such compounds must be considered carefully as large 
hydrophobic groups with high cLogP values are likely to further reduce solubility and 
can lead to poor bioavailability and toxicity (Hughes et al., 2008) but the use of 
halogenated substituents can be utilised to reduce the effects as well as gain potency. 
 
6.2.7. Additional studies 
The majority of the work presented forms part of a wider project to improve inhibitors 
targeting PTR1 in the search for new therapies against HAT and Leishmaniasis.  A brief 
summary of additional studies and some comparisons with results of biochemical 
investigations are provided. 
 
6.2.7.1. Compound synthesis 
As noted in 5.2, chemical synthesis of all SDG compounds was performed by the 
laboratories of Professor Colin Suckling and Dr Colin Gibson at the department of Pure 
and Applied Chemistry, University of Strathclyde (Glasgow, UK). 
 
6.2.7.2. Biological activity 
Experiments to assess the effect of SDG compounds on the activity of T. brucei brucei 
parasites in vitro were performed by Professor Michael Barrett’s laboratory at the 
Institute of Infection, Immunity and Inflamation, University of Glasgow (UK).  
Compounds that demonstrated activity against both recombinant TbPTR1 and T. b. 
brucei cells were progressed for study against HEK (human embryonic kidney) and L. 
mexicana amastigote cell lines.  In some cases, compounds displayed inhibition of 
recombinant TbPTR1 but were inactive against the parasite, suggestive of problems in 
cell uptake.  For example, SDG 65 gave a Ki of 0.32 µM and Kd of 0.36 µM against 
 
 
Part II Pteridine reductase 1  Chapter 6: Results and discussion 
158 
TbPTR1 but resulted in an IC50 of 170 µM when evaluated against T. b. brucei cells.  
Conversely, compounds that appeared effective against T. b. brucei but showed little 
inhibition of TbPTR1 were perhaps acting in a non-specific manner.   Compounds were 
tested using both folate-rich HMI9 and folate-deficient CMM growth media with 
similar results, indicative of a non-competitive relationship with folate unlike the DHFR 
inhibitor, MTX. 
 
Some molecules that have been shown to target PTR1 with submicromolar Ki values 
were found to display high nanomolar or low micromolar trypanocidal activity whilst 
not producing significant HEK cell toxicity.  IC50 values of less than 1 µM against T. b. 
brucei with at least 50-fold greater IC50 against HEK cells were considered significant.  
For example, SDG 112 displayed an IC50 against T. b. brucei of 0.321 µM (HMI9) or 
0.082 µM (CMM) compared to 49.190 µM against HEK cells.  As a reference, MTX 
IC50 against T. b. brucei was 3.656 µM in HMI9 media or 0.011 µM in folate deficient 
media, a change of > 300-fold.  Most compounds assessed also showed greater activity 
against T. b. brucei than L. mexicana amastigotes where activity was typically poorer 
than that of MTX and amphotericin B controls (IC50 approximately 7.4 µM and 0.2 µM, 
respectively).  Overall, SDG 99, 100, 111-114, 122, 124, 127, 128, 133 and 134 were 
found to be most effective with IC50 values against T. b. brucei lower than that of MTX 
in folate-rich media, from 0.265 µM (SDG 122) to 2.247 µM (SDG 100) as shown in 
Table 6.9.  While not restricted to a single scaffold, all of these compounds contain 
phenyl substitutions at both R2 and R3, shown structurally to generate hydrophobic 
interactions in two active site sub-pockets.  Indeed, SDG 127 was the most potent in the 
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series against TbPTR1 and, while other scaffold I compounds were toxic in vivo, both 
SDG 127 and SDG 122 were able to significantly reduce parasitaemia. 
 
  IC50 (µM) 
Compound Ki (µM) 
T.b.brucei 
CMM media 
T.b.brucei 
HMI9 media HEK L.mexicana 
SDG 112 0.24 0.321 0.082 49.190 19.460 
SDG 122 0.58 0.265 0.083 39.140 20.450 
SDG 128 0.95 0.396 0.135 33.180 9.140 
SDG 114 0.30 0.594 0.149 47.340 21.180 
SDG 134 0.29 0.392 0.185 34.593 24.400 
SDG 127 0.14 0.970 0.248 39.630 34.090 
SDG 99 1.17 0.640 0.407 Not 
available 
7.652 
SDG 100 0.59 2.247 0.583 62.883 >100 
SDG 111 0.51 0.738 0.614 >200 >100 
SDG 113 0.76 1.390 0.739 160.600 >100 
SDG 133 0.47 1.405 0.767 57.700 >100 
Table 6.9. Biological activity 
The most effective compounds that were found to display IC50 values of less than 1 µM 
against T. b. brucei and low toxicity, where IC50 values against HEK cells were at least 
50-fold greater than those against T. b. brucei.  Compounds are listed in order of 
effectiveness when all parameters are considered.  Scaffold I compounds are in white 
rows and scaffold II compounds are highlighted grey.  Biochemical Ki values against 
recombinant TbPTR1 and L. mexicana IC50 values are also shown.  Error values are 
omitted for clarity.  Kd values were not achieved for these compounds by ITC.  
 
6.2.7.3. PTR1 selectivity 
A number of compounds were analysed against TcDHFR activity by the laboratory of 
Professor Debasish Chattopadhyay at the University of Alabama (Birmingham, 
Alabama, USA).  SDG 5, 23, 32, 53, 57, 60 and 68 were tested and displayed little or no 
DHFR inhibition indicating specificity for PTR1.  Previous results of collaborators have 
also shown that pyrrolopyrimidines do not inhibit HsDHFR. 
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6.2.7.4. Pharmacokinetics 
Selected compounds were assessed by the Drug Metabolism and Pharmacokinetics 
group (DMPK) of Dr. Kevin Read (Biological Chemistry and Drug Discovery, 
University of Dundee, UK).  Of those tested, it was found that toxicity levels were 
above ideal and prevented effective assessment using a HAT mouse model.  Together 
with relatively modest nanomolar in vitro potency and the low fraction of unbound 
compound in plasma protein binding studies, high dosage levels were necessary but this 
amplified the toxic effects.  Despite this, SDG 99, SDG 112 and SDG 122 displayed 
acceptable exposure levels on initial dosage and for SDG 112 in particular, the exposure 
was maintained by a longer half-life.  Overall, DMPK studies provided proof-of-
concept that compounds of this series do have potential if further optimised to reduce 
toxicity. 
 
6.3. Part II summary and concluding remarks 
The crystal structure of PTR1 from L. donovani has been determined using diffraction 
data to 2.5 Å resolution.  Unfortunately, this crystal form of LdPTR1 is not amenable 
for further ligand interaction studies.  A sulfate obtained from the crystallisation 
mixture blocks the cofactor binding site and due to the sequential ordered mechanism of 
PTR1, neither substrate or inhibitor can then form a complex.  As no fully apo-PTR1 
structures have been reported, this model of LdPTR1 confirms the structural importance 
of the NADP(H) cofactor.  It also provides new information on the mobile nature of the 
β5-α5 loop as well as the important substrate binding loop and other residues known to 
be critical for function. 
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Recombinant T. brucei PTR1 was used to assess the inhibition of over 100 novel small 
molecules, 23 of which were co-crystallised in a ternary complex with TbPTR1 and 
oxidised cofactor, NADP+.  The thermodynamics of ligand binding was also 
characterised for seven inhibitors and compared with that of substrate and an archetypal 
dihydrofolate reductase inhibitor, methotrexate, while an additional high resolution 
crystal structure of PTR1 complexed with another known antifolate, trimetrexate, was 
also determined.  Examination of these structures has revealed a number of interesting 
new features.  Most adopt a binding mode similar to substrate and allowed the 
development of larger substitutions at positions 5 and 6 of a pyrrolopyrimidine core.  
Previously unexplored position 4 substitutions were also shown to be accommodated 
through movement of the flexible substrate-binding loop.  Two compounds attached 
covalently to an active site cysteine and two compounds were observed to bind at 
multiple locations in the active site.  While a similar binding mode has been shown 
previously, these molecules were able to simultaneously make important contacts with 
cofactor in substrate-like orientation as well as at the secondary site, providing guidance 
for future developments. 
 
Valuable data can be obtained from ITC but this is strongly dependent on the behaviour 
of both protein and compound under the selected experimental conditions.  Here, many 
compounds could not be tested due to their relatively low aqueous solubility.  Based on 
the seven SDG inhibitors for which acceptable experimental data were obtained, some 
difficulties in data interpretation were also encountered.  Crystallographic information 
was important to validate ligand:protein stoichiometry where it was necessary to 
account for errors that might have been introduced in sample preparation.  While 
structural data cannot always identify the precise cause in changes to enthalpy and 
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entropy as it can be considered a ‘snapshot’ of a dynamic system, it remains extremely 
important to employ a strategy where multiple biophysical techniques can be used 
complement one another and allow for the most reliable overall analysis.  ITC has 
highlighted the improvements made to the interaction entropy as well as the importance 
of further optimising the enthalpic contribution.  Together with structural and kinetic 
data, the ligand binding profiles and SAR produced by these studies forms a solid 
platform for future advances targeting the inhibition of trypanosomatid PTR1. 
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APPENDIX A
Name Structure 
SDG 1 
(I) 
  
SDG 2 
(I) 
 
SDG 3 
(I)  
SDG 4 
(K) 
 
SDG 5 
(K, C) 
 
SDG 6 
(I) 
 
SDG 7 
(K) 
 
SDG 10 
(K) 
 
SDG 22 
 
SDG 23 
(K, C) 
 
Name Structure 
SDG 24 
(I) 
 
SDG 25 
 
SDG 26 
 
SDG 27 
 
SDG 28 
 
SDG 29 
(I) 
 
SDG 30 
 
SDG 31 
 
SDG 32 
(K, C) 
 
SDG 33 
(K, C) 
 
Name Structure 
SDG 34 
 
SDG 35 
 
SDG 36 
 
SDG 37 
 
SDG 38 
 
SDG 39 
 
SDG 41 
 
SDG 42 
 
SDG 43 
 
SDG 44 
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Name Structure 
SDG 45 
 
SDG 46 
 
SDG 47 
(I) 
 
SDG 48 
 
SDG 49 
(I) 
 
SDG 50 
 
SDG 51 
 
SDG 52 
 
SDG 53 
(K, C) 
 
SDG 54 
(K) 
 
 
Name Structure 
SDG 55 
(I) 
 
SDG 56 
 
SDG 57 
(K, C) 
 
SDG 58 
 
SDG 59 
 
SDG 60 
(K, C) 
 
SDG 61 
(K) 
 
SDG 62 
(K) 
 
SDG 63 
(I) 
 
SDG 64 
 
 
Name Structure 
SDG 65 
(K, C) 
 
SDG 66 
(I) 
 
SDG 67 
(K, C) 
 
SDG 68 
(K, C) 
 
SDG 69 
(K) 
 
SDG 70 
(K) 
 
SDG 71 
(K) 
 
SDG 72 
(K) 
 
SDG 73 
(K, C) 
 
SDG 74 
(K) 
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Name Structure 
SDG 75 
(K, C) 
 
SDG 76 
(K) 
 
SDG 77 
(K) 
 
SDG 78 
 
SDG 79 
 
SDG 80 
(K, C) 
 
SDG 81 
(K) 
 
SDG 82 
(K, C)  
SDG 83 
 
SDG 84 
(K) 
 
 
Name Structure 
SDG 85 
(K) 
 
SDG 86 
 
SDG 87 
 
SDG 88 
(K)  
SDG 89 
(K) 
 
SDG 90 
 
SDG 91 
(K) 
 
SDG 92 
 
SDG 93 
(K) 
 
SDG 94 
 
 
Name Structure 
SDG 99 
(K, C) 
 
SDG 100 
(K, C) 
 
SDG 101 
 
SDG 102 
(K) 
 
SDG 103 
 
SDG 104 
 
SDG 105 
 
SDG 106 
(K, C) 
 
SDG 107 
(K, C) 
 
SDG 108 
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Name Structure 
SDG 109 
 
SDG 110 
 
SDG 111 
(K) 
 
SDG 112 
(K) 
 
SDG 113 
(K) 
 
SDG 114 
(K) 
 
SDG 115 
(K) 
 
SDG 116 
(I) 
 
SDG 117 
(I) 
 
 
Name Structure 
SDG 118 
(I) 
 
SDG 119 
(I) 
 
SDG 120 
(K, C) 
 
SDG 121 
(I) 
 
SDG 122 
(K, C) 
 
SDG 123 
(K) 
 
SDG 124 
 
SDG 125 
(I) 
 
SDG 126 
(K, C) 
 
 
Name Structure 
SDG 127 
(K, C) 
 
SDG 128 
(K, C) 
 
SDG 129 
 
SDG 130 
(K) 
 
SDG 131 
(I) 
 
SDG 132 
(K) 
 
SDG 133 
(K) 
 
SDG 134 
(K) 
 
SDG 135 
 
 
 
 
Table A.1. SDG compounds 
SDG compounds are listed with according to name.  Compounds insoluble at the required 
concentration are marked (I).  Compounds listed in Table 6.2 with associated kinetic data are 
marked (K) and those with crystal structures determined are marked (C).  All other 
compounds were not progressed beyond screening at two concentration points.  The structures 
of twelve insoluble and three soluble compounds assessed are unavailable and not listed here. 
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APPENDIX B 
Figures of all 24 TbPTR1-ligand complex structures are shown individually along with 
selected active site residues and solvent.  Subunit A was used to prepare all figures 
where inhibitors adopt the same conformation in all tetramer chains.  For ligands that 
displayed significantly different conformations between chains, a second figure is 
provided.  Atoms are all coloured accordingly: C, yellow (NADP+), cyan (TbPTR1) or 
grey (inhibitor); O, red; N, blue; S, gold; P, orange; F, pale blue; Br, brown.  Phe97 is 
shown as thin lines and is unlabelled.  Water molecules within 3.5 Å of the inhibitor are 
depicted as red spheres. 
Figure B.1. SDG 5  
2,4-diamino-6-(3-formylphenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 
 
 
Figure B.2. SDG 23 
2-amino-4-thiomorpholino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 
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Figure B.3. SDG 32  
Subunit A, left; subunit B, right. 
4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
 
 
Figure B.4. SDG 33 
4-thiomorpholino-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
 
 
Figure B.5. SDG 53 
5-(phenylethynyl)-4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
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Figure B.6. SDG 57 
2-amino-5-methyl-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one 
 
 
Figure B.7. SDG 60 
2-amino-5-(p-tolyl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one 
 
 
Figure B.8. SDG 65 
Subunit A, left; subunit B, right. 
5-(p-tolyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
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Figure B.9. SDG 67 
5-phenyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
 
 
Figure B.10. SDG 68 
5-(4-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
 
 
Figure B.11. SDG 73 
2-amino-6-(3-formylphenyl)-4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-
carbonitrile 
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Figure B.12. SDG 75 
(E)-2-amino-4-oxo-6-styryl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 
 
 
Figure B.13. SDG 80 
5-phenethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
 
 
Figure B.14. SDG 82 
(E)-2,4-diamino-6-(4-methylstyryl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 
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Figure B.15. SDG 99 
2-amino-5,6-diphenyl-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one 
 
 
Figure B.16. SDG 100 
5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
 
 
Figure B.17. SDG 106 
N4-cyclohexyl-5-(4-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine  
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Figure B.18. SDG 107 
N4-cyclohexyl-5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
 
 
Figure B.19. SDG 120 
N4,N4-dimethyl-5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
 
 
Figure B.20. SDG 122 
6-(4-fluorophenyl)-5-(4-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
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Figure B.21. SDG 126 
2-amino-6-(4-bromophenyl)-5-phenyl-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one 
 
 
Figure B.22. SDG 127 
6-(4-bromophenyl)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
 
 
Figure B.23. SDG 128 
2-amino-5-phenethyl-6-phenyl-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one 
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Figure B.24. TMQ 
5-methyl-6-[(3,4,5-trimethoxyphenyl)aminomethyl]quinazoline-2,4-diamine 
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